Partitioning and processing of analytes and other species

Information

  • Patent Grant
  • 11193121
  • Patent Number
    11,193,121
  • Date Filed
    Thursday, October 25, 2018
    5 years ago
  • Date Issued
    Tuesday, December 7, 2021
    2 years ago
Abstract
The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.
Description
SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 25, 2018, is named 43487-705303SL.txt and is 4,650 bytes in size.


BACKGROUND

The partitioning and processing of species such as analytes and reagents is important for a variety of applications, including molecular biology applications and medical applications. Appropriate sample preparation is often needed prior to performing a reaction such as a polynucleotide sequencing reaction or an analyte detection reaction. For example, a sample such as a biological sample, including a collection of cells, tissue, and/or nucleic acids may need to be lysed, fragmented, or otherwise manipulated in order to permit downstream analysis. Sample preparation may also involve isolating certain molecules, and/or attaching unique identifiers to certain molecules, among other processes. There is a need in the art for improved methods, compositions, systems, devices, and kits for partitioning and processing of species.


SUMMARY

This disclosure provides methods, compositions, systems, devices, and kits for partitioning and processing of species. The exemplary embodiments provided in this summary are, in no way, intended to be limiting, and are only provided for illustrative purposes. Other embodiments are disclosed throughout this disclosure.


I. Capsules Within Droplets

In some cases, the disclosure provides compositions comprising a plurality of capsules, the capsules situated within droplets in an emulsion, wherein the capsules are configured to release their contents into the droplets upon the application of a stimulus.


In some cases, the capsules comprise a species selected from the group consisting of a reagent and an analyte. In some cases, the droplets comprise a species selected from the group consisting of a reagent and an analyte.


In some cases a reagent is a protein, a polynucleotide, an enzyme, an antibody, a barcode, an adapter, a buffer, a small molecule, a detergent, a dye, a polymer and combinations thereof. In some cases, a reagent is an enzyme selected from the group consisting of a proteinase, a restriction enzyme, a ligase, a polymerase, a fragmentase, a reverse transcriptase, a transposase, and combinations thereof. In some cases an enzyme is a restriction enzyme that is a rare cutter. A reagent that is a barcode may be, for example, an oligonucleotide barcode.


An analyte may be any suitable analyte, for example a cell, a polynucleotide, a chromosome, a protein, a peptide, a polysaccharide, a sugar, a lipid, a small molecule, and combinations thereof. In some cases, an analyte is a polynucleotide. In some cases, the polynucleotide is selected from the group consisting of DNA, RNA, cDNA, and combinations thereof. In some cases, the amount of polynucleotide in a composition disclosed herein is about 1-3 ng. In some cases, the amount of polynucleotide in a composition disclosed herein is an amount sufficient to provide about 100-200× sequence coverage.


In some cases, a capsule may comprise on average, about one chromosome per capsule.


In some cases, each droplet may comprise, on average, about 1 capsule per droplet. In some cases, each droplet can hold, at most, a single capsule.


In some cases, at least one of the capsules comprises a further partition. The further partition may be, for example, selected from the group consisting of a capsule and a droplet in an emulsion.


In some cases, at least one of the capsules has a shell selected from the group consisting of a polymeric shell, a hydrogel, a hydrophilic shell, a hydrophobic shell, a shell with a net positive charge, a shell with a net negative charge, a shell with a neutral charge, and combinations thereof. In some cases, a capsule is formed from a hydrogel droplet.


In some cases, a capsule is responsive to a stimulus is selected from the group consisting of a chemical stimulus, a bulk stimulus, a biological stimulus, a light stimulus, a thermal stimulus, a magnetic stimulus, and combinations thereof. In some cases, a thermal stimulus comprises causing the composition to reach a temperature of at least 32 degrees Celsius. In some cases, the stimulus is selected from the group consisting of a change in pH, a change in ion concentration, reduction of disulfide bonds, and combinations thereof.


In some cases, capsules have a mean diameter of 1 micron to 250 microns, 1 micron to 100 microns, 1 micron to 50 microns, 10 microns to 100 microns, or 50 microns to 100 microns. In some cases droplets have a mean diameter of about 1 micron to about 250 microns, 1 micron to 100 microns, 1 micron to 50 microns, 10 microns to 100 microns, or 50 microns to 100 microns.


In some cases capsules have a mean volume of 1 picoliter to 1 microliter, 1 picoliter to 0.5 microliters, 1 picoliter to 0.1 microliters, 100 picoliters to 0.1 microliters, or 100 nanoliters to 500 nanoliters. In some cases droplets have a mean volume of about 1 picoliter to about 1 microliter, 1 picoliter to 0.5 microliters, 1 picoliter to 0.1 microliters, 100 picoliters to 0.1 microliters, or 100 nanoliters to 500 nanoliters.


In some cases the droplets comprise a fluid that is of a lesser density than the density of the capsules. In some cases the droplets comprise a fluid that is of a greater density than the density of the capsules.


In some cases capsules are produced by a method selected from the group consisting of emulsification polymerization, layer-by-layer assembly with polyelectrolytes, coacervation, internal phase separation, flow focusing, and combinations thereof.


In some cases a stimulus is applied to the capsules. In some cases a stimulus is applied to the droplets.


II. Capsules in Capsules

In some cases this disclosure provides compositions comprising a plurality of outer capsules, the outer capsules comprising at least one inner capsule, wherein the at least one inner capsule is configured to release its contents into at least one outer capsule among the plurality of outer capsules upon the application of a stimulus.


In some cases the inner capsule comprises a species selected from the group consisting of a reagent and an analyte. In some cases the outer capsules comprise a species selected from the group consisting of a reagent and an analyte.


In some cases the reagent is selected from the group consisting of a protein, a polynucleotide, an enzyme, an antibody, a barcode, an adapter, a buffer, a small molecule, a detergent, a dye, a polymer and combinations thereof. In some cases an enzyme is selected from the group consisting of a proteinase, a restriction enzyme, a ligase, a polymerase, a fragmentase, a reverse transcriptase, a transposase, and combinations thereof. In some cases the restriction enzyme is a restriction enzyme that is a rare cutter. In some cases the reagent is a barcode that is an oligonucleotide barcode.


In some cases the analyte is selected from the group consisting of a cell, a polynucleotide, a chromosome, a protein, a peptide, a polysaccharide, a sugar, a lipid, a small molecule, and combinations thereof. In some cases the analyte is a polynucleotide. In some cases the polynucleotide is selected from the group consisting of DNA, RNA, cDNA, and combinations thereof. In some cases the amount of the polynucleotide in a composition of this disclosure is about 1-3 ng. In some cases the amount of the polynucleotide in a composition of this disclosure is an amount sufficient to provide about 100-200× sequence coverage.


In some cases capsule comprises, on average, about one chromosome. In some cases each outer capsule comprises, on average, about 1 inner capsule per outer capsule. In some cases each outer capsule can hold, at most, a single inner capsule.


In some cases at least one inner capsule comprises a further partition. In some cases, the further partition is selected from the group consisting of a capsule and a droplet in an emulsion.


In some cases a capsule has a shell selected from the group consisting of a polymeric shell, a hydrogel, a hydrophilic shell, a hydrophobic shell, a shell with a net positive charge, a shell with a net negative charge, a shell with a neutral charge, and combinations thereof.


In some cases a capsule is responsive to a stimulus is selected from the group consisting of a chemical stimulus, a bulk stimulus, a biological stimulus, a light stimulus, a thermal stimulus, a magnetic stimulus, and combinations thereof. In some cases the thermal stimulus comprises causing the composition to reach a temperature of at least 32 degrees Celsius. In some cases the stimulus is selected from the group consisting of a change in pH, a change in ion concentration, reduction of disulfide bonds, and combinations thereof.


In some cases the inner capsules have a mean diameter of 1 micron to 250 microns, 1 micron to 100 microns, 1 micron to 50 microns, 10 microns to 100 microns, or 50 microns to 100 microns. In some cases the outer capsules have a mean diameter of 1 micron to 250 microns, 1 micron to 100 microns, 1 micron to 50 microns, 10 microns to 100 microns, or 50 microns to 100 microns.


In some cases the inner capsules have a mean volume of 1 picoliter to 1 microliter, 1 picoliter to 0.5 microliters, 1 picoliter to 0.1 microliters, 100 picoliters to 0.1 microliters, or 100 nanoliters to 500 nanoliters. In some cases the outer capsules have a mean volume of 1 picoliter to 1 microliter, 1 picoliter to 0.5 microliters, 1 picoliter to 0.1 microliters, 100 picoliters to 0.1 microliters, or 100 nanoliters to 500 nanoliters.


In some cases the outer capsules comprise a fluid that is of a lesser density than the density of the inner capsules. In some cases the outer capsules comprise a fluid that is of a greater density than the density of the inner capsules.


In some cases the capsules are produced by a method selected from the group consisting of emulsification polymerization, layer-by-layer assembly with polyelectrolytes, coacervation, internal phase separation, flow focusing, and combinations thereof.


In some cases the stimulus is applied to the inner capsule. In some cases the stimulus is applied to the outer capsule.


III. Spots in Wells

In some cases this disclosure provides a composition comprising a plurality of discrete spots disposed on a surface within a well, wherein each spot comprises a species and the spots are configured to release the species upon application of a stimulus. In some cases the species is selected from the group consisting of a reagent and an analyte. In some cases a composition of this disclosure further comprises a medium, wherein the medium comprises a species selected from the group consisting of a reagent and an analyte.


In some cases the reagent is selected from the group consisting of a protein, a polynucleotide, an enzyme, an antibody, a barcode, an adapter, a buffer, a small molecule, a detergent, a dye, a polymer and combinations thereof. In some cases the enzyme is selected from the group consisting of a proteinase, a restriction enzyme, a ligase, a polymerase, a fragmentase, a reverse transcriptase, a transposase, and combinations thereof. In some cases the restriction enzyme is a restriction enzyme that is a rare cutter. In some cases the barcode is an oligonucleotide barcode.


In some cases the analyte is selected from the group consisting of a cell, a polynucleotide, a chromosome, a protein, a peptide, a polysaccharide, a sugar, a lipid, a small molecule, and combinations thereof. In some cases the analyte is a polynucleotide. In some cases polynucleotide is selected from the group consisting of DNA, RNA, cDNA, and combinations thereof. In some cases the amount of the polynucleotide in the composition is about 1-3 ng. In some cases the amount of the polynucleotide in a composition of this disclosure is an amount sufficient to provide about 100-200× sequence coverage.


In some cases each well comprises at least 4 spots. In some cases at least one of the spots comprises a further partition. In some cases the further partition is selected from the group consisting of a capsule and a droplet in an emulsion.


In some cases the stimulus that releases a species from a spot is the introduction of a medium comprising an analyte into the well.


In some cases the spots have a mean diameter of about 1 micron to about 250 microns, 1 micron to 150 microns, 1 micron to 100 microns, 1 micron to 50 microns, 1 micron to 25 microns, or 1 micron to 10 microns.


IV. Devices Comprising Capsules in Droplets

In some cases this disclosure provides devices comprising a plurality of partitions, wherein at least one partition of the plurality of partitions comprises a capsule, wherein the capsule is situated within a droplet in an emulsion, wherein the capsule is configured to release its contents into the droplet upon the application of a stimulus. In some cases the plurality of partitions are selected from the group consisting of wells and spots.


In some cases the device is formed from a material selected from the group consisting of fused silica, soda lime glass, borosilicate glass, poly(methyl methacrylate), sapphire, silicon, germanium, cyclic olefin copolymer, polyethylene, polypropylene, polyacrylate, polycarbonate, plastic, and combinations thereof.


In some cases the device comprises at least 1,000 partitions. In some cases the partitions have a density selected from the group consisting of at least about 1,000 partitions/cm2 and at least about 10,000 partitions/cm2.


In some cases the partitions are disposed along a fluid flow path having a fluid inlet and a fluid outlet.


In some cases the partitions are wells are disposed within a glass slide. In some cases the partitions are spots disposed on a glass slide.


In some cases the partitions have an interior surface comprising a hydrophilic material. In some cases a surface exterior to the partitions comprises a hydrophobic material. In some cases a fluid flow path comprises a surface comprising a hydrophobic material.


IV. Devices Comprising Capsules in Capsules

In some cases this disclosure provides devices comprising a plurality of partitions, wherein at least one partition of the plurality of partitions comprises an outer capsule, the outer capsule comprising at least one inner capsule, wherein the at least one inner capsule is configured to release its contents into the outer capsule upon the application of a stimulus. In some cases the plurality of partitions are selected from the group consisting of wells and spots.


In some cases the device is formed from a material selected from the group consisting of fused silica, soda lime glass, borosilicate glass, poly(methyl methacrylate), sapphire, silicon, germanium, cyclic olefin copolymer, polyethylene, polypropylene, polyacrylate, polycarbonate, plastic, and combinations thereof.


In some cases the device comprises at least 1,000 partitions. In some cases the partitions have a density selected from the group consisting of at least about 1,000 partitions/cm2 and at least about 10,000 partitions/cm2.


In some cases the partitions are disposed along a fluid flow path having a fluid inlet and a fluid outlet.


In some cases the partitions are wells are disposed within a glass slide. In some cases the partitions are spots disposed on a glass slide.


In some cases the partitions have an interior surface comprising a hydrophilic material. In some cases a surface exterior to the partitions comprises a hydrophobic material. In some cases the fluid flow path comprises a surface comprising a hydrophobic material.


IV. Devices Comprising Spots in Wells

In some cases this disclosure provides devices comprising a plurality of wells, wherein at least one well of the plurality of wells comprises a plurality of discrete spots disposed on a surface within the well, wherein each spot comprises a species and the spots are configured to release the species upon application of a stimulus.


In some cases the device is formed from a material selected from the group consisting of fused silica, soda lime glass, borosilicate glass, poly(methyl methacrylate), sapphire, silicon, germanium, cyclic olefin copolymer, polyethylene, polypropylene, polyacrylate, polycarbonate, plastic, and combinations thereof.


In some cases the device comprises at least 1,000 wells. In some cases the wells have a density selected from the group consisting of at least about 1,000 wells/cm2 and at least about 10,000 wells/cm2.


In some cases the wells are disposed along a fluid flow path having a fluid inlet and a fluid outlet.


In some cases the wells are disposed within a glass slide. In some cases the spots are disposed on a glass slide.


In some cases the wells have an interior surface comprising a hydrophilic material. In some cases a surface exterior to the wells comprises a hydrophobic material. In some cases the fluid flow path comprises a surface comprising a hydrophobic material.


IV. Methods Utilizing Capsules in Droplets

In some cases this disclosure provides a method comprising: (a) providing a plurality of capsules, the capsules situated within droplets in an emulsion, wherein the capsules are configured to release their contents into the droplets upon the application of a stimulus; and (b) providing a stimulus to cause the capsules to release their contents into the droplets.


In some cases the capsules comprise a species selected from the group consisting of a reagent and an analyte. In some cases the droplets comprise a species selected from the group consisting of a reagent and an analyte.


In some cases causing the capsules to release their contents into the droplets results in contact between a polynucleotide and an enzyme. In some cases causing the capsules to release their contents into the droplets results in contact between a polynucleotide and a barcode.


In some cases the analyte is a polynucleotide present in a predetermined coverage amount.


In some cases the method further comprises the step of sequencing the polynucleotide. In some cases the method further comprises the step of performing a polynucleotide phasing analysis.


V. Methods Utilizing Capsules in Capsules

In some cases this disclosure provides a method comprising: (a) providing a plurality of inner capsules, the inner capsules situated within outer capsules, wherein the inner capsules are configured to release their contents into the outer capsules upon the application of a stimulus; and (b) providing a stimulus to cause the inner capsules to release their contents into the outer capsules.


In some cases the inner capsules comprise a species selected from the group consisting of a reagent and an analyte. In some cases the outer capsules comprise a species selected from the group consisting of a reagent and an analyte.


In some cases causing the inner capsules to release their contents into the outer capsules results in contact between a polynucleotide and an enzyme. In some cases causing the inner capsules to release their contents into the outer capsules results in contact between a polynucleotide and a barcode.


In some cases the analyte is a polynucleotide present in a predetermined coverage amount.


In some cases the method further comprises the step of sequencing the polynucleotide. In some cases the method further comprises the step of performing a polynucleotide phasing analysis.


VI. Methods Utilizing Spots in Wells

In some cases this disclosure provides a method comprising: (a) providing a well comprising a plurality of discrete spots disposed on a surface within the well, wherein each spot comprises a species and the spots are configured to release the species upon application of a stimulus; (b) adding a medium comprising a species to the well; and (c) providing a stimulus to cause the spots to release their contents into the well.


In some cases the spots comprise a species selected from the group consisting of a reagent and an analyte. In some cases the medium comprises a species selected from the group consisting of a reagent and an analyte.


In some cases causing the spots to release their contents into the well results in contact between a polynucleotide and an enzyme. In some cases causing the spots to release their contents into the well results in contact between a polynucleotide and a barcode.


In some cases the analyte is a polynucleotide present in a predetermined coverage amount.


In some cases the method further comprises the step of sequencing the polynucleotide. In some cases the method further comprises the step of performing a polynucleotide phasing analysis.


VI. Methods of Encapsulating Polynucleotides, Including Whole Chromosomes

In some cases this disclosure provides a method comprising: (a) providing a sample comprising a cell; (b) lysing the cell, thereby generating a lysate; and (c) partitioning the lysate into a capsule.


In some cases the sample comprises a plurality of cells. In some cases the plurality of cells comprises 1 to 100,000 cells, 10 to 10,000 cells, 100 to 5,000 cells, or 1,000 to 5,000 cells.


In some cases lysing comprises a treatment with a proteinase. In some cases the proteinase is proteinase K.


In some cases after the partitioning, at least one of the capsules comprises a single copy of a polynucleotide from the cell. In some cases, at least one capsule comprises a mixture of polynucleotides, wherein none of the polynucleotides in the mixture are overlapping.


In some cases the polynucleotide is a chromosome.


In some cases the capsule comprises a shell with pores that restrict trans-shell transport of the polynucleotide but allow trans-shell transport of a species. In some cases the method further comprises the step of transporting an inner species from the interior of the capsule to the exterior of the capsule. In some cases the inner species is selected from the group consisting of a component of a buffer, a component of a cell, and a macromolecule. In some cases the method further comprises the step of transporting an outer species from the exterior of the capsule to the interior of the capsule. In some cases the outer species is selected from the group consisting of a reagent, a protein, a polynucleotide, an enzyme, an antibody, a barcode, an adapter, a buffer, a small molecule, a detergent, a dye, a polymer and combinations thereof. In some cases the outer species is a reagent for nucleic acid amplification.


In some cases the method further comprises the step of amplifying the encapsulated polynucleotide. In some cases the amplifying is performed by a method selected from the group consisting of multiple displacement amplification, polymerase chain reaction, ligase chain reaction, helicase-dependent amplification, and combinations thereof.


In some cases the method further comprises the step of fragmenting the encapsulated polynucleotide, thereby generating a fragmented polynucleotide. In some cases the method further comprises the step of attaching a barcode to the fragmented polynucleotide.


In some cases the method further comprises the step of placing the capsule comprising polynucleotide (or processed polynucleotide) into a partition. In some cases the partition is selected from the group consisting of a well, a droplet in an emulsion, and a capsule.


In some cases the capsule comprising the polynucleotide is configured to release its contents upon the application of a stimulus. In some cases the stimulus is selected from the group consisting of a chemical stimulus, a bulk stimulus, a biological stimulus, a light stimulus, a thermal stimulus, a magnetic stimulus, and combinations thereof.


In some cases the method further comprises the step of performing a polynucleotide phasing analysis.


VII. Kits

In some cases this disclosure provides kits. In some cases the disclosure provides kits for generating capsules within droplets in an emulsion, the kits comprising reagents for generating capsules, reagents for generating an emulsion, and instructions for generating the capsules within droplets in an emulsion. In some cases the capsules are configured to release their contents into the droplets upon the application of a stimulus. In some cases the kits further comprise a species for inclusion in a partition selected from the group consisting of the capsules, the droplets, and combinations thereof.


In some cases, this disclosure provides kits for generating capsules within capsules, the kits comprising reagents for generating inner capsules, reagents for generating outer capsules, and instructions for generating capsules within capsules. In some cases the inner capsules are configured to release their contents into the outer capsules upon the application of a stimulus. In some cases, the kits further comprise a species for inclusion in a partition selected from the group consisting of the inner capsules, the outer capsules, and combinations thereof.


In some cases this disclosure provides kits comprising a plurality of discrete spots disposed on a surface within a well, wherein each spot comprises a species and the spots are configured to release the species upon application of a stimulus, and instructions for use of the kit to process a sample. In some cases the stimulus is the addition of a sample to the well.


VIII. Partitioning and Fragmenting Methods

In some cases this disclosure provides a method of partitioning polynucleotides comprising: (a) isolating polynucleotides from a source of polynucleotides; (b) partitioning the polynucleotides at a predetermined coverage amount, to produce a plurality of partitions, wherein at least one partition comprises a mixture of non-overlapping polynucleotides, thereby generating partitioned polynucleotides; and (c) fragmenting the partitioned polynucleotides, thereby generating fragmented polynucleotides.


In some cases the source is a cell.


In some cases at least about 50% of the partitions comprise a mixture of non-overlapping polynucleotides.


In some cases the method further comprises the step of amplifying the partitioned polynucleotides. In some cases, the method further comprises the step of barcoding the fragmented polynucleotides.


In some cases this disclosure provides a method of fragmenting a polynucleotide comprising: (a) providing a polynucleotide; (b) encapsulating the polynucleotide, thereby generating an encapsulated polynucleotide; and (c) fragmenting the polynucleotide, thereby generating an encapsulated fragmented polynucleotide.


In some cases the fragmenting is performed by ultrasonic waves.


In some cases the encapsulating disposes the polynucleotide within a capsule. In some cases the encapsulating disposes the polynucleotide within a droplet of a hydrogel.


In some cases the method further comprises the step of encapsulating the encapsulated polynucleotide within a capsule. In some cases the method further comprises the step of encapsulating the encapsulated polynucleotide within a droplet of a hydrogel.


An additional aspect of the disclosure provides the use of a composition, device, method, or kit described herein in partitioning species, in partitioning oligonucleotides, in stimulus-selective release of species from partitions, in performing reactions (e.g., ligation and amplification reactions) in partitions, in performing nucleic acid synthesis reactions, in barcoding nucleic acid, in preparing polynucleotides for sequencing, in sequencing polynucleotides, in mutation detection, in neurologic disorder diagnostics, in diabetes diagnostics, in fetal aneuploidy diagnostics, in cancer mutation detection and forensics, in disease detection, in medical diagnostics, in low input nucleic acid applications, in circulating tumor cell (CTC) sequencing, in polynucleotide phasing, in sequencing polynucleotides from small numbers of cells, in analyzing gene expression, in partitioning polynucleotides from cells, or in a combination thereof.


INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of methods, compositions, systems, and devices of this disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of this disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the methods, compositions, systems, and devices of this disclosure are utilized, and the accompanying drawings of which:



FIGS. 1A-B are schematic examples of wells comprising other types of partitions.



FIGS. 2A-B are schematic examples of spots comprising other types of partitions.



FIGS. 3A-B are schematic examples of a droplet of an emulsion comprising other types of partitions.



FIGS. 4A-B are schematic examples of capsules comprising other types of partitions.



FIG. 5 is a schematic example of a flow focusing method for the production of capsules and/or emulsions.



FIG. 6 is a schematic example of a flow focusing method for the production of capsules within capsules, capsules within droplets of an emulsion, or droplets of an emulsion within capsules.



FIG. 7 is a schematic example of a method for the batch production of capsules.



FIGS. 8A-8D are schematic examples of partition-in-partition configurations.



FIGS. 9A-B provide micrographs of capsules formed as described in Example 1.



FIG. 10 provides a micrograph of a capsule formed as described in Example 2.



FIG. 11 provides micrographs of temperature-responsive capsules formed as described in Example 3.



FIG. 12 provides micrographs of chemically-responsive capsules formed as described in Example 4.



FIGS. 13A-E provide schematic examples of certain configurations of partitions, as described in Example 5.



FIG. 14 provides a schematic example of discrete spots on a surface of a well, as described in Example 6.



FIG. 15A-B provide schematic examples of shearing encapsulated DNA and exposing it to reagents for further processing, as described in Example 7.





DETAILED DESCRIPTION

While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.


This disclosure provides methods, compositions, systems, devices, and kits for partitioning and processing of species. A species may be contained within a sample that may also comprise other species. The sample may be partitioned. A sample may comprise any suitable species, as described more fully elsewhere in this disclosure. In some cases, a sample comprises a species that is a reagent or an analyte. The methods, compositions, systems, devices, and kits may be used for a variety of applications. Analyte may be processed for any suitable application, including, for example, processing polynucleotides for polynucleotide sequencing. Polynucleotides sequencing includes the sequencing of whole genomes, detection of specific sequences such as single nucleotide polymorphisms (SNPs) and other mutations, detection of nucleic acid (e.g., deoxyribonucleic acid) insertions, and detection of nucleic acid deletions.


Utilization of the methods, compositions, systems, devices, and kits described herein may incorporate, unless otherwise indicated, any conventional techniques of organic chemistry, polymer technology, microfluidics, molecular biology, recombinant techniques, cell biology, biochemistry, and immunology. Such conventional techniques include well and microwell construction, capsule generation, generation of emulsions, spotting, microfluidic device construction, polymer chemistry, restriction digestion, ligation, cloning, polynucleotide sequencing, and polynucleotide sequence assembly. Specific, non-limiting, illustrations of suitable techniques are described throughout this disclosure. However, equivalent procedures may also be utilized. Descriptions of certain techniques may be found in standard laboratory manuals, such as Genome Analysis: A Laboratory Manual Series (Vols. I-IV), Using Antibodies: A Laboratory Manual, Cells: A Laboratory Manual, PCR Primer: A Laboratory Manual, and Molecular Cloning: A Laboratory Manual (all from Cold Spring Harbor Laboratory Press), and “Oligonucleotide Synthesis: A Practical Approach” 1984, IRL Press London, all of which are herein incorporated in their entirety by reference for all purposes.


I. Definitions

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.


As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including,” “includes,” “having,” “has,” “with,” “such as,” or variants thereof, are used in either the specification and/or the claims, such terms are not limiting and are intended to be inclusive in a manner similar to the term “comprising”.


The term “about,” as used herein, generally refers to a range that is 15% greater than or less than a stated numerical value within the context of the particular usage. For example, “about 10” would include a range from 8.5 to 11.5.


The term “barcode,” as used herein, generally refers to a label that may be attached to an analyte to convey information about the analyte. For example, a barcode may be a polynucleotide sequence attached to all fragments of a target polynucleotide contained within a particular partition. This barcode may then be sequenced with the fragments of the target polynucleotide. The presence of the same barcode on multiple sequences may provide information about the origin of the sequence. For example, a barcode may indicate that the sequence came from a particular partition and/or a proximal region of a genome. This may be particularly useful when several partitions are pooled before sequencing.


The term “bp,” as used herein, generally refers to an abbreviation for “base pairs”.


The term “microwell,” as used herein, generally refers to a well with a volume of less than 1 mL. Microwells may be made in various volumes, depending on the application. For example, microwells may be made in a size appropriate to accommodate any of the partition volumes described herein.


The term “partition,” as used herein, may be a verb or a noun. When used as a verb (e.g., “to partition,” or “partitioning”), the term generally refers to the fractionation (subdivision) of a species or sample (e.g., a polynucleotide) between vessels that can be used to sequester one fraction (or subdivision) from another. Such vessels are referred to using the noun “partition.” Partitioning may be performed, for example, using microfluidics, dilution, dispensing, and the like. A partition may be, for example, a well, a microwell, a hole, a droplet (e.g., a droplet in an emulsion), a continuous phase of an emulsion, a test tube, a spot, a capsule, or any other suitable container for sequestering one fraction of a sample from another.


The terms “polynucleotide” or “nucleic acid,” as used herein, generally refer to molecules comprising a plurality of nucleotides. Exemplary polynucleotides include deoxyribonucleic acids, ribonucleic acids, and synthetic analogues thereof, including peptide nucleic acids.


The term “species,” as used herein, generally refers to any substance that can be used with the methods, compositions, systems, devices, and kits of this disclosure. Examples of species include reagents, analytes, cells, chromosomes, tagging molecules or groups of molecules, barcodes, and any sample comprising any of these species. Any suitable species may be used, as more fully discussed elsewhere in this disclosure.


II. Partitions

a. General Characteristics of Partitions


As described throughout this disclosure, certain methods, compositions, systems, devices, and kits of the disclosure may utilize the subdivision (partitioning) of certain species into separate partitions. A partition may be, for example, a well, a microwell, a hole, a droplet (e.g., a droplet in an emulsion), a continuous phase of an emulsion, a test tube, a spot, a bead (e.g., a gel bead, a paraffin bead, a wax bead), a capsule, or any other suitable container for sequestering one fraction of a sample or a species. In some cases, a capsule is a bead (e.g., a gel bead). Partitions may be used to contain a species for further processing. For example, if a species is a polynucleotide analyte, further processing may comprise cutting, ligating, and/or barcoding with species that are reagents. Any number of devices, systems or containers may be used to hold, support or contain partitions. In some cases, a microwell plate may be used to hold, support, or contain partitions. Any suitable microwell plate may be used, for example microwell plates having 96, 384, or 1536 wells.


Each partition may also contain, or be contained within any other suitable partition. For example, a well, microwell, hole, or tube may comprise a droplet (e.g., a droplet in an emulsion), a continuous phase in an emulsion, a spot, a capsule, or any other suitable partition. A droplet may comprise a capsule or another droplet. A capsule may comprise a droplet or another capsule. These descriptions are merely illustrative, and all suitable combinations and pluralities are also envisioned. For example, any suitable partition may comprise a plurality of the same or different partitions. In one example, a well or microwell comprises a plurality of droplets and a plurality of capsules. In another example, a capsule comprises a plurality of capsules and a plurality of droplets. All combinations of partitions are envisioned. Table 1 shows non-limiting examples of partitions that may be combined with each other.









TABLE 1







Examples of partitions that may be combined with each other.












Well
Spot
Droplet
Capsule















Well
Well
Spot
Droplet
Capsule



inside well
inside well
inside well
inside well


Spot
Spot
Spot
Droplet
Capsule



inside well
inside spot
inside spot
inside spot


Droplet
Droplet
Droplet
Droplet
Droplet



inside well
inside spot
inside droplet
inside capsule






Capsule






inside droplet


Capsule
Capsule
Capsule
Capsule
Capsule



inside well
inside spot
inside droplet
inside capsule




Spot
Droplet




inside capsule
inside capsule









Any partition described herein may comprise multiple partitions. For example, a partition may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, or 50000 partitions. A partition may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, or 50000 partitions. In some cases, a partition may comprise less than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, or 50000 partitions. In some cases, each partition may comprise 2-50, 2-20, 2-10, or 2-5 partitions.


A partition may comprise any suitable species or mixture of species. For example, in some cases a partition may comprise a reagent, an analyte, a sample, a cell, and combinations thereof. A partition comprising other partitions may comprise certain species in the same partitions and certain species in different partitions. Species may be distributed between any suitable partitions, depending on the needs of the particular process. For example, any of the partitions in Table 1 may contain at least one first species and any of the partitions in Table 1 may contain at least one second species. In some cases the first species may be a reagent and the second species may be an analyte.


In some cases, a species is a polynucleotide isolated from a cell. For example, in some cases polynucleotides (e.g., genomic DNA, RNA, etc.) is isolated from a cell utilizing any suitable method (e.g., a commercially available kit). The polynucleotide may be quantified. The quantified polynucleotide may then be partitioned into a plurality of partitions as described herein. The partitioning of the polynucleotide may be performed at a predetermined coverage amount, according to the quantification and the needs of the assay. In some cases, all or most partitions do not comprise polynucleotides that overlap, such that separate mixtures of non-overlapping fragments are formed across the plurality of partitions. The partitioned polynucleotides may then be treated according to any suitable method known in the art or described in this disclosure. For example, the partitioned polynucleotides may be fragmented, amplified, barcoded, and the like.


Species may be partitioned using a variety of methods. For example, species may be diluted and dispensed across a plurality of partitions. A terminal dilution of a medium comprising species may be performed such that the number of partitions exceeds the number of species. Dilution may also be used prior to forming an emulsion or capsules, or prior to spotting a species on a substrate. The ratio of the number of species to the number of partitions may be about 0.1, 0.5, 1, 2, 4, 8, 10, 20, 50, 100, or 1000. The ratio of the number of species to the number of partitions may be at least about 0.1, 0.5, 1, 2, 4, 8, 10, 20, 50, 100, or 1000. The ratio of the number of species to the number of partitions may be less than about 0.1, 0.5, 1, 2, 4, 8, 10, 20, 50, 100, or 1000. The ratio of the number of species to the number of partitions may range from about 0.1-10, 0.5-10, 1-10, 2-10, 10-100, 100-1000, or more.


Partitioning may also be performed using piezoelectric droplet generation (e.g., Bransky et al., Lab on a Chip, 2009, 9, 516-520) or surface acoustic waves (e.g., Demirci and Montesano, Lab on a Chip, 2007, 7, 1139-1145).


The number of partitions employed may vary depending on the application. For example, the number of partitions may be about 5, 10, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 5000, 7500, or 10,000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100,000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1,000,000, 2000000, 3000000, 4000000, 5000000, 10000000, 20000000 or more. The number of partitions may be at least about 5, 10, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 5000, 7500, 10,000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1000000, 2000000, 3000000, 4000000, 5000000, 10000000, 20000000 or more. The number of partitions may be less than about 5, 10, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 5000, 7500, 10,000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1000000, 2000000, 3000000, 4000000, 5000000, 10000000, or 20000000. The number of partitions may be about 5-10000000, 5-5000000, 5-1,000,000, 10-10,000, 10-5,000, 10-1,000, 1,000-6,000, 1,000-5,000, 1,000-4,000, 1,000-3,000, or 1,000-2,000.


The volume of the partitions may vary depending on the application. For example, the volume of any of the partitions described in this disclosure (e.g., wells, spots, droplets (e.g., in an emulsion), and capsules) may be about 1000 μl, 900 μl, 800 μl, 700 μl, 600 μl, 500 μl, 400 μl, 300 μl, 200 μl, 100 μl, 50 μl, 25 μl, 10 μl, 5 μl, 1 μl, 900 nL, 800 nL, 700 nL, 600 nL, 500 nL, 400 nL, 300 nL, 200 nL, 100 nL, 50 nL, 25 nL, 10 nL, 5 nL, 2.5 nL, 1 nL, 900 pL, 800 pL, 700 pL, 600 pL, 500 pL, 400 pL, 300 pL, 200 pL, 100 pL, 50 pL, 25 pL, 10 pL, 5 pL, 1 pL, 900 fL, 800 fL, 700 fL, 600 fL, 500 fL, 400 fL, 300 fL, 200 fL, 100 fL, 50 fL, 25 fL, 10 fL, 5 fL, 1 fL, or 0.5 fL. The volume of the partitions may be at least about 1000 μl, 900 μl, 800 μl, 700 μl, 600 μl, 500 μl, 400 μl, 300 μl, 200 μl, 100 μl, 50 μl, 25 μl, 10 μl, 5 μl, 1 μl, 900 nL, 800 nL, 700 nL, 600 nL, 500 nL, 400 nL, 300 nL, 200 nL, 100 nL, 50 nL, 25 nL, 10 nL, 5 nL, 5 nL, 2.5 nL, 1 nL, 900 pL, 800 pL, 700 pL, 600 pL, 500 pL, 400 pL, 300 pL, 200 pL, 100 pL, 50 pL, 25 pL, 10 pL, 5 pL, 1 pL, 900 fL, 800 fL, 700 fL, 600 fL, 500 fL, 400 fL, 300 fL, 200 fL, 100 fL, 50 fL, 25 fL, 10 fL, 5 fL, 1 fL, or 0.5 fL. The volume of the partitions may be less than about 1000 μl, 900 μl, 800 μl, 700 μl, 600 μl, 500 μl, 400 μl, 300 μl, 200 μl, 100 μl, 50 μl, 25 μl, 10 μl, 5 μl, 1 μl, 900 nL, 800 nL, 700 nL, 600 nL, 500 nL, 400 nL, 300 nL, 200 nL, 100 nL, 50 nL, 25 nL, 10 nL, 5 nL, 5 nL, 2.5 nL, 1 nL, 900 pL, 800 pL, 700 pL, 600 pL, 500 pL, 400 pL, 300 pL, 200 pL, 100 pL, 50 pL, 25 pL, 10 pL, 5 pL, 1 pL, 900 fL, 800 fL, 700 fL, 600 fL, 500 fL, 400 fL, 300 fL, 200 fL, 100 fL, 50 fL, 25 fL, 10 fL, 5 fL, 1 fL, or 0.5 fL. The volume of the partitions may be about 0.5 fL-5 pL, 10 pL-10 nL, 10 nL-10 μl, 10 μl-100 μl, or 100 μl to 1 mL.


There may be variability in the volume of fluid in different partitions. More specifically, the volume of different partitions may vary by at least (or at most) plus or minus 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, or 1000% across a set of partitions. For example, a well (or other partition) may comprise a volume of fluid that is at most 80% of the fluid volume within a second well (or other partition).


Particular species may also be targeted to specific partitions. For example, in some cases, a capture reagent (e.g., an oligonucleotide probe) may be immobilized or placed within a partition to capture specific species (e.g., polynucleotides).


The number of different species or different sets of species that are partitioned may vary depending upon, for example, the particular species to be partitioned and/or the application. Different sets of species may be, for example, sets of identical species where the identical species differ between each set. Or different sets of species may be, for example, sets of different species, where each set differs in its included species. For example, about 1, 5, 10, 50, 100, 1000, 10000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, 100000000, or more different species or different sets of species may be partitioned. In some examples, at least about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, 100000000, or more different species or different sets of species may be partitioned. In some examples, less than about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, or 100000000 different species or different sets of species may be partitioned. In some examples, about 1-5, 5-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, 100000-1000000, 10000-1000000, 10000-10000000, or 10000-100000000 species may be partitioned.


Species may also be partitioned at a particular density. For example, species may be partitioned so that each partition contains about 1, 5, 10, 50, 100, 1000, 10000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, or 20000000 species per partition. Species may be partitioned so that each partition contains at least about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, or 20000000 or more species per partition. Species may be partitioned so that each partition contains less than about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, or 20000000 species per partition. Species may be partitioned such that each partition contains about 1-5, 5-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, 100000-1000000, 10000-1000000, or 10000-10000000 species per partition.


Species may also be partitioned such that identical species are partitioned at a particular density. For example, identical species may be partitioned so that each partition contains about 1, 5, 10, 50, 100, 1000, 10000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, or 20000000 identical species per partition. Species may be partitioned so that each partition contains at least about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, or 20000000 or more identical species per partition. Species may be partitioned so that each partition contains less than about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, or 20000000 identical species per partition. Species may be partitioned such that each partition contains about 1-5, 5-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, 100000-1000000, 10000-1000000, or 10000-10000000 identical species per partition.


Species may also be partitioned such that different species are partitioned at a particular density. For example, different species may be partitioned so that each partition contains about 1, 5, 10, 50, 100, 1000, 10000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, or 20000000 different species per partition. Species may be partitioned so that each partition contains at least about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, or 20000000 or more different species per partition. Species may be partitioned so that each partition contains less than about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, or 20000000 different species per partition. Species may be partitioned such that each partition contains about 1-5, 5-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, 100000-1000000, 10000-1000000, or 10000-10000000 different species per partition.


As will be appreciated, any of the above-described different numbers of species may be provided with any of the above-described barcode densities per partition, and in any of the above-described numbers of partitions.


Species may be partitioned such that at least one partition comprises a species that is unique within that partition. This may be true for about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more of the partitions. This may be true for at least about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more of the partitions. This may be true for less than about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the partitions.


a. Wells as Partitions


In some cases, wells are used as partitions. The wells may be microwells. With reference to FIG. 1A, a well 101 may comprise a medium 102 comprising a species or plurality of species 103. Species may be contained within a well in various configurations. In one example, a species is dispensed directly into a well (e.g., FIG. 1A). A species dispensed directly into a well may be overlaid with a layer that is, for example, dissolvable, meltable, or permeable 104. This layer may be, for example, an oil, wax, membrane, or the like. The layer may be dissolved or melted prior to or after introduction of another species into the well. The well may be sealed at any point, with a sealing layer 105, for example after addition of any species.


In one example, reagents for sample processing are dispensed directly into a well and overlaid with a layer that is dissolvable, meltable, or permeable. A sample comprising an analyte to be processed is introduced on top of the layer. The layer is dissolved or melted, or the analyte (or reagent) diffuses through the layer. The well is sealed and incubated under appropriate conditions for the processing of the analyte. Processed analyte may then be recovered.


In some cases, wells comprise other partitions. A well may comprise any suitable partition including, for example, with reference to FIG. 1B, another well 106, a spot 107, a droplet (e.g., a droplet in an emulsion) 108, a capsule 109, and the like. Each partition may be present as a single partition or a plurality of partitions, and each partition may comprise the same species or different species.


In one example, a well comprises a capsule comprising reagents for sample processing. A capsule may be loaded into a well using a liquid medium, or loaded into a well without a liquid medium (e.g., essentially dry). As described elsewhere in this disclosure, a capsule may contain one or more capsules, or other partitions. A sample comprising an analyte to be processed is introduced into the well. The well is sealed and a stimulus is applied to cause release of the contents of the capsule into the well, resulting in contact between the reagents and the analyte to be processed. The well is incubated under appropriate conditions for the processing of the analyte. Processed analyte may then be recovered. While this example describes an embodiment where a reagent is in a capsule and an analyte is in the well, the opposite configuration—i.e., reagent in the well and analyte in the capsule—is also possible.


In another example, a well comprises an emulsion and the droplets of the emulsion comprise capsules comprising reagents for sample processing. A sample comprising an analyte to be processed is contained within the droplets of the emulsion. The well is sealed and a stimulus is applied to cause release of the contents of the capsules into the droplets, resulting in contact between the reagents and the analyte to be processed. The well is incubated under appropriate conditions for the processing of the analyte. Processed analyte may then be recovered. While this example describes an embodiment where a reagent is in a capsule and an analyte is in a droplet, the opposite configuration—i.e., reagent in the droplet and analyte in the capsule—is also possible.


Wells may be arranged as an array, for example a microwell array. Based on the dimensions of individual wells and the size of the substrate, the well array may comprise a range of well densities. In some cases, the well density may be 10 wells/cm2, 50 wells/cm2, 100 wells/cm2, 500 wells/cm2, 1000 wells/cm2, 5000 wells/cm2, 10000 wells/cm2, 50000 wells/cm2, or 100000 wells/cm2. In some cases, the well density may be at least 10 wells/cm2, 50 wells/cm2, 100 wells/cm2, 500 wells/cm2, 1000 wells/cm2, 5000 wells/cm2, 10000 wells/cm2, 50000 wells/cm2, or 100000 wells/cm2. In some cases, the well density may be less than 10 wells/cm2, 50 wells/cm2, 100 wells/cm2, 500 wells/cm2, 1000 wells/cm2, 5000 wells/cm2, 10000 wells/cm2, 50000 wells/cm2, or 100000 wells/cm2.


b. Spots as Partitions


In some cases, spots are used as partitions. With reference to FIG. 2A, a spot may be made, for example, by dispensing a substance 201 on a surface 202. Species may be contained within a spot in various configurations. In one example, a species is dispensed directly into a spot by including the species in the medium used to form the spot. A species dispensed directly onto a spot may be overlaid with a layer that is, for example, dissolvable, meltable, or permeable 203. This layer may be, for example, an oil, wax, membrane, or the like. The layer may be dissolved or melted prior to or after introduction of another species onto the spot. The spot may be sealed at any point, for example after addition of any species, by an overlay 204.


In one example, reagents for sample processing are dispensed directly onto a spot, for example on a glass slide, and overlaid with a layer that is dissolvable, meltable, or permeable. A sample comprising an analyte to be processed is introduced on top of the layer. The layer is dissolved or melted, or the analyte (or reagent) diffuses through the layer. The spot is sealed and incubated under appropriate conditions for the processing of the analyte. Processed analyte may then be recovered.


As described elsewhere in this disclosure (e.g., Table 1), spots may also be arranged within a well. In some cases, a plurality of spots may be arranged within a well such that the contents of each spot do not mix. Such a configuration may be useful, for example, when it is desirable to prevent species from contacting each other. In some cases, a well may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more spots. In some cases, a well may comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more spots. In some cases, a well may comprise less than 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 spots. In some cases, a well may comprise 2-4, 2-6, 2-8, 4-6, 4-8, 5-10, or 4-12 spots. Upon addition of a substance (e.g., a medium containing an analyte) to the well, the species in the spot may mix. Moreover, using separate spots to contain different species (or combinations of species) may also be useful to prevent cross-contamination of devices used to place the spots inside the well.


In some cases, spots comprise other partitions. A spot may comprise any suitable partition including, for example, with reference to FIG. 2B, another spot 205, a droplet (e.g., a droplet in an emulsion) 206, a capsule 207, and the like. Each partition may be present as a single partition or a plurality of partitions, and each partition may comprise the same species or different species.


In one example, a spot comprises a capsule comprising reagents for sample processing. As described elsewhere in this disclosure, a capsule may contain one or more capsules, or other partitions. A sample comprising an analyte to be processed is introduced into the spot. The spot is sealed and a stimulus is applied to cause release of the contents of the capsule into the spot, resulting in contact between the reagents and the analyte to be processed. The spot is incubated under appropriate conditions for the processing of the analyte. Processed analyte may then be recovered. While this example describes an embodiment where a reagent is in a capsule and an analyte is in the spot, the opposite configuration—i.e., reagent in the spot and analyte in the capsule—is also possible.


In another example, a spot comprises an emulsion and the droplets of the emulsion comprise capsules comprising reagents for sample processing. A sample comprising an analyte to be processed is contained within the droplets of the emulsion. The spot is sealed and a stimulus is applied to cause release of the contents of the capsules into the droplets, resulting in contact between the reagents and the analyte to be processed. The spot is incubated under appropriate conditions for the processing of the analyte. Processed analyte may then be recovered. While this example describes an embodiment where a reagent is in a capsule and an analyte is in a droplet, the opposite configuration—i.e., reagent in the droplet and analyte in the capsule—is also possible.


Spots may be of uniform size or heterogeneous size. In some cases, the diameter of a spot may be about 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, 1 mm, 2 mm, 5 mm, or 1 cm. A spot may have a diameter of at least about 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, 1 mm, 1 mm, 2 mm, 5 mm, or 1 cm. In some cases, a spot may have a diameter of less than about 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, 1 mm, 1 mm, 2 mm, 5 mm, or 1 cm. In some cases, a spot may have a diameter of about 0.1 μm to 1 cm, 100 μm to 1 mm, 100 μm to 500 μm, 100 μm to 600 μm, 150 μm to 300 μm, or 150 μm to 400 μm.


Spots may be arranged as an array, for example a spot array. Based on the dimensions of individual spots and the size of the substrate, the spot array may comprise a range of spot densities. In some cases, the spot density may be 10 spots/cm2, 50 spots/cm2, 100 spots/cm2, 500 spots/cm2, 1000 spots/cm2, 5000 spots/cm2, 10000 spots/cm2, 50000 spots/cm2, or 100000 spots/cm2. In some cases, the spot density may be at least 10 spots/cm2, 50 spots/cm2, 100 spots/cm2, 500 spots/cm2, 1000 spots/cm2, 5000 spots/cm2, 10000 spots/cm2, 50000 spots/cm2, or 100000 spots/cm2. In some cases, the spot density may be less than 10 spots/cm2, 50 spots/cm2, 100 spots/cm2, 500 spots/cm2, 1000 spots/cm2, 5000 spots/cm2, 10000 spots/cm2, 50000 spots/cm2, or 100000 spots/cm2.


c. Emulsions as Partitions


In some cases, the droplets in an emulsion are used as partitions. An emulsion may be prepared, for example, by any suitable method, including methods known in the art. (See e.g., Weizmann et al., Nature Methods, 2006, 3(7):545-550; Weitz et al. U.S. Pub. No. 2012/0211084). In some cases, water-in-fluorocarbon emulsions may be used. These emulsions may incorporate fluorosurfactants such as oligomeric perfluorinated polyethers (PFPE) with polyethylene glycol (PEG). (Holtze et al., Lab on a Chip, 2008, 8(10):1632-1639). In some cases, monodisperse emulsions may be formed in a microfluidic flow focusing device. (Garstecki et al., Applied Physics Letters, 2004, 85(13):2649-2651).



FIG. 3A illustrates exemplary embodiments. With reference to FIG. 3A, a species may be contained within a droplet 301 in an emulsion containing, for example, a first phase (e.g., oil or water) forming the droplet 301 and a second (continuous) phase (e.g., water or oil) 302. An emulsion may be a single emulsion, for example, a water-in-oil or an oil-in-water emulsion. An emulsion may be a double emulsion, for example a water-in-oil-in-water or an oil-in-water-in-oil emulsion. Higher-order emulsions are also possible. The emulsion may be held in any suitable container, including any suitable partition described in this disclosure.


In some cases, droplets in an emulsion comprise other partitions. A droplet in an emulsion may comprise any suitable partition including, for example, with reference to FIG. 3B, another droplet (e.g., a droplet in an emulsion) 303, a capsule 304, and the like. Each partition may be present as a single partition or a plurality of partitions, and each partition may comprise the same species or different species.


In one example, a droplet in an emulsion comprises a capsule comprising reagents for sample processing. As described elsewhere in this disclosure, a capsule may contain one or more capsules, or other partitions. A sample comprising an analyte to be processed is contained within the droplet. A stimulus is applied to cause release of the contents of the capsule into the droplet, resulting in contact between the reagents and the analyte to be processed. The droplet is incubated under appropriate conditions for the processing of the analyte. Processed analyte may then be recovered. While this example describes an embodiment where a reagent is in a capsule and an analyte is in the droplet, the opposite configuration—i.e., reagent in the droplet and analyte in the capsule—is also possible.


The droplets in an emulsion may be of uniform size or heterogeneous size. In some cases, the diameter of a droplet in an emulsion may be about 0.001 μm, 0.01 μm, 0.05 μm, 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1 mm. A droplet may have a diameter of at least about 0.001 μm, 0.01 μm, 0.05 μm, 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1 mm. In some cases, a droplet may have a diameter of less than about 0.001 μm, 0.01 μm, 0.05 μm, 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1 mm. In some cases, a droplet may have a diameter of about 0.001 μm to 1 mm, 0.01 μm to 900 μm, 0.1 μm to 600 μm, 100 μm to 200 μm, 100 μm to 300 μm, 100 μm to 400 μm, 100 μm to 500 μm, 100 μm to 600 μm, 150 μm to 200 μm, 150 μm to 300 μm, or 150 μm to 400 μm.


Droplets in an emulsion also may have a particular density. In some cases, the droplets are less dense than an aqueous fluid (e.g., water); in some cases, the droplets are denser than an aqueous fluid. In some cases, the droplets are less dense than a non-aqueous fluid (e.g., oil); in some cases, the droplets are denser than a non-aqueous fluid. Droplets may have a density of about 0.05 g/cm3, 0.1 g/cm3, 0.2 g/cm3, 0.3 g/cm3, 0.4 g/cm3, 0.5 g/cm3, 0.6 g/cm3, 0.7 g/cm3, 0.8 g/cm3, 0.81 g/cm3, 0.82 g/cm3, 0.83 g/cm3, 0.84 g/cm3, 0.85 g/cm3, 0.86 g/cm3, 0.87 g/cm3, 0.88 g/cm3, 0.89 g/cm3, 0.90 g/cm3, 0.91 g/cm3, 0.92 g/cm3, 0.93 g/cm3, 0.94 g/cm3, 0.95 g/cm3, 0.96 g/cm3, 0.97 g/cm3, 0.98 g/cm3, 0.99 g/cm3, 1.00 g/cm3, 1.05 g/cm3, 1.1 g/cm3, 1.2 g/cm3, 1.3 g/cm3, 1.4 g/cm3, 1.5 g/cm3, 1.6 g/cm3, 1.7 g/cm3, 1.8 g/cm3, 1.9 g/cm3, 2.0 g/cm3, 2.1 g/cm3, 2.2 g/cm3, 2.3 g/cm3, 2.4 g/cm3, or 2.5 g/cm3. Droplets may have a density of at least about 0.05 g/cm3, 0.1 g/cm3, 0.2 g/cm3, 0.3 g/cm3, 0.4 g/cm3, 0.5 g/cm3, 0.6 g/cm3, 0.7 g/cm3, 0.8 g/cm3, 0.81 g/cm3, 0.82 g/cm3, 0.83 g/cm3, 0.84 g/cm3, 0.85 g/cm3, 0.86 g/cm3, 0.87 g/cm3, 0.88 g/cm3, 0.89 g/cm3, 0.90 g/cm3, 0.91 g/cm3, 0.92 g/cm3, 0.93 g/cm3, 0.94 g/cm3, 0.95 g/cm3, 0.96 g/cm3, 0.97 g/cm3, 0.98 g/cm3, 0.99 g/cm3, 1.00 g/cm3, 1.05 g/cm3, 1.1 g/cm3, 1.2 g/cm3, 1.3 g/cm3, 1.4 g/cm3, 1.5 g/cm3, 1.6 g/cm3, 1.7 g/cm3, 1.8 g/cm3, 1.9 g/cm3, 2.0 g/cm3, 2.1 g/cm3, 2.2 g/cm3, 2.3 g/cm3, 2.4 g/cm3, or 2.5 g/cm3. In other cases, droplet densities may be at most about 0.7 g/cm3, 0.8 g/cm3, 0.81 g/cm3, 0.82 g/cm3, 0.83 g/cm3, 0.84 g/cm3, 0.85 g/cm3, 0.86 g/cm3, 0.87 g/cm3, 0.88 g/cm3, 0.89 g/cm3, 0.90 g/cm3, 0.91 g/cm3, 0.92 g/cm3, 0.93 g/cm3, 0.94 g/cm3, 0.95 g/cm3, 0.96 g/cm3, 0.97 g/cm3, 0.98 g/cm3, 0.99 g/cm3, 1.00 g/cm3, 1.05 g/cm3, 1.1 g/cm3, 1.2 g/cm3, 1.3 g/cm3, 1.4 g/cm3, 1.5 g/cm3, 1.6 g/cm3, 1.7 g/cm3, 1.8 g/cm3, 1.9 g/cm3, 2.0 g/cm3, 2.1 g/cm3, 2.2 g/cm3, 2.3 g/cm3, 2.4 g/cm3, or 2.5 g/cm3. Such densities can reflect the density of the capsule in any particular fluid (e.g., aqueous, water, oil, etc.)


d. Capsules as Partitions


In some cases, capsules are used as partitions. With reference to FIG. 4A, a capsule 401 may be prepared by any suitable method, including methods known in the art, including emulsification polymerization (Weitz et al. (U.S. Pub. No. 2012/0211084)), layer-by-layer assembly with polyelectrolytes, coacervation, internal phase separation, and flow focusing. Any suitable species may be contained within a capsule. The capsule may be held in any suitable container, including any suitable partition described in this disclosure.


In some cases, capsules comprise other partitions. A capsule may comprise any suitable partition including, for example, with reference to FIG. 4B, another capsule 402, a droplet in an emulsion 403, and the like. Each partition may be present as a single partition or a plurality of partitions, and each partition may comprise the same species or different species.


In one example, an outer capsule comprises an inner capsule. The inner capsule comprises reagents for sample processing. An analyte is encapsulated in the medium between the inner capsule and the outer capsule. A stimulus is applied to cause release of the contents of the inner capsule into the outer capsule, resulting in contact between the reagents and the analyte to be processed. The outer capsule is incubated under appropriate conditions for the processing of the analyte. Processed analyte may then be recovered. While this example describes an embodiment where a reagent is in an inner capsule and an analyte in the medium between the inner capsule and the outer capsule, the opposite configuration—i.e., reagent in the medium between the inner capsule and the outer capsule, and analyte in the inner capsule—is also possible.


Capsules may be pre-formed and filled with reagents by injection. For example, the picoinjection methods described in Abate et al. (Proc. Natl. Acad. Sci. U.S.A., 2010, 107(45), 19163-19166) and Weitz et al. (U.S. Pub. No. 2012/0132288) may be used to introduce reagents into the interior of capsules described herein. Generally, the picoinjection will be performed prior to the hardening of the capsule shell, for example by injecting species into the interior of a capsule precursor, such as a droplet of an emulsion, before formation of the capsule shell.


Capsules may be of uniform size or heterogeneous size. In some cases, the diameter of a capsule may be about 0.001 μm, 0.01 μm, 0.05 μm, 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1 mm. A capsule may have a diameter of at least about 0.001 μm, 0.01 μm, 0.05 μm, 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1 mm. In some cases, a capsule may have a diameter of less than about 0.001 μm, 0.01 μm, 0.05 μm, 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm, 150 μm, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, or 1 mm. In some cases, a capsule may have a diameter of about 0.001 μm to 1 mm, 0.01 μm to 900 μm, 0.1 μm to 600 μm, 100 μm to 200 μm, 100 μm to 300 μm, 100 μm to 400 μm, 100 μm to 500 μm, 100 μm to 600 μm, 150 μm to 200 μm, 150 μm to 300 μm, or 150 μm to 400 μm.


Capsules also may have a particular density. In some cases, the capsules are less dense than an aqueous fluid (e.g., water); in some cases, the capsules are denser than an aqueous fluid. In some cases, the capsules are less dense than a non-aqueous fluid (e.g., oil); in some cases, the capsules are denser than a non-aqueous fluid. Capsules may have a density of about 0.05 g/cm3, 0.1 g/cm3, 0.2 g/cm3, 0.3 g/cm3, 0.4 g/cm3, 0.5 g/cm3, 0.6 g/cm3, 0.7 g/cm3, 0.8 g/cm3, 0.81 g/cm3, 0.82 g/cm3, 0.83 g/cm3, 0.84 g/cm3, 0.85 g/cm3, 0.86 g/cm3, 0.87 g/cm3, 0.88 g/cm3, 0.89 g/cm3, 0.90 g/cm3, 0.91 g/cm3, 0.92 g/cm3, 0.93 g/cm3, 0.94 g/cm3, 0.95 g/cm3, 0.96 g/cm3, 0.97 g/cm3, 0.98 g/cm3, 0.99 g/cm3, 1.00 g/cm3, 1.05 g/cm3, 1.1 g/cm3, 1.2 g/cm3, 1.3 g/cm3, 1.4 g/cm3, 1.5 g/cm3, 1.6 g/cm3, 1.7 g/cm3, 1.8 g/cm3, 1.9 g/cm3, 2.0 g/cm3, 2.1 g/cm3, 2.2 g/cm3, 2.3 g/cm3, 2.4 g/cm3, or 2.5 g/cm3. Capsules may have a density of at least about 0.05 g/cm3, 0.1 g/cm3, 0.2 g/cm3, 0.3 g/cm3, 0.4 g/cm3, 0.5 g/cm3, 0.6 g/cm3, 0.7 g/cm3, 0.8 g/cm3, 0.81 g/cm3, 0.82 g/cm3, 0.83 g/cm3, 0.84 g/cm3, 0.85 g/cm3, 0.86 g/cm3, 0.87 g/cm3, 0.88 g/cm3, 0.89 g/cm3, 0.90 g/cm3, 0.91 g/cm3, 0.92 g/cm3, 0.93 g/cm3, 0.94 g/cm3, 0.95 g/cm3, 0.96 g/cm3, 0.97 g/cm3, 0.98 g/cm3, 0.99 g/cm3, 1.00 g/cm3, 1.05 g/cm3, 1.1 g/cm3, 1.2 g/cm3, 1.3 g/cm3, 1.4 g/cm3, 1.5 g/cm3, 1.6 g/cm3, 1.7 g/cm3, 1.8 g/cm3, 1.9 g/cm3, 2.0 g/cm3, 2.1 g/cm3, 2.2 g/cm3, 2.3 g/cm3, 2.4 g/cm3, or 2.5 g/cm3. In other cases, capsule densities may be at most about 0.7 g/cm3, 0.8 g/cm3, 0.81 g/cm3, 0.82 g/cm3, 0.83 g/cm3, 0.84 g/cm3, 0.85 g/cm3, 0.86 g/cm3, 0.87 g/cm3, 0.88 g/cm3, 0.89 g/cm3, 0.90 g/cm3, 0.91 g/cm3, 0.92 g/cm3, 0.93 g/cm3, 0.94 g/cm3, 0.95 g/cm3, 0.96 g/cm3, 0.97 g/cm3, 0.98 g/cm3, 0.99 g/cm3, 1.00 g/cm3, 1.05 g/cm3, 1.1 g/cm3, 1.2 g/cm3, 1.3 g/cm3, 1.4 g/cm3, 1.5 g/cm3, 1.6 g/cm3, 1.7 g/cm3, 1.8 g/cm3, 1.9 g/cm3, 2.0 g/cm3, 2.1 g/cm3, 2.2 g/cm3, 2.3 g/cm3, 2.4 g/cm3, or 2.5 g/cm3. Such densities can reflect the density of the capsule in any particular fluid (e.g., aqueous, water, oil, etc.)


1. Production of Capsules by Flow Focusing


In some cases, capsules may be produced by flow focusing. Flow focusing is a method whereby a first fluid that is immiscible with a second fluid is flowed into the second fluid. With reference to FIG. 5, a first (e.g., aqueous) fluid comprising a monomer, crosslinker, initiator, and aqueous surfactant 501 is flowed into a second (e.g., oil) fluid comprising a surfactant and an accelerator 502. After entering the second fluid at a T-junction in a microfluidic device 503, a droplet of first fluid breaks off from the first fluid stream and a capsule shell begins to form 504 due to the mixing of the monomer, crosslinker, and initiator in the first fluid and the accelerator in the second fluid. Thus, a capsule is formed. As the capsule proceeds downstream, the shell becomes thicker due to increased exposure to the accelerator. Varying the concentrations of the reagents may also be used to vary the thickness and permeability of the capsule shell.


A species, or other partition such as a droplet, may be encapsulated by, for example, including the species in the first fluid. Including the species in the second fluid may embed the species in the shell of the capsule. Of course, depending on the needs of the particular sample processing method, the phases may also be reversed—i.e., the first phase may be an oil phase and the second phase may be an aqueous phase.


2. Production of Capsules Within Capsules by Flow Focusing


In some cases, capsules within capsules may be produced by flow focusing. With reference to FIG. 6, a first (e.g., aqueous) fluid comprising a capsule, monomer, crosslinker, initiator, and aqueous surfactant 601 is flowed into a second (oil) fluid comprising a surfactant and an accelerator 602. After entering the second fluid at a T-junction in a microfluidic device 603, a droplet of first fluid breaks off from the first fluid stream and a second capsule shell begins to form around the capsule 604 due to the mixing of the monomer, crosslinker, and initiator in the first fluid and the accelerator in the second fluid. Thus, a capsule within a capsule is formed. As the capsule proceeds downstream, the shell becomes thicker due to increased exposure to the accelerator. Varying the concentrations of the reagents may also be used to vary the thickness and permeability of the second capsule shell.


A species may be encapsulated by, for example, including the species in the first fluid. Including the species in the second fluid may embed the species in the second shell of the capsule. Of course, depending on the needs of the particular sample processing method, the phases may also be reversed—i.e., the first phase may be an oil phase and the second phase may be an aqueous phase.


3. Production of Capsules in Batch


In some cases, capsules may be produced in batch, using capsule precursors, such as the droplets in an emulsion. With reference to FIG. 7, capsule precursors 701 may be formed by any suitable method, for example by producing an emulsion with droplets comprising a monomer, a crosslinker, an initiator, and a surfactant. An accelerator may then be added to the medium, resulting in the formation of capsules 702. As for the methods of flow focusing, the thickness of the shell can be varied by varying the concentrations of the reactants, and the time of exposure to the accelerator. The capsules may then be washed and recovered. As for any method described herein, a species, including other partitions, may be encapsulated within the capsule or, if suitable, within the shell.


In another example, the droplets of an emulsion may be exposed to an accelerator that is present in an outlet well during the emulsion generation process. For example, capsule precursors may be formed by any suitable method, such as the flow focusing method illustrated in FIG. 5. Rather than including the accelerator in second fluid 502, the accelerator may be included in a medium located at the exit of the T-junction (e.g., a medium located at the far-right of the horizontal channel of FIG. 5. As the emulsion droplets (i.e., capsule precursors) exit the channel, they contact the medium comprising the accelerator (i.e., the outlet medium). If the capsule precursor has a density that is less than the density of outlet medium, the capsule precursors will rise through the medium, ensuring convectional and diffusional exposure to the accelerator and reducing the likelihood of polymerization at the outlet of the channel.


III. Species

The methods, compositions, systems, devices, and kits of this disclosure may be used with any suitable species. A species can be, for example, any substance used in sample processing, such as a reagent or an analyte. Exemplary species include whole cells, chromosomes, polynucleotides, organic molecules, proteins, polypeptides, carbohydrates, saccharides, sugars, lipids, enzymes, restriction enzymes, ligases, polymerases, barcodes, adapters, small molecules, antibodies, fluorophores, deoxynucleotide triphosphates (dNTPs), dideoxynucleotide triphosphates (ddNTPs), buffers, acidic solutions, basic solutions, temperature-sensitive enzymes, pH-sensitive enzymes, light-sensitive enzymes, metals, metal ions, magnesium chloride, sodium chloride, manganese, aqueous buffer, mild buffer, ionic buffer, inhibitors, saccharides, oils, salts, ions, detergents, ionic detergents, non-ionic detergents, oligonucleotides, nucleotides, DNA, RNA, peptide polynucleotides, complementary DNA (cDNA), double stranded DNA (dsDNA), single stranded DNA (ssDNA), plasmid DNA, cosmid DNA, chromosomal DNA, genomic DNA, viral DNA, bacterial DNA, mtDNA (mitochondrial DNA), mRNA, rRNA, tRNA, nRNA, siRNA, snRNA, snoRNA, scaRNA, microRNA, dsRNA, ribozyme, riboswitch and viral RNA, a locked nucleic acid (LNA) in whole or part, locked nucleic acid nucleotides, any other type of nucleic acid analogue, proteases, nucleases, protease inhibitors, nuclease inhibitors, chelating agents, reducing agents, oxidizing agents, probes, chromophores, dyes, organics, emulsifiers, surfactants, stabilizers, polymers, water, small molecules, pharmaceuticals, radioactive molecules, preservatives, antibiotics, aptamers, and the like. In summary, the species that are used will vary depending on the particular sample processing needs.


In some cases, a partition comprises a set of species that have a similar attribute (e.g., a set of enzymes, a set of minerals, a set of oligonucleotides, a mixture of different barcodes, a mixture of identical barcodes). In other cases, a partition comprises a heterogeneous mixture of species. In some cases, the heterogeneous mixture of species comprises all components necessary to perform a particular reaction. In some cases, such mixture comprises all components necessary to perform a reaction, except for 1, 2, 3, 4, 5, or more components necessary to perform the reaction. In some cases, such additional components are contained within a different partition or within a solution within or surrounding a partition.


A species may be naturally-occurring or synthetic. A species may be present in a sample obtained using any methods known in the art. In some cases, a sample may be processed before analyzing it for an analyte.


A species may be obtained from any suitable location, including from organisms, whole cells, cell preparations and cell-free compositions from any organism, tissue, cell, or environment. A species may be obtained from environmental samples, biopsies, aspirates, formalin fixed embedded tissues, air, agricultural samples, soil samples, petroleum samples, water samples, or dust samples. In some instances, a species may be obtained from bodily fluids which may include blood, urine, feces, serum, lymph, saliva, mucosal secretions, perspiration, central nervous system fluid, vaginal fluid, or semen. Species may also be obtained from manufactured products, such as cosmetics, foods, personal care products, and the like. Species may be the products of experimental manipulation including, recombinant cloning, polynucleotide amplification, polymerase chain reaction (PCR) amplification, purification methods (such as purification of genomic DNA or RNA), and synthesis reactions.


In some cases, a species may quantified by mass. A species may be provided in a mass of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000 ng, 1 μg, 5 μg, 10 μg, 15 μg, or 20 μg. A species may be provided in a mass of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000 ng, 1 μg, 5 μg, 10 μg, 15 μg, or 20 μg. A species may be provided in a mass of less than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000 ng 1 μg, 5 μg, 10 μg, 15 μg, or 20 μg. A species may be provided in a mass ranging from about 1-10, 10-50, 50-100, 100-200, 200-1000, 1000-10000 ng, 1-5 μg, or 1-20 μg. As described elsewhere in this disclosure, if a species is a polynucleotide, amplification may be used to increase the quantity of a polynucleotide.


Polynucleotides may also be quantified as “genome equivalents.” A genome equivalent is an amount of polynucleotide equivalent to one haploid genome of an organism from which the target polynucleotide is derived. For example, a single diploid cell contains two genome equivalents of DNA. Polynucleotides may be provided in an amount ranging from about 1-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, or 100000-1000000 genome equivalents. Polynucleotides may be provided in an amount of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 20000, 30000, 40000, 50000, 60000 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, or 1000000 genome equivalents. Polynucleotides may be provided in an amount less than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 20000, 30000, 40000, 50000, 60000 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, or 1000000 genome equivalents.


Polynucleotides may also be quantified by the amount of sequence coverage provided. The amount of sequence coverage refers to the average number of reads representing a given nucleotide in a reconstructed sequence. Generally, the greater the number of times a region is sequenced, the more accurate the sequence information obtained. Polynucleotides may be provided in an amount that provides a range of sequence coverage from about 0.1×-10×, 10-×-50×, 50×-100×, 100×-200×, or 200×-500×. Polynucleotides may be provided in an amount that provides at least about 0.1×, 0.2×, 0.3×, 0.4×, 0.5×, 0.6×, 0.7×, 0.8×, 0.9×, 1.0×, 5×, 10×, 25×, 50×, 100×, 125×, 150×, 175×, or 200× sequence coverage. Polynucleotides may be provided in an amount that provides less than about 0.2×, 0.3×, 0.4×, 0.5×, 0.6×, 0.7×, 0.8×, 0.9×, 1.0×, 5×, 10×, 25×, 50×, 100×, 125×, 150×, 175×, or 200× sequence coverage.


In some cases, species are introduced into a partition either before or after a particular step. For example, a lysis buffer reagent may be introduced into a partition following partitioning of a cellular sample into the partitions. In some cases, reagents and/or partitions comprising reagents are introduced sequentially such that different reactions or operations occur at different steps. The reagents (or partitions comprising reagents) may be also be loaded at steps interspersed with a reaction or operation step. For example, capsules comprising reagents for fragmenting molecules (e.g., nucleic acids) may be loaded into a well, followed by a fragmentation step, which may be followed by loading of capsules comprising reagents for ligating barcodes (or other unique identifiers, e.g., antibodies) and subsequent ligation of the barcodes to the fragmented molecules.


IV. Processing of Analytes and Other Species

In some cases, the methods, compositions, systems, devices, and kits of this disclosure may be used to process a sample containing a species, for example an analyte. Any suitable process can be performed.


a. Fragmentation of Target Polynucleotides


In some cases, the methods, compositions, systems, devices, and kits of this disclosure may be used for polynucleotide fragmentation. Fragmentation of polynucleotides is used as a step in a variety of methods, including polynucleotide sequencing. The size of the polynucleotide fragments, typically described in terms of length (quantified by the linear number of nucleotides per fragment), may vary depending on the source of the target polynucleotide, the method used for fragmentation, and the desired application. A single fragmentation step or a plurality of fragmentation steps may be used.


Fragments generated using the methods described herein may be about 1-10, 10-20, 20-50, 50-100, 50-200, 100-200, 200-300, 300-400, 400-500, 500-1000, 1000-5000, 5000-10000, 10000-100000, 100000-250000, or 250000-500000 nucleotides in length. Fragments generated using the methods described herein may be at least about 10, 20, 100, 200, 300, 400, 500, 1000, 5000, 10000, 100000, 250000, 500000, or more nucleotides in length. Fragments generated using the methods described herein may be less than about 10, 20, 100, 200, 300, 400, 500, 1000, 5000, 10000, 100000, 250000, 500000, nucleotides in length.


Fragments generated using the methods described herein may have a mean or median length of about 1-10, 10-20, 20-50, 50-100, 50-200, 100-200, 200-300, 300-400, 400-500, 500-1000, 1000-5000, 5000-10000, 10000-100000, 100000-250000, or 250000-500000 nucleotides. Fragments generated using the methods described herein may have a mean or median length of at least about 10, 20, 100, 200, 300, 400, 500, 1000, 5000, 10000, 100000, 250000, 500000, or more nucleotides. Fragments generated using the methods described herein may have a mean or median length of less than about 10, 20, 100, 200, 300, 400, 500, 1000, 5000, 10000, 100000, 250000, 500000, nucleotides.


Numerous fragmentation methods are known in the art. For example, fragmentation may be performed through physical, mechanical or enzymatic methods. Physical fragmentation may include exposing a target polynucleotide to heat or to UV light. Mechanical disruption may be used to mechanically shear a target polynucleotide into fragments of the desired range. Mechanical shearing may be accomplished through a number of methods known in the art, including repetitive pipetting of the target polynucleotide, sonication (e.g., using ultrasonic waves), cavitation and nebulization. Target polynucleotides may also be fragmented using enzymatic methods. In some cases, enzymatic digestion may be performed using enzymes such as using restriction enzymes.


While the methods of fragmentation described in the preceding paragraph, and in some paragraphs of the disclosure, are described with reference to “target” polynucleotides, this is not meant to be limiting, above or anywhere else in this disclosure. Any method of fragmentation described herein, or known in the art, can be applied to any polynucleotide used with the invention. In some cases, this polynucleotide may be a target polynucleotide, such as a genome. In other cases, this polynucleotide may be a fragment of a target polynucleotide which one wishes to further fragment. In still other cases, still further fragments may be still further fragmented. Any suitable polynucleotide may be fragmented according the methods described herein.


Restriction enzymes may be used to perform specific or non-specific fragmentation of target polynucleotides. The methods of the present disclosure may use one or more types of restriction enzymes, generally described as Type I enzymes, Type II enzymes, and/or Type III enzymes. Type II and Type III enzymes are generally commercially available and well known in the art. Type II and Type III enzymes recognize specific sequences of nucleotide base pairs within a double stranded polynucleotide sequence (a “recognition sequence” or “recognition site”). Upon binding and recognition of these sequences, Type II and Type III enzymes cleave the polynucleotide sequence. In some cases, cleavage will result in a polynucleotide fragment with a portion of overhanging single stranded DNA, called a “sticky end.” In other cases, cleavage will not result in a fragment with an overhang, creating a “blunt end.” The methods of the present disclosure may comprise use of restriction enzymes that generate either sticky ends or blunt ends.


Restriction enzymes may recognize a variety of recognition sites in the target polynucleotide. Some restriction enzymes (“exact cutters”) recognize only a single recognition site (e.g., GAATTC). Other restriction enzymes are more promiscuous, and recognize more than one recognition site, or a variety of recognition sites. Some enzymes cut at a single position within the recognition site, while others may cut at multiple positions. Some enzymes cut at the same position within the recognition site, while others cut at variable positions.


The present disclosure provides method of selecting one or more restriction enzymes to produce fragments of a desired length. Polynucleotide fragmentation may be simulated in silico, and the fragmentation may be optimized to obtain the greatest number or fraction of polynucleotide fragments within a particular size range, while minimizing the number or fraction of fragments within undesirable size ranges. Optimization algorithms may be applied to select a combination of two or more enzymes to produce the desired fragment sizes with the desired distribution of fragments quantities.


A polynucleotide may be exposed to two or more restriction enzymes simultaneously or sequentially. This may be accomplished by, for example, adding more than one restriction enzyme to a partition, or by adding one restriction enzyme to a partition, performing the digestion, deactivating the restriction enzyme (e.g., by heat treatment) and then adding a second restriction enzyme. Any suitable restriction enzyme may be used alone, or in combination, in the methods presented herein.


In some cases, a species is a restriction enzyme that is a “rare-cutter.” The term “rare-cutter enzyme,” as used herein, generally refers to an enzyme with a recognition site that occurs only rarely in a genome. The size of restriction fragments generated by cutting a hypothetical random genome with a restriction enzyme may be approximated by 4N, where N is the number of nucleotides in the recognition site of the enzyme. For example, an enzyme with a recognition site consisting of 7 nucleotides would cut a genome once every 47 bp, producing fragments of about 16,384 bp. Generally rare-cutter enzymes have recognition sites comprising 6 or more nucleotides. For example, a rare cutter enzyme may have a recognition site comprising or consisting of 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides. Examples of rare-cutter enzymes include NotI (GCGGCCGC), XmaIII (CGGCCG), SstII (CCGCGG), SalI (GTCGAC), NruI (TCGCGA), NheI (GCTAGC), Nb.BbvCI (CCTCAGC), BbvCI (CCTCAGC), AscI (GGCGCGCC), AsiSI (GCGATCGC), FseI (GGCCGGCC), PacI (TTAATTAA), PmeI (GTTTAAAC), SbfI (CCTGCAGG), SgrAI (CRCCGGYG), SwaI (ATTTAAAT), BspQI (GCTCTTC), SapI (GCTCTTC), SfiI (GGCCNNNNNGGCC), CspCI (CAANNNNNGTGG), AbsI (CCTCGAGG), CciNI (GCGGCCGC), FspAI (RTGCGCAY), MauBI (CGCGCGCG), MreI (CGCCGGCG), MssI (GTTTAAAC), PalAI (GGCGCGCC), RgaI (GCGATCGC), RigI (GGCCGGCC), SdaI (CCTGCAGG), SfaAI (GCGATCGC), SgfI (GCGATCGC), SgrDI (CGTCGACG), SgsI (GGCGCGCC), SmiI (ATTTAAAT), SrfI (GCCCGGGC), Sse2321 (CGCCGGCG), Sse83871 (CCTGCAGG), LguI (GCTCTTC), PciSI (GCTCTTC), AarI (CACCTGC), AjuI (GAANNNNNNNTTGG), AloI (GAACNNNNNNTCC), BarI (GAAGNNNNNNTAC), PpiI (GAACNNNNNCTC), PsrI (GAACNNNNNNTAC), and others.


In some cases, polynucleotides may be fragmented and barcoded at the same time. For example, a transposase (e.g., NEXTERA) may be used to fragment a polynucleotide and add a barcode to the polynucleotide.


b. Barcoding


Certain downstream applications, for example polynucleotide sequencing, may rely on the barcodes to identify the origin of a sequence and, for example, to assemble a larger sequence from sequenced fragments. Therefore, it may be desirable to add barcodes to polynucleotide fragments before sequencing. Barcodes may be of a variety of different formats, including polynucleotide barcodes. Depending upon the specific application, barcodes may be attached to polynucleotide fragments in a reversible or irreversible manner. Barcodes may also allow for identification and/or quantification of individual polynucleotide fragments during sequencing.


Barcodes may be loaded into partitions so that one or more barcodes are introduced into a particular partition. Each partition may contain a different set of barcodes. In some cases, each different set of barcodes may comprise a set of identical barcodes. This may be accomplished by directly dispensing the barcodes into the partitions, or by placing the barcodes within a partition within a partition.


The number of different barcodes or different sets of barcodes that are partitioned may vary depending upon, for example, the particular barcodes to be partitioned and/or the application. Different sets of barcodes may be, for example, sets of identical barcodes where the identical barcodes differ between each set. Or different sets of barcodes may be, for example, sets of different barcodes, where each set differs in its included barcodes. For example, about 1, 5, 10, 50, 100, 1000, 10000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, 100000000, or more different barcodes or different sets of barcodes may be partitioned. In some examples, at least about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, 100000000, or more different barcodes or different sets of barcodes may be partitioned. In some examples, less than about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, or 100000000 different barcodes or different sets of barcodes may be partitioned. In some examples, about 1-5, 5-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, 100000-1000000, 10000-1000000, 10000-10000000, or 10000-100000000 barcodes may be partitioned.


Barcodes may be partitioned at a particular density. For example, barcodes may be partitioned so that each partition contains about 1, 5, 10, 50, 100, 1000, 10000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, or 100000000 barcodes per partition. Barcodes may be partitioned so that each partition contains at least about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, 100000000, or more barcodes per partition. Barcodes may be partitioned so that each partition contains less than about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, or 100000000 barcodes per partition. Barcodes may be partitioned such that each partition contains about 1-5, 5-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, 100000-1000000, 10000-1000000, 10000-10000000, or 10000-100000000 barcodes per partition.


Barcodes may be partitioned such that identical barcodes are partitioned at a particular density. For example, identical barcodes may be partitioned so that each partition contains about 1, 5, 10, 50, 100, 1000, 10000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, or 100000000 identical barcodes per partition. Barcodes may be partitioned so that each partition contains at least about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, 100000000, or more identical barcodes per partition. Barcodes may be partitioned so that each partition contains less than about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, or 100000000 identical barcodes per partition. Barcodes may be partitioned such that each partition contains about 1-5, 5-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, 100000-1000000, 10000-1000000, 10000-10000000, or 10000-100000000 identical barcodes per partition.


Barcodes may be partitioned such that different barcodes are partitioned at a particular density. For example, different barcodes may be partitioned so that each partition contains about 1, 5, 10, 50, 100, 1000, 10000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, or 100000000 different barcodes per partition. Barcodes may be partitioned so that each partition contains at least about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, 100000000, or more different barcodes per partition. Barcodes may be partitioned so that each partition contains less than about 1, 5, 10, 50, 100, 1000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200,000, 300,000, 400,000, 500,000, 600,000, 700,000, 800,000, 900,000, 1000000, 2000000, 3000000, 4000000, 5000000, 6000000, 7000000, 8000000, 9000000, 10000000, 20000000, 50000000, or 100000000 different barcodes per partition. Barcodes may be partitioned such that each partition contains about 1-5, 5-10, 10-50, 50-100, 100-1000, 1000-10000, 10000-100000, 100000-1000000, 10000-1000000, 10000-10000000, or 10000-100000000 different barcodes per partition.


The number of partitions employed to partition barcodes may vary, for example, depending on the application and/or the number of different barcodes to be partitioned. For example, the number of partitions employed to partition barcodes may be about 5, 10, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 5000, 7500, or 10,000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100,000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1,000,000, 2000000, 3000000, 4000000, 5000000, 10000000, 20000000 or more. The number of partitions employed to partition barcodes may be at least about 5, 10, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 5000, 7500, 10,000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1000000, 2000000, 3000000, 4000000, 5000000, 10000000, 20000000 or more. The number of partitions employed to partition barcodes may be less than about 5, 10, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 5000, 7500, 10,000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1000000, 2000000, 3000000, 4000000, 5000000, 10000000, or 20000000. The number of partitions employed to partition barcodes may be about 5-10000000, 5-5000000, 5-1,000,000, 10-10,000, 10-5,000, 10-1,000, 1,000-6,000, 1,000-5,000, 1,000-4,000, 1,000-3,000, or 1,000-2,000.


As described above, different barcodes or different sets of barcodes (e.g., each set comprising a plurality of identical barcodes or different barcodes) may be partitioned such that each partition comprises a different barcode or different barcode set. In some cases, each partition may comprise a different set of identical barcodes. Where different sets of identical barcodes are partitioned, the number of identical barcodes per partition may vary. For example, about 100,000 or more different sets of identical barcodes may be partitioned across about 100,000 or more different partitions, such that each partition comprises a different set of identical barcodes. In each partition, the number of identical barcodes per set of barcodes may be about 1,000,000 identical barcodes. In some cases, the number of different sets of barcodes may be equal to or substantially equal to the number of partitions. Any suitable number of different barcodes or different barcode sets (including numbers of different barcodes or different barcode sets to be partitioned described elsewhere herein), number of barcodes per partition (including numbers of barcodes per partition described elsewhere herein), and number of partitions (including numbers of partitions described elsewhere herein) may be combined to generate a diverse library of partitioned barcodes with high numbers of barcodes per partition. Thus, as will be appreciated, any of the above-described different numbers of barcodes may be provided with any of the above-described barcode densities per partition, and in any of the above-described numbers of partitions.


The barcodes may be loaded into the partitions at an expected or predicted ratio of barcodes per species to be barcoded (e.g., polynucleotide fragment, strand of polynucleotide, cell, etc.). In some cases, the barcodes are loaded into partitions such that more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, or 200000 barcodes are loaded per species. In some cases, the barcodes are loaded in the partitions so that less than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, or 200000 barcodes are loaded per species. In some cases, the average number of barcodes loaded per species is less than, or greater than, about 0.0001, 0.001, 0.01, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, or 200000 barcodes per species.


When more than one barcode is present per polynucleotide fragment, such barcodes may be copies of the same barcode, or multiple different barcodes. For example, the attachment process may be designed to attach multiple identical barcodes to a single polynucleotide fragment, or multiple different barcodes to the polynucleotide fragment.


The methods provided herein may comprise loading a partition with the reagents necessary for the attachment of barcodes to polynucleotide fragments. In the case of ligation reactions, reagents including restriction enzymes, ligase enzymes, buffers, adapters, barcodes and the like may be loaded into a partition. In the case barcoding by amplification, reagents including primers, DNA polymerases, DNTPs, buffers, barcodes and the like may be loaded into a partition. As described throughout this disclosure, these reagents may be loaded directly into the partition, or via another partition.


Barcodes may be ligated to a polynucleotide fragment using sticky or blunt ends. Barcoded polynucleotide fragments may also be generated by amplifying a polynucleotide fragment with primers comprising barcodes. As with any other species discussed in this disclosure, these modules may be contained within the same or different partitions, depending on the needs of assay or process.


Barcodes may be assembled combinatorially, from smaller components designed to assemble in a modular format. For example, three modules, 1A, 1B, and 1C may be combinatorially assembled to produce barcode 1ABC. Such combinatorial assembly may significantly reduce the cost of synthesizing a plurality of barcodes. For example, a combinatorial system consisting of 3 A modules, 3 B modules, and 3 C modules may generate 3*3*3=27 possible barcode sequences from only 9 modules.


In some cases, barcodes may be combinatorially assembled by mixing two oligonucleotides and hybridizing them to produce annealed or partially annealed oligonucleotides (e.g., forked adapters). These barcodes may comprise an overhang of one or more nucleotides, in order to facilitate ligation with polynucleotide fragments that are to be barcoded. In some cases, the 5′ end of the antisense strand may be phosphorylated in order to ensure double-stranded ligation. Using this approach, different modules may be assembled by, for example, mixing oligonucleotides A and B, A and C, A and D, B and C, B, and D, and so on. The annealed oligonucleotides may also be synthesized as a single molecule with a hairpin loop that may be cut after ligation to the polynucleotide to be barcoded.


c. Amplification


In some cases, a polynucleotide is amplified during sample processing. This amplification may be performed in one or more of the partitions described in this disclosure. Amplification may be useful for a variety of purposes, including but not limited to generating multiple copies of polynucleotide sequences, addition of adapter sequences or barcodes to polynucleotides, mutation or error detection, producing higher quality samples for further downstream processing and the like.


An suitable amplification method may be utilized, including polymerase chain reaction (PCR), ligase chain reaction (LCR), helicase-dependent amplification, linear after the exponential PCR (LATE-PCR) asymmetric amplification, digital PCR, degenerate oligonucleotide primer PCR (DOP-PCR), primer extension pre-amplification PCR (PEP-PCR) and ligation mediated PCR, rolling circle amplification, multiple displacement amplification (MDA), and single primer isothermal linear amplification. In one example, MDA may be performed on a species contained within a partition. In some cases, this species is a whole chromosome from a cell.


V. Stimuli-Responsiveness

In some cases, stimuli may be used to trigger the release of a species from a partition. Generally, a stimulus may cause disruption of the structure of a partition, such as the wall of a well, a component of a spot, the stability of a droplet (e.g., a droplet in an emulsion), or the shell of a capsule. These stimuli are particularly useful in inducing a partition to release its contents. Because a partition may be contained within another partition, and each partition may be responsive (or not responsive) to different stimuli, stimuli-responsiveness may be employed to release the contents of one partition (e.g., a partition responsive to the stimulus) into another partition (e.g., a partition not responsive to that stimulus, or less responsive to that stimulus).



FIG. 8A shows one non-limiting example using a capsule as an exemplary partition. More specifically, FIG. 8A shows selective release of the contents of an inner capsule 801 into the contents of an outer capsule 802 by applying a stimulus that dissolves the inner capsule 803, resulting in a capsule containing a mixed sample 804.



FIG. 8B shows another non-limiting example using a multiple partitions in a partition scheme. An outer partition 805 comprises inner partitions 806 and 807. Inner partition 806 comprises species A and inner partition 807 comprises species B along with its own inner partition 809 comprising species C. For example, the two inner partitions 806 and 807 may be droplets of an emulsion and outer partition 805 comprising the two droplets may be a well. In some cases, one or both of the two droplets may be a micelle. Inner partition 809 may also be a droplet of an emulsion and may be capable of being dissolved or degraded by species A. In some cases species A may be chemical stimulus, such as, for example, a reducing agent (e.g., DTT, TCEP, etc.) capable of breaking disulfide bonds and inner partition 809 may comprise disulfide bonds (e.g., a gel bead comprising disulfide bonds) capable of being broken by species A.


Via diffusion or other means, inner partitions 806 and 807 may come into contact and fuse 812 together such that a new partition 808 can be generated comprising the combined contents of inner partitions 806 and 807 (e.g., species A+B+inner partition 809). The action 810 of species A on inner partition 809 can degrade or dissolve inner partition 809 such that the contents (e.g., species C) of inner partition 809 can be released into partition 808 to generate a new partition 811. Partition 811 comprises the combined contents of inner partitions 806, 807, and 809 (e.g., species A+B+C).



FIG. 8C shows another non-limiting example using a multiple partitions in a partition scheme. Outer partition 814 may comprise inner partition 815 and one or more inner partitions 816 (multiple inner partitions 816 are shown) and may be, for example, a droplet of an emulsion. Inner partition 815 comprises species A and inner partition 816 comprises species B. In some cases, species B may be a chemical stimulus capable of degrading or dissolving inner partition 815. Species B may be, for example, a reducing agent (e.g., DTT, TCEP, etc.) capable of breaking disulfide bonds and inner partition 815 may comprise disulfide bonds (e.g., a gel bead comprising disulfide bonds) capable of being dissolved or degraded by species B. Moreover, inner partition 816 may be heat sensitive (e.g., a paraffin or other wax bead) such that upon application of heat, species B can be released into the interior of outer partition 814.


Upon application of an appropriate stimulus 817 (e.g., heat), inner partitions 816 may be disrupted or degraded such that species B is released to the interior of outer partition 814. The action 818 of species B on inner partition 815 can degrade or dissolve inner partition 815 such that the contents of inner partition 815 can be released to the interior of outer partition 814. Outer partition 814 can then comprise the combined contents (e.g., species A+B) of inner partitions 815 and 816.


In another example, species B as described above with respect to FIG. 8C, may be a reagent necessary to start a reaction in the interior of outer partition 814, such as, for example, an amplification reaction. Upon degradation or disruption of inner partition 816 with the appropriate stimulus (e.g., heat), species B may be released to the interior of outer partition 814, and the desired reaction allowed to commence with or without the application of an additional stimulus.



FIG. 8D shows another non-limiting example using a multiple partitions in a partition scheme. Outer partition 819 comprises species A and inner partition 820 and may be, for example, a droplet of an emulsion. Inner partition 820 can be impermeable to species A. Inner partition 820 can comprise its own inner partition 821 which comprises species B. Inner partition 820 may be sensitive to a stimulus such that when the stimulus is applied to inner partition 820, inner partition 820 is dissolved or degraded and inner partition 821 is released to the interior of outer partition 819. Inner partition 820 may be, for example, a microcapsule with a hardened shell that comprises, for example, a heat-sensitive shell that degrades or melts when heat is applied to inner partition 820. Inner partition 821 may be sensitive to species A, such that species A is capable of degrading or dissolving inner partition 821. For example, species A may be a reducing agent capable of breaking disulfide bonds and inner partition 821 may comprise a species comprising disulfide bonds (e.g., a gel bead comprising disulfide bonds) capable of being broken with species A.


Upon application of an appropriate stimulus 822 (e.g., heat), inner partition 820 may be disrupted or degraded such that inner partition 821 is released to the interior of outer partition 819. The action 823 of species A on inner partition 821 can degrade or dissolve inner partition 821 such that the contents of inner partition 821 (e.g., species B) can be released to the interior of outer partition 819. Outer partition 819 can then comprise the combined contents (e.g., species A+B) of inner partition 821 and outer partition 819.


Of course, the configuration shown in FIGS. 8A-8D are merely illustrative, and stimuli-responsiveness may be used to release the contents of any suitable partition into any other suitable partition, medium, or container (see, e.g., Table 1 for more specific examples of partitions within partitions).


Examples of stimuli that may be used include chemical stimuli, bulk changes, biological stimuli, light, thermal stimuli, magnetic stimuli, addition of a medium to a well, and any combination thereof, as described more fully below. (See, e.g., Esser-Kahn et al., (2011) Macromolecules 44: 5539-5553; Wang et al., (2009) ChemPhysChem 10:2405-2409.)


a. Chemical Stimuli and Bulk Changes


Numerous chemical triggers may be used to trigger the disruption of partitions (e.g., Plunkett et al., Biomacromolecules, 2005, 6:632-637). Examples of these chemical changes may include, but are not limited to pH-mediated changes to the integrity of a component of a partition, disintegration of a component of a partition via chemical cleavage of crosslink bonds, and triggered depolymerization of a component of a partition. Bulk changes may also be used to trigger disruption of partitions.


A change in pH of a solution, such as a decrease in pH, may trigger disruption of a partition via a number of different mechanisms. The addition of acid may cause degradation or disassembly a portion of a partition through a variety of mechanisms. Addition of protons may disassemble cross-linking of polymers in a component of a partition, disrupt ionic or hydrogen bonds in a component of a partition, or create nanopores in a component of a partition to allow the inner contents to leak through to the exterior. A change in pH may also destabilize an emulsion, leading to release of the contents of the droplets.


In some examples, a partition is produced from materials that comprise acid-degradable chemical cross-linkers, such a ketals. A decrease in pH, particular to a pH lower than 5, may induce the ketal to convert to a ketone and two alcohols and facilitate disruption of the partition. In other examples, the partitions may be produced from materials comprising one or more polyelectrolytes that are pH sensitive. A decrease in pH may disrupt the ionic- or hydrogen-bonding interactions of such partitions, or create nanopores therein. In some cases, partitions made from materials comprising polyelectrolytes comprise a charged, gel-based core that expands and contracts upon a change of pH.


Disruption of cross-linked materials comprising a partition can be accomplished through a number of mechanisms. In some examples, a partition can be contacted with various chemicals that induce oxidation, reduction or other chemical changes. In some cases, a reducing agent, such as beta-mercaptoethanol, can be used, such that disulfide bonds of a partition are disrupted. In addition, enzymes may be added to cleave peptide bonds in materials forming a partition, thereby resulting in a loss of integrity of the partition.


Depolymerization can also be used to disrupt partitions. A chemical trigger may be added to facilitate the removal of a protecting head group. For example, the trigger may cause removal of a head group of a carbonate ester or carbamate within a polymer, which in turn causes depolymerization and release of species from the inside of a partition.


In yet another example, a chemical trigger may comprise an osmotic trigger, whereby a change in ion or solute concentration in a solution induces swelling of a material used to make a partition. Swelling may cause a buildup of internal pressure such that a partition ruptures to release its contents. Swelling may also cause an increase in the pore size of the material, allowing species contained within the partition to diffuse out, and vice versa.


A partition may also be made to release its contents via bulk or physical changes, such as pressure induced rupture, melting, or changes in porosity.


b. Biological Stimuli


Biological stimuli may also be used to trigger disruption of partitions. Generally, biological triggers resemble chemical triggers, but many examples use biomolecules, or molecules commonly found in living systems such as enzymes, peptides, saccharides, fatty acids, nucleic acids and the like. For example, partitions may be made from materials comprising polymers with peptide cross-links that are sensitive to cleavage by specific proteases. More specifically, one example may comprise a partition made from materials comprising GFLGK peptide cross links. Upon addition of a biological trigger such as the protease Cathepsin B, the peptide cross links of the shell well are cleaved and the contents of the capsule are released. In other cases, the proteases may be heat-activated. In another example, partitions comprise a component comprising cellulose. Addition of the hydrolytic enzyme chitosan serves as biologic trigger for cleavage of cellulosic bonds, depolymerization of component of the partition comprising chitosan, and release of its inner contents.


c. Thermal Stimuli


Partitions may also be induced to release their contents upon the application of a thermal stimulus. A change in temperature can cause a variety changes to a partition. A change in heat may cause melting of a partition such that a portion of the partition disintegrates, or disruption of an emulsion. In other cases, heat may increase the internal pressure of the inner components of a partition such that the partition ruptures or explodes. In still other cases, heat may transform a partition into a shrunken dehydrated state. Heat may also act upon heat-sensitive polymers used as materials to construct partitions.


In one example, a partition is made from materials comprising a thermo-sensitive hydrogel. Upon the application of heat, such as a temperature above 35 C, the hydrogel material shrinks. The sudden shrinkage of the material increases the pressure and ruptures the partition.


In some cases, a material used to produce a partition may comprise a diblock polymer, or a mixture of two polymers, with different heat sensitivities. One polymer may be particularly likely to shrink after the application of heat, while the other is more heat-stable. When heat is applied to such shell wall, the heat-sensitive polymer may shrink, while the other remains intact, causing a pore to form. In still other cases, a material used to produce a partition may comprise magnetic nanoparticles. Exposure to a magnetic field may cause the generation of heat, leading to rupture of the partition.


d. Magnetic Stimuli


Inclusion of magnetic nanoparticles in a material used to produce a partition may allow triggered rupture of the partition, as described above, as well as enable guidance of these partitions to other partitions (e.g., guidance of capsules to wells in an array). In one example, incorporation of Fe3O4 nanoparticles into materials used to produce partitions triggers rupture in the presence of an oscillating magnetic field stimulus.


e. Electrical and Light Stimuli


A partition may also be disrupted as the result of electrical stimulation. Similar to the magnetic particles described in the previous section, electrically sensitive particles can allow for both triggered rupture of partitions, as well as other functions such as alignment in an electric field or redox reactions. In one example, partitions made from materials comprising electrically sensitive material are aligned in an electric field such that release of inner reagents can be controlled. In other examples, electric fields may induce redox reactions within a partition that may increase porosity.


A light stimulus may also be used to disrupt the partitions. Numerous light triggers are possible and may include systems that use various molecules such as nanoparticles and chromophores capable of absorbing photons of specific ranges of wavelengths. For example, metal oxide coatings can be used to produce certain partitions. UV irradiation of partitions coated with SiO2/TiO2 may result in disintegration of the partition wall. In yet another example, photo switchable materials such as azobenzene groups may be incorporated in the materials used to produce the partitions. Upon the application of UV or visible light, chemicals such as these undergo a reversible cis-to-trans isomerization upon absorption of photons. In this aspect, incorporation of photo switches results in disintegration of a portion of a partition, or an increase in porosity of a portion of a partition.


f. Application of Stimuli


The devices, methods, compositions, systems, and kits of this disclosure may be used in combination with any apparatus or device that provides such trigger or stimulus. For example, if the stimulus is thermal, a device may be used in combination with a heated or thermally controlled plate, which allows heating of the wells and may induce the rupture of capsules. Any of a number of methods of heat transfer may be used for thermal stimuli, including but not limited to applying heat by radiative heat transfer, convective heat transfer, or conductive heat transfer. In other cases, if the stimulus is a biological enzyme, the enzyme may be injected into a device such that it is deposited into each well. In another aspect, if the stimulus is a magnetic or electric field, a device may be used in combination with a magnetic or electric plate.


VI. Applications

a. Polynucleotide Sequencing


Generally, the methods and compositions provided herein are useful for preparation of polynucleotide fragments for downstream applications such as sequencing. Sequencing may be performed by any available technique. For example, sequencing may be performed by the classic Sanger sequencing method. Sequencing methods may also include: high-throughput sequencing, pyrosequencing, sequencing-by-synthesis, single-molecule sequencing, nanopore sequencing, sequencing-by-ligation, sequencing-by-hybridization, RNA-Seq (Illumina), Digital Gene Expression (Helicos), next generation sequencing, single molecule sequencing by synthesis (SMSS) (Helicos), massively-parallel sequencing, clonal single molecule Array (Solexa), shotgun sequencing, SMRT sequencing (Pacific Biosciences) Maxim-Gilbert sequencing, primer walking, and any other sequencing methods known in the art.


In some cases varying numbers of fragments are sequenced. For example, in some cases about 30%-90% of the fragments are sequenced. In some cases, about 35%-85%, 40%-80%, 45%-75%, 50%-70%, 55%-65%, or 50%-60% of the fragments are sequenced. In some cases, at least about 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the fragments are sequenced. In some cases less than about 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the fragments are sequenced.


In some cases sequences from fragments are assembled to provide sequence information for a contiguous region of the original target polynucleotide that is longer than the individual sequence reads. Individual sequence reads may be about 10-50, 50-100, 100-200, 200-300, 300-400, or more nucleotides in length.


The identities of the barcode tags may serve to order the sequence reads from individual fragments as well as to differentiate between haplotypes. For example, during the partitioning of individual fragments, parental polynucleotide fragments may separated into different partitions. With an increase in the number of partitions, the likelihood of a fragment from both a maternal and paternal haplotype contained in the same partition becomes negligibly small. Thus, sequence reads from fragments in the same partition may be assembled and ordered.


b. Polynucleotide Phasing


This disclosure also provides methods and compositions to prepare polynucleotide fragments in such a manner that may enable phasing or linkage information to be generated. Such information may allow for the detection of linked genetic variations in sequences, including genetic variations (e.g., SNPs, mutations, indels, copy number variations, transversions, translocations, inversions, etc.) that are separated by long stretches of polynucleotides. The term “indel” refers to a mutation resulting in a colocalized insertion and deletion and a net gain or loss in nucleotides. A “microindel” is an indel that results in a net gain or loss of 1 to 50 nucleotides. These variations may exist in either a cis or trans relationship. In a cis relationship, two or more genetic variations exist in the same polynucleotide or strand. In a trans relationship, two or more genetic variations exist on multiple polynucleotide molecules or strands.


Methods provided herein may be used to determine polynucleotide phasing. For example, a polynucleotide sample (e.g., a polynucleotide that spans a given locus or loci) may be partitioned such that at most one molecule of polynucleotide is present per partition. The polynucleotide may then be fragmented, barcoded, and sequenced. The sequences may be examined for genetic variation. The detection of genetic variations in the same sequence tagged with two different bar codes may indicate that the two genetic variations are derived from two separate strands of DNA, reflecting a trans relationship. Conversely, the detection of two different genetic variations tagged with the same bar codes may indicate that the two genetic variations are from the same strand of DNA, reflecting a cis relationship.


Phase information may be important for the characterization of a polynucleotide fragment, particularly if the polynucleotide fragment is derived from a subject at risk of, having, or suspected of a having a particular disease or disorder (e.g., hereditary recessive disease such as cystic fibrosis, cancer, etc.). The information may be able to distinguish between the following possibilities: (1) two genetic variations within the same gene on the same strand of DNA and (2) two genetic variations within the same gene but located on separate strands of DNA. Possibility (1) may indicate that one copy of the gene is normal and the individual is free of the disease, while possibility (2) may indicate that the individual has or will develop the disease, particularly if the two genetic variations are damaging to the function of the gene when present within the same gene copy. Similarly, the phasing information may also be able to distinguish between the following possibilities: (1) two genetic variations, each within a different gene on the same strand of DNA and (2) two genetic variations, each within a different gene but located on separate strands of DNA.


c. Sequencing Polynucleotides from Small Numbers of Cells


Methods provided herein may also be used to prepare polynucleotide contained within cells in a manner that enables cell-specific information to be obtained. The methods enable detection of genetic variations (e.g., SNPs, mutations, indels, copy number variations, transversions, translocations, inversions, etc.) from very small samples, such as from samples comprising about 10-100 cells. In some cases, about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 cells may be used in the methods described herein. In some cases, at least about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 cells may be used in the methods described herein. In other cases, at most about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 cells may be used in the methods described herein.


In an example, a method comprises partitioning a cellular sample (or crude cell extract) such that at most one cell (or extract of one cell) is present per partition, lysing the cells, fragmenting the polynucleotides contained within the cells by any of the methods described herein, attaching the fragmented polynucleotides to barcodes, pooling, and sequencing.


As described elsewhere herein, the barcodes and other reagents may be contained within a partition (e.g., a capsule). These capsules may be loaded into another partition (e.g., a well) before, after, or concurrently with the loading of the cell, such that each cell is contacted with a different capsule. This technique may be used to attach a unique barcode to polynucleotides obtained from each cell. The resulting tagged polynucleotides may then be pooled and sequenced, and the barcodes may be used to trace the origin of the polynucleotides. For example, polynucleotides with identical barcodes may be determined to originate from the same cell, while polynucleotides with different barcodes may be determined to originate from different cells.


The methods described herein may be used to detect the distribution of oncogenic mutations across a population of cancerous tumor cells. For example, some tumor cells may have a mutation, or amplification, of an oncogene (e.g., HER2, BRAF, EGFR, KRAS) in both alleles (homozygous), others may have a mutation in one allele (heterozygous), and still others may have no mutation (wild-type). The methods described herein may be used to detect these differences, and also to quantify the relative numbers of homozygous, heterozygous, and wild-type cells. Such information may be used, for example, to stage a particular cancer and/or to monitor the progression of the cancer and its treatment over time.


In some examples, this disclosure provides methods of identifying mutations in two different oncogenes (e.g., KRAS and EGFR). If the same cell comprises genes with both mutations, this may indicate a more aggressive form of cancer. In contrast, if the mutations are located in two different cells, this may indicate that the cancer is more benign, or less advanced.


d. Analysis of Gene Expression


Methods of the disclosure may be applicable to processing samples for the detection of changes in gene expression. A sample may comprise a cell, mRNA, or cDNA reverse transcribed from mRNA. The sample may be a pooled sample, comprising extracts from several different cells or tissues, or a sample comprising extracts from a single cell or tissue.


Cells may be placed directly into a partition (e.g., a microwell) and lysed. After lysis, the methods of the invention may be used to fragment and barcode the polynucleotides of the cell for sequencing. Polynucleotides may also be extracted from cells prior to introducing them into a partition used in a method of the invention. Reverse transcription of mRNA may be performed in a partition described herein, or outside of such a partition. Sequencing cDNA may provide an indication of the abundance of a particular transcript in a particular cell over time, or after exposure to a particular condition.


The methods presented above provide several advantages over current polynucleotide processing methods. First, inter-operator variability is greatly reduced. Second, the methods may be carried out in microfluidic devices, which have a low cost and can be easily fabricated. Third, the controlled fragmentation of the target polynucleotides allows the user to produce polynucleotide fragments with a defined and appropriate length. This aids in partitioning the polynucleotides and also reduces the amount of sequence information loss due to the present of overly-large fragments. The methods and systems also provide a facile workflow that maintains the integrity of the processed polynucleotide. Additionally, the use of restriction enzymes enables the user to create DNA overhangs (“sticky ends”) that may be designed for compatibility with adapters and/or barcodes.


e. Partitioning of Polynucleotides, Such as Chromosomes, from Cells


In one example the methods, compositions, systems, devices, and kits provided in this disclosure may be used to partition polynucleotides, including whole chromosomes, from cells. In one example, a single cell or a plurality of cells (e.g., 2, 10, 50, 100, 1000, 10000, 25000, 50000, 100000, 500000, 1000000, or more cells) is loaded into a vessel with lysis buffer and proteinase K, and incubated for a specified period of time. Utilization of a plurality of cells will enable polynucleotide phasing, for example, by partitioning each polynucleotide to be analyzed in its own partition.


After incubation, the cell lysate is partitioned, for example by flow focusing the cell lysate into a capsule. If phasing is to be performed, flow focusing is performed such that each capsule comprises only a single analyte (e.g., a single chromosome), or only a single copy of any particular chromosome (e.g., one copy of a first chromosome and one copy of a second chromosome). In some cases, a plurality of chromosomes may be encapsulated within the same capsule, so long as the chromosomes are not the same chromosome. The encapsulation is performed under gentle flow, to minimize shearing of the polynucleotides. The capsule may be porous, to allow washing of the contents of the capsule, and introduction of reagents into the capsule, while maintaining the polynucleotides (e.g., chromosomes) within the capsules. The encapsulated polynucleotides (e.g., chromosomes) may then be processed according to any of the methods provided in this disclosure, or known in the art. The capsule shells protect the encapsulated polynucleotides (e.g., chromosomes) from shearing and further degradation. Of course, this method can also be applied to any other cellular component.


As described above, the capsule shell may be used to protect a polynucleotide from shearing. However, a capsule may also be used as a partition to enable compartmentalized shearing of a polynucleotide or other analyte. For example, in some cases a polynucleotide may be encapsulated within a capsule and then subject to ultrasonic shear, or any other suitable shearing. The capsule shell may be configured to remain intact under the shear, while the encapsulated polynucleotide may be sheared, but will remain within the capsule. In some cases, a hydrogel droplet may be used to accomplish the same end.


VIII. Kits

In some cases, this disclosure provides kits comprising reagents for the generation of partitions. The kit may comprise any suitable reagents and instructions for the generation of partitions and partitions within partitions.


In one example, a kit comprises reagents for generating capsules within droplets in an emulsion. For example, a kit may comprise reagents for generating capsules, reagents for generating an emulsion, and instructions for introducing the capsules into the droplets of the emulsion. As specified throughout this disclosure, any suitable species may be incorporated into the droplets and/or into the capsule. A kit of this disclosure may also provide any of these species. Similarly, as described throughout the disclosure, the capsule may be designed to release its contents into the droplets of the emulsion upon the application of a stimulus.


In another example, a kit comprises reagents for generating capsules within capsules. For example, a kit may comprise reagents for generating inner capsules, reagents for generating outer capsules, and instructions for generating capsules within capsules. As specified throughout this disclosure, any suitable species may be incorporated into the inner and/or outer capsules. A kit of this disclosure may also provide any of these species. Similarly, as described throughout the disclosure, the inner capsule may be designed to release its contents into the outer capsule upon the application of a stimulus.


IX. Devices

In some cases, this disclosure provides devices comprising partitions for the processing of analytes. A device may be a microwell array, or a micro spot array, as described elsewhere in this disclosure. A device may formed in a manner that it comprises any suitable partition. In some cases, a device comprises a plurality of wells, or a plurality of spots. Of course, any partition in a device may also hold other partitions, such as a capsule, a droplet in an emulsion, and the like.


A device may be formed from any suitable material. In some examples, a device is formed from a material selected from the group consisting of fused silica, soda lime glass, borosilicate glass, poly(methyl methacrylate), sapphire, silicon, germanium, cyclic olefin copolymer, polyethylene, polypropylene, polyacrylate, polycarbonate, plastic, and combinations thereof.


In some cases, a device comprises channels for the flow of fluids into and between partitions. Any suitable channels may be used. A device may comprise a fluid inlet and a fluid outlet. The inlet and outlet may be attached to liquid handling devices to introduce species into the device. The device may be sealed, before or after introduction of any species.


Materials that are hydrophilic and/or hydrophobic may be used in different parts of the device. For example, in some cases a device of this disclosure comprises a partition with an interior surface comprising a hydrophilic material. In some cases a surface exterior to the partitions comprises a hydrophobic material. In some cases, a fluid flow path is coated with a hydrophobic or hydrophilic material.


As will be appreciated, the instant disclosure provides for the use of any of the compositions, methods, devices, and kits described herein for a particular use or purpose, including the various applications, uses, and purposes described herein. For example, the disclosure provides for the use of the compositions, methods, devices, and kits described herein, in partitioning species, in partitioning oligonucleotides, in stimulus-selective release of species from partitions, in performing reactions (e.g., ligation and amplification reactions) in partitions, in performing nucleic acid synthesis reactions, in barcoding nucleic acid, in preparing polynucleotides for sequencing, in sequencing polynucleotides, in mutation detection, in neurologic disorder diagnostics, in diabetes diagnostics, in fetal aneuploidy diagnostics, in cancer mutation detection and forensics, in disease detection, in medical diagnostics, in low input nucleic acid applications, in circulating tumor cell (CTC) sequencing, in polynucleotide phasing, in sequencing polynucleotides from small numbers of cells, in analyzing gene expression, in partitioning polynucleotides from cells, in a combination thereof, and in any other application, method, process or use described herein.


EXAMPLES
Example 1: Production of Capsules by Flow Focusing

Capsules were produced according to the method illustrated in FIG. 5 and the corresponding description of FIG. 5. The first fluid 501 was an aqueous fluid that contained 8% (w/v) N-isopropylacrylamide, 0.5% (w/v) PLURONIC F67, 2.5% (w/v) ammonium persulfate, and 1% (w/v) N,N′-methylenebisacrylamide. The second fluid 502 was a fluorous oil (HFE-7500) fluid that contained 2% (w/v) KRYTOX FSH and 1% (v/v) N,N,N,N-tetramethylethylene diamine. The T-junction was 100 microns in width, in either direction. The flow rate was adjusted to maintain an oil to aqueous ratio of 2:1 (20 uL/min and 10 uLmin, respectively). The resulting capsules are shown in FIG. 9A. The shells of the capsules are clearly visible as dark layers surrounding the interior. The size of the capsules is approximately 120 um.


The capsules were washed and resuspended in water. FIG. 9B shows a micrograph of a single capsule, indicating that the integrity of the capsules is maintained during washing and resuspension.


Example 2: Production of Capsules in Batch

Capsules were produced according to the method illustrated in FIG. 7 and the corresponding description of FIG. 7. The first capsule precursors 701 contained 8% (w/v) N-isopropylacrylamide, 0.5% (w/v) PLURONIC F67, 2.5% (w/v) ammonium persulfate, and 1% (w/v) N,N′-methylenebisacrylamide stabilized by 2% (w/v) KRYTOX FSL in HFE7500. N,N,N, N-tetramethylethylene diamine was added to the medium containing the capsule precursors, at a concentration of 2% (w/v). A micrograph of a resulting capsule is shown in FIG. 10. The shell of the capsules is clearly visible as dark layers surrounding the interior. The size of the capsules is approximately 120 microns.


Example 3: Thermally-Responsive Capsules

Capsules were produced according to the method illustrated in FIG. 7 and the corresponding description of FIG. 7. The capsule shell wall was produced from N-isopropylacrylamide, a polymer that shrinks at a temperature above 32° C. With reference to FIG. 11, the capsules were made from a shell comprising the thermally responsive polymer 1101 and contained an aqueous interior 1102. The capsules were suspended in a oil phase 1103. Upon raising the temperature above 32° C. (ΔT), the polymer in the capsule shell shrinks, leading to bursting of the capsule and release of the aqueous phase 1102 within the capsule directly into the surrounding oil phase 1103. The empty capsule shell 1104 is visible.


Example 4: Chemically-Responsive Capsules

Capsules were produced according to the method illustrated in FIG. 7 and the corresponding description of FIG. 7. The capsule shell wall was produced from a polymer comprising disulfide cross-links, which were dissolved after exposure to dithiothreitol (DTT). FIG. 12 shows selective dissolution of a capsule comprising disulfide cross-links after exposure to a medium containing 0.1M of DTT. The intact capsule 1201 was made with a shell comprising disulfide crosslinks. After 12.5 minutes of exposure to 0.1M DTT, the capsule shell dissolves, releasing the contents of the capsule, as shown in 1202. The appearance of the capsule at 2.5 minutes and 7.5 minutes is shown in 1203 and 1204, respectively.


Example 5: Examples of Configurations of Partitions

Many examples of different configurations of partitions are provided throughout this disclosure. FIG. 13 illustrates additional examples of configurations of partitions. In FIG. 13, the letters “A”, “B”, and “C” represent polynucleotide barcodes. The letter “S” represents an analyte (e.g., a sample). The letter “Z” represents another species, such as reagents that may be used to attach a barcode to a polynucleotide analyte. These configurations are in no way meant to be limiting and are provided only for the purposes of further illustrating certain embodiments of the invention. As described throughout this disclosure, any suitable configuration of any species (including species that are barcodes, analytes, and reagents) may be used. As described elsewhere in this disclosure, species may be introduced into capsules and droplets using any suitable method. Examples of suitable methods include flow focusing and picoinjection.


The configuration of FIG. 13A is produced, using the methods described in this disclosure. With reference to FIG. 13A, an inner capsule or droplet of an emulsion 1301 comprising a barcode (A) is depicted. The inner capsule or droplet of an emulsion 1301 is contained within a partition 1302 that may be an outer capsule or a droplet of an emulsion. The medium between the inner capsule or droplet of an emulsion 1301 and the outer capsule or droplet of an emulsion 1302 comprises an analyte (S) and another species (Z) (e.g., a ligase, polymerase, etc.) for attaching the barcode (A) to the analyte (S). Using the methods described in this disclosure, the inner capsule or droplet of an emulsion 1301 can be induced to release its contents into the outer capsule or droplet of an emulsion 1302 in response to a stimulus, causing mixing of A, S, and Z.


The configuration of FIG. 13B is produced, using the methods described in this disclosure. With reference to FIG. 13B, an inner capsule or droplet of an emulsion 1303 comprising two modular components of a barcode (A+B) is depicted. The inner capsule or droplet of an emulsion 1303 is contained within a partition 1304 that may be an outer capsule or droplet of an emulsion. The medium between the inner capsule or droplet of an emulsion 1303 and the outer capsule or droplet of an emulsion 1304 comprises an analyte (S) and another species (Z) (e.g., a ligase, polymerase, etc.) for attaching the barcode (A) to the analyte (S). The other species (Z) may also be used to assemble the two modular components of the barcode (A+B) and add the assembled barcode to the analyte (S), for example in a single ligation step. Using the methods described in this disclosure, the inner capsule or droplet of an emulsion 1303 can be induced to release its contents into the outer capsule or droplet of an emulsion 1304 in response to a stimulus, causing mixing of A, B, S, and Z.


The configuration of FIG. 13C is produced, using the methods described in this disclosure. With reference to FIG. 13C, an inner capsule or droplet of an emulsion 1305 comprising a first modular component of a barcode (A) is depicted. The inner capsule or droplet of an emulsion 1305 is contained within a partition 1306 that may be an intermediate capsule or a droplet of an emulsion. The medium between the inner capsule or droplet of an emulsion 1305 and the intermediate capsule or droplet of an emulsion 1306 comprises a second modular component of a barcode (B). The intermediate capsule or droplet of an emulsion 1306 is contained within a partition 1307 that may be an outer capsule or droplet of an emulsion. The medium between the intermediate capsule or droplet of an emulsion 1306 and the outer capsule or droplet of an emulsion 1307 comprises an analyte (S) and another species (Z), each of which may be used as described above. Using the methods described in this disclosure, the inner capsule or droplet of an emulsion 1305 can be induced to release its contents into the intermediate capsule or droplet of an emulsion 1306 in response to a stimulus, causing mixing of A and B. Similarly, the intermediate capsule or droplet of an emulsion 1306 can be induced to release its contents into the outer capsule or droplet of an emulsion 1307, causing mixing of A, B, S, and Z (if the contents of 1305 have been released) or B, S, and Z (if the contents of 1305 have not been released).


The configuration of FIG. 13D is produced, using the methods described in this disclosure. With reference to FIG. 13D, a first inner capsule or droplet of an emulsion 1308 comprises a first modular component of a barcode (A) and a second inner capsule or droplet of an emulsion 1309 comprises a second modular component of a barcode (B). The first and second inner capsules or droplets of an emulsion (1308 and 1309) are contained within a partition 1310 that may be an outer capsule or droplet of an emulsion. The medium between the first and second inner capsules or droplets of an emulsion (1308 and 1309) and the outer capsule or droplet of an emulsion 1310 comprises an analyte (S) and another species (Z), each of which may be used as described above. Using the methods described in this disclosure, either or both of the first 1308 or second 1309 inner capsules or droplets of an emulsion can be induced to release their contents into the outer capsule or droplet of an emulsion 1310 in response to a stimulus, causing mixing of A and/or B (depending on which inner capsules have released their contents), S, and Z.


The configuration of FIG. 13E is produced, using the methods described in this disclosure. With reference to FIG. 13E, a first inner capsule or droplet of an emulsion 1311 comprises a first modular component of a barcode (A) and a second inner capsule or droplet of an emulsion 1312 comprises a second modular component of a barcode (B). The first and second inner capsules or droplets of an emulsion (1311 and 1312) are contained within an intermediate capsule or droplet of an emulsion 1313. The medium between the first and second inner capsules or droplets of an emulsion (1311 and 1312) and the intermediate capsule or droplet of an emulsion 1313 comprises a third modular component of a barcode (C). The intermediate capsule or droplet of an emulsion 1313 is contained within an outer capsule or droplet of an emulsion 1314. The medium between the intermediate capsule or droplet of an emulsion 1313 and the outer capsule or droplet of an emulsion 1314 comprises an analyte (S) and another species (Z), each of which may be used as described above. Using the methods described in this disclosure, either or both of the first 1311 or second 1312 inner capsules or droplets of an emulsion can be induced to release their contents into the intermediate capsule or droplet of an emulsion 1313 in response to a stimulus, causing mixing of A and/or B (depending on which inner capsules have released their contents) with C. Similarly, the intermediate capsule or droplet of an emulsion 1313 can be induced to release its contents into the outer capsule or droplet of an emulsion 1314, causing mixing of A, B, C, S, and Z, depending on which contents of 1311 and 1312 have been released.


Example 6: Spotting of Species Within Wells

A well comprising spots in the configuration of FIG. 14 is produced, using the methods described in this disclosure. With reference to FIG. 14, the bottom surface of a well 1401 is depicted. The shapes used for the well and the spots are merely for illustrative purposes and in no way meant to be limiting. Any suitable shape may be used for the well and/or any spot. With reference to FIG. 14, four spots are shown, each spot in one quadrant of the bottom surface of the well. The number of spots, and the contents of the spots, are also merely illustrative. Any number of spots or suitable contents of spots may be used. In FIG. 14, spot 1402 comprises a first modular component of a barcode (A), spot 1403 comprises a second modular component of a barcode (B), spot 1404 comprises a third modular component of a barcode (C), and spot 1405 comprises a reagent (Z). The spots are separated, to prevent mixing of the contents of the spots before a sample is added. By adding a sample (e.g., an analyte in a medium) to the well, the contents of the spots can be mixed with the sample at the appropriate time.


Example 7: Sonication of Encapsulated Polynucleotide

Polynucleotides (e.g., genomic DNA) are isolated from cells according to methods known in the art. The polynucleotides are encapsulated in a capsule and/or within a hydrogel matrix. The polynucleotides are fragmented by exposing the capsules and/or hydrogel matrix to shear stress induced by ultrasonic waves. Sheared, encapsulated polynucleotide is generated.


With reference to FIG. 15A, a polynucleotide (e.g., isolated from a cell) is encapsulated in a capsule or a gel droplet 1501. As described elsewhere in this disclosure, the polynucleotide can be encapsulated such that each capsule or gel droplet comprises only a single copy of a particular polynucleotide, so that each capsule or gel droplet contains a mixture of non-overlapping fragments. The capsule or gel droplet is sonicated 1502 to shear the polynucleotide. The capsule or gel droplet is configured to withstand the sonication. The result is a capsule or gel droplet comprising fragmented polynucleotide 1503.


The encapsulated fragmented polynucleotide can then be processed according to any suitable method, including methods known in the art and methods described in this disclosure. FIG. 15B shows an example of further processing. With reference to FIG. 15B, the a first inner capsule or hydrogel droplet comprising sheared polynucleotides 1504 (as generated, e.g., in FIG. 15A) is encapsulated into an outer capsule 1506. The outer capsule 1506 also comprises a second inner capsule 1505. The second inner capsule 1505 comprises two modular components of a barcode (A+B). The medium between the outer capsule 1506 and the two inner capsules 1504 and 1505 comprises a reagent (Z). Upon releasing the contents of the inner capsules, the sheared polynucleotide will mix with A, B, and Z. In some cases, a plurality of capsules or hydrogel droplets comprising a sheared polynucleotide (i.e., a plurality of 1504s) may be encapsulated in the outer capsule 1506.


While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims
  • 1. A system, comprising: a plurality of capsules; anda plurality of partitions,wherein a partition of said plurality of partitions comprises (i) a first species and (ii) a capsule of said plurality of capsules, wherein said capsule comprises a second species, wherein said capsule is configured to release said second species into said partition upon application of a stimulus, and wherein said stimulus comprises one or more members selected from the group consisting of a change in ion concentration, a reducing agent, a light stimulus, an electrical stimulus, and a magnetic stimulus.
  • 2. The system of claim 1, wherein at least one of said first species and said second species is selected from the group consisting of a reagent and an analyte.
  • 3. The system of claim 2, wherein said reagent comprises one or more members selected from the group consisting of a protein, a polynucleotide, an enzyme, an antibody, a barcode, an adapter, a buffer, a small molecule, a detergent, a dye, and a polymer.
  • 4. The system of claim 3, wherein said enzyme comprises a proteinase, a restriction enzyme, a ligase, a polymerase, a fragmentase, a reverse transcriptase, or a transposase.
  • 5. The system of claim 4, wherein said restriction enzyme is a rare cutter.
  • 6. The system of claim 3, wherein said barcode comprises an oligonucleotide barcode molecule.
  • 7. The system of claim 2, wherein said analyte comprises a cell, a polynucleotide, a chromosome, a protein, a peptide, a polysaccharide, a sugar, a lipid, or a small molecule.
  • 8. The system of claim 2, wherein said analyte comprises a polynucleotide molecule.
  • 9. The system of claim 8, wherein said polynucleotide molecule is a deoxyribonucleic acid (DNA) molecule, a ribonucleic acid molecule, or complementary DNA (cDNA) molecule.
  • 10. The system of claim 2, wherein said analyte comprises a cell.
  • 11. The system of claim 10, wherein said partition comprises said cell and does not include any additional cells.
  • 12. The system of claim 2, wherein said first species is said reagent and said second species is said analyte.
  • 13. The system of claim 2, wherein said first species is said analyte and said second species is said reagent.
  • 14. The system of claim 1, wherein capsules of said plurality of capsules comprise, on average, one chromosome.
  • 15. The system of claim 1, wherein partitions of said plurality of partitions comprise, on average, a single capsule of said plurality of capsules.
  • 16. The system of claim 1, wherein said partition does not include any additional capsule of said plurality of capsules.
  • 17. The system of claim 1, wherein said capsule comprises an additional partition.
  • 18. The system of claim 17, wherein said additional partition is selected from the group consisting of an additional capsule and a droplet.
  • 19. The system of claim 1, wherein said capsule comprises a shell selected from the group consisting of a polymeric shell, a hydrogel, a hydrophilic shell, a hydrophobic shell, a shell with a net positive charge, a shell with a net negative charge, and a shell with a neutral charge.
  • 20. The system of claim 1, wherein said partition comprises a fluid that is less dense than said capsule.
  • 21. The system of claim 1, wherein said partition comprises a fluid that is more dense than said capsule.
  • 22. The system of claim 1, wherein said plurality of partitions is a plurality of aqueous droplets, wherein said first species is a cell, wherein said capsule is a gel bead, and wherein said second species is an oligonucleotide barcode molecule.
  • 23. The system of claim 1, wherein said capsule is configured to be degraded or disrupted by said stimulus, thereby releasing said second species into said partition.
  • 24. The system of claim 1, wherein said second species is an oligonucleotide barcode molecule releasably attached to said capsule.
  • 25. The system of claim 24, wherein said capsule comprises at least 10,000 oligonucleotide barcode molecules releasably attached thereto, wherein said at least 10,000 oligonucleotide barcode molecules comprises said oligonucleotide barcode molecule, and wherein said oligonucleotide barcode molecule is configured to release from said capsule upon application of said stimulus.
  • 26. The system of claim 1, wherein said capsule is a gel bead.
  • 27. The system of claim 1, wherein said plurality of partitions comprises a plurality of wells.
  • 28. The system of claim 1, wherein said change in ion concentration includes a change in pH within said capsule.
  • 29. The system of claim 1, wherein said partition comprises magnetic nanoparticles responsive to said magnetic stimulus.
  • 30. The system of claim 1, wherein said partition comprises electrically sensitive particles responsive to said electrical stimulus.
  • 31. The system of claim 1, wherein said partition comprises nanoparticles or chromophores responsive to said light stimulus.
  • 32. The system of claim 1, wherein said partition comprises photo switchable materials responsive to said light stimulus.
  • 33. The system of claim 1, wherein said electrical stimulus comprises application of an electric field.
  • 34. The system of claim 1, wherein said magnetic stimulus comprises application of a magnetic field.
  • 35. The system of claim 1, wherein said light stimulus comprises application of ultraviolet or visible light.
  • 36. The system of claim 1, wherein said stimulus is said change in ion concentration.
  • 37. The system of claim 1, wherein said stimulus is said reducing agent.
  • 38. The system of claim 1, wherein said stimulus is said light stimulus.
  • 39. The system of claim 1, wherein said stimulus is said electrical stimulus.
  • 40. The system of claim 1, wherein said stimulus is said magnetic stimulus.
CROSS-REFERENCE

This application is a continuation of U.S. patent application Ser. No. 15/693,374, filed on Aug. 31, 2017, which is a continuation application of U.S. patent application Ser. No. 15/470,814, filed Mar. 27, 2017, which is a continuation application of U.S. patent application Ser. No. 14/175,935, filed Feb. 7, 2014, now U.S. Pat. No. 9,644,204, which claims the benefit of U.S. Provisional Patent Application No. 61/762,435, filed Feb. 8, 2013, U.S. Provisional Patent Application No. 61/800,223, filed Mar. 15, 2013, U.S. Provisional Patent Application No. 61/840,403, filed Jun. 27, 2013, and U.S. Provisional Patent Application No. 61/844,804, filed Jul. 10, 2013, said applications are incorporated herein by reference in their entireties for all purposes.

US Referenced Citations (852)
Number Name Date Kind
2797149 Skeggs Jun 1957 A
3047367 Kessler Jul 1962 A
3479141 William et al. Nov 1969 A
4124638 Hansen Nov 1978 A
4253846 Smythe et al. Mar 1981 A
4582802 Zimmerman et al. Apr 1986 A
4804450 Mochizuki Feb 1989 A
5137829 Nag et al. Aug 1992 A
5149625 Church et al. Sep 1992 A
5185099 Delpuech et al. Feb 1993 A
5202231 Drmanac et al. Apr 1993 A
5270183 Corbett et al. Dec 1993 A
5413924 Kosak et al. May 1995 A
5418149 Gelfand et al. May 1995 A
5436130 Mathies et al. Jul 1995 A
5456986 Majetich Oct 1995 A
5478893 Ghosh et al. Dec 1995 A
5489523 Mathur Feb 1996 A
5512131 Kumar et al. Apr 1996 A
5558071 Ward et al. Sep 1996 A
5585069 Zanzucchi et al. Dec 1996 A
5587128 Wilding et al. Dec 1996 A
5605793 Stemmer et al. Feb 1997 A
5618711 Gelfand et al. Apr 1997 A
5658548 Padhye et al. Aug 1997 A
5695940 Drmanac et al. Dec 1997 A
5700642 Monforte et al. Dec 1997 A
5705628 Hawkins Jan 1998 A
5708153 Dower et al. Jan 1998 A
5736330 Fulton Apr 1998 A
5739036 Parris Apr 1998 A
5744311 Fraiser et al. Apr 1998 A
5756334 Perler et al. May 1998 A
5830663 Embleton et al. Nov 1998 A
5834197 Parton Nov 1998 A
5842787 Kopf-Sill et al. Dec 1998 A
5846719 Brenner et al. Dec 1998 A
5846727 Soper et al. Dec 1998 A
5851769 Gray et al. Dec 1998 A
5856174 Lipshutz et al. Jan 1999 A
5872010 Karger et al. Feb 1999 A
5897783 Howe et al. Apr 1999 A
5900481 Lough et al. May 1999 A
5942609 Hunkapiller et al. Aug 1999 A
5958703 Dower et al. Sep 1999 A
5965443 Reznikoff Oct 1999 A
5994056 Higuchi Nov 1999 A
5997636 Gamarnik et al. Dec 1999 A
6033880 Haff et al. Mar 2000 A
6046003 Mandecki Apr 2000 A
6051377 Mandecki Apr 2000 A
6057107 Fulton May 2000 A
6057149 Burns et al. May 2000 A
6103537 Ullman et al. Aug 2000 A
6110678 Weisburg et al. Aug 2000 A
6123798 Gandhi et al. Sep 2000 A
6133436 Koester et al. Oct 2000 A
6143496 Brown et al. Nov 2000 A
6159717 Savakis et al. Dec 2000 A
6171850 Nagle et al. Jan 2001 B1
6172218 Brenner Jan 2001 B1
6176962 Soane et al. Jan 2001 B1
6207384 Mekalanos et al. Mar 2001 B1
6258571 Chumakov et al. Jul 2001 B1
6265552 Schatz Jul 2001 B1
6291243 Fogarty et al. Sep 2001 B1
6294385 Goryshin et al. Sep 2001 B1
6296020 McNeely et al. Oct 2001 B1
6297006 Drmanac et al. Oct 2001 B1
6297017 Schmidt et al. Oct 2001 B1
6303343 Kopf-Sill Oct 2001 B1
6306590 Mehta et al. Oct 2001 B1
6327410 Walt et al. Dec 2001 B1
6355198 Kim et al. Mar 2002 B1
6361950 Mandecki Mar 2002 B1
6372813 Johnson et al. Apr 2002 B1
6379929 Burns et al. Apr 2002 B1
6406848 Bridgham et al. Jun 2002 B1
6409832 Weigl et al. Jun 2002 B2
6432290 Harrison et al. Aug 2002 B1
6432360 Church Aug 2002 B1
6485944 Church et al. Nov 2002 B1
6492118 Abrams et al. Dec 2002 B1
6511803 Church et al. Jan 2003 B1
6524456 Ramsey et al. Feb 2003 B1
6569631 Pantoliano et al. May 2003 B1
6579851 Goeke et al. Jun 2003 B2
6586176 Trnovsky et al. Jul 2003 B1
6593113 Tenkanen et al. Jul 2003 B1
6613752 Kay et al. Sep 2003 B2
6632606 Ullman et al. Oct 2003 B1
6632655 Mehta et al. Oct 2003 B1
6670133 Knapp et al. Dec 2003 B2
6723513 Lexow Apr 2004 B2
6767731 Hannah Jul 2004 B2
6800298 Burdick et al. Oct 2004 B1
6806052 Bridgham et al. Oct 2004 B2
6806058 Jesperson et al. Oct 2004 B2
6859570 Walt et al. Feb 2005 B2
6880576 Karp et al. Apr 2005 B2
6884788 Bulpitt et al. Apr 2005 B2
6913935 Thomas Jul 2005 B1
6915679 Chien et al. Jul 2005 B2
6929859 Chandler et al. Aug 2005 B2
6969488 Bridgham et al. Nov 2005 B2
6974669 Mirkin et al. Dec 2005 B2
7041481 Anderson et al. May 2006 B2
7115400 Adessi et al. Oct 2006 B1
7129091 Ismagilov et al. Oct 2006 B2
7138267 Jendrisak et al. Nov 2006 B1
7211654 Gao et al. May 2007 B2
7262056 Wooddell et al. Aug 2007 B2
7268167 Higuchi et al. Sep 2007 B2
7282370 Bridgham et al. Oct 2007 B2
7294503 Quake et al. Nov 2007 B2
7297485 Bornarth et al. Nov 2007 B2
7316903 Yanagihara et al. Jan 2008 B2
7323305 Leamon et al. Jan 2008 B2
7329493 Chou et al. Feb 2008 B2
7425431 Church et al. Sep 2008 B2
7536928 Kazuno May 2009 B2
7544473 Brenner Jun 2009 B2
7604938 Takahashi et al. Oct 2009 B2
7608434 Reznikoff et al. Oct 2009 B2
7608451 Cooper et al. Oct 2009 B2
7622076 Davies et al. Nov 2009 B2
7622280 Holliger et al. Nov 2009 B2
7638276 Griffiths et al. Dec 2009 B2
7645596 Williams et al. Jan 2010 B2
7666664 Sarofim et al. Feb 2010 B2
7700325 Cantor et al. Apr 2010 B2
7708949 Stone et al. May 2010 B2
7709197 Drmanac May 2010 B2
7745178 Dong Jun 2010 B2
7745218 Kim et al. Jun 2010 B2
7772287 Higuchi et al. Aug 2010 B2
7776927 Chu et al. Aug 2010 B2
RE41780 Anderson et al. Sep 2010 E
7799553 Mathies et al. Sep 2010 B2
7842457 Berka et al. Nov 2010 B2
7901891 Drmanac Mar 2011 B2
7910354 Drmanac et al. Mar 2011 B2
7927797 Nobile et al. Apr 2011 B2
7943671 Herminghaus et al. May 2011 B2
7947477 Schroeder et al. May 2011 B2
7960104 Drmanac et al. Jun 2011 B2
7968287 Griffiths et al. Jun 2011 B2
7972778 Brown et al. Jul 2011 B2
8003312 Krutzik et al. Aug 2011 B2
8008018 Quake et al. Aug 2011 B2
8053192 Bignell et al. Nov 2011 B2
8067159 Brown et al. Nov 2011 B2
8101346 Takahama Jan 2012 B2
8124404 Alphey et al. Feb 2012 B2
8133719 Drmanac et al. Mar 2012 B2
8137563 Ma et al. Mar 2012 B2
8168385 Brenner et al. May 2012 B2
8252539 Quake et al. Aug 2012 B2
8268564 Roth et al. Sep 2012 B2
8273573 Ismagilov et al. Sep 2012 B2
8278071 Brown et al. Oct 2012 B2
8298767 Brenner et al. Oct 2012 B2
8304193 Ismagilov et al. Nov 2012 B2
8318433 Brenner Nov 2012 B2
8318460 Cantor et al. Nov 2012 B2
8329407 Ismagilov et al. Dec 2012 B2
8337778 Stone et al. Dec 2012 B2
8361299 Sabin et al. Jan 2013 B2
8420386 Ivics et al. Apr 2013 B2
8461129 Bolduc et al. Jun 2013 B2
8563274 Brenner et al. Oct 2013 B2
8592150 Drmanac et al. Nov 2013 B2
8598328 Koga et al. Dec 2013 B2
8603749 Gillevet et al. Dec 2013 B2
8658430 Miller et al. Feb 2014 B2
8679756 Brenner et al. Mar 2014 B1
8748094 Weitz et al. Jun 2014 B2
8748102 Berka et al. Jun 2014 B2
8765380 Berka et al. Jul 2014 B2
8822148 Ismagliov et al. Sep 2014 B2
8829171 Steemers et al. Sep 2014 B2
8835358 Fodor et al. Sep 2014 B2
8846883 Brown et al. Sep 2014 B2
8871444 Griffiths et al. Oct 2014 B2
8889083 Ismagilov et al. Nov 2014 B2
8927218 Forsyth Jan 2015 B2
8975302 Light et al. Mar 2015 B2
8986286 Tanghoj et al. Mar 2015 B2
8986628 Stone et al. Mar 2015 B2
9005935 Belyaev Apr 2015 B2
9012370 Hong Apr 2015 B2
9012390 Holtze et al. Apr 2015 B2
9017948 Agresti et al. Apr 2015 B2
9029083 Griffiths et al. May 2015 B2
9029085 Agresti et al. May 2015 B2
9040256 Grunenwald et al. May 2015 B2
9068210 Agresti et al. Jun 2015 B2
9074251 Steemers et al. Jul 2015 B2
9080211 Grunenwald et al. Jul 2015 B2
9085798 Chee Jul 2015 B2
9089844 Hiddessen et al. Jul 2015 B2
9102980 Brenner et al. Aug 2015 B2
9126160 Ness et al. Sep 2015 B2
9133009 Baroud et al. Sep 2015 B2
9150916 Christen et al. Oct 2015 B2
9156010 Colston et al. Oct 2015 B2
9175295 Kaminaka et al. Nov 2015 B2
9194861 Hindson et al. Nov 2015 B2
9216392 Hindson et al. Dec 2015 B2
9222128 Saxonov Dec 2015 B2
9238206 Rotem et al. Jan 2016 B2
9238671 Goryshin et al. Jan 2016 B2
9249460 Pushkarev et al. Feb 2016 B2
9266104 Link Feb 2016 B2
9273349 Nguyen et al. Mar 2016 B2
9290808 Fodor et al. Mar 2016 B2
9328382 Drmanac et al. May 2016 B2
9347059 Saxonov May 2016 B2
9388465 Hindson et al. Jul 2016 B2
9410201 Hindson Aug 2016 B2
9417190 Hindson et al. Aug 2016 B2
9436088 Seul et al. Sep 2016 B2
9486757 Romanowsky et al. Nov 2016 B2
9498761 Holtze et al. Nov 2016 B2
9500664 Ness et al. Nov 2016 B2
9567631 Hindson et al. Feb 2017 B2
9574226 Gormley et al. Feb 2017 B2
9623384 Hindson et al. Apr 2017 B2
9637799 Fan et al. May 2017 B2
9644204 Hindson May 2017 B2
9689024 Hindson Jun 2017 B2
9694361 Bharadwaj Jul 2017 B2
9695468 Hindson et al. Jul 2017 B2
9701998 Hindson Jul 2017 B2
9764322 Hiddessen et al. Sep 2017 B2
9824068 Wong Nov 2017 B2
9856530 Hindson et al. Jan 2018 B2
9946577 Stafford et al. Apr 2018 B1
9951386 Hindson Apr 2018 B2
9957558 Leamon et al. May 2018 B2
9975122 Masquelier et al. May 2018 B2
10011872 Belgrader et al. Jul 2018 B1
10017759 Kaper et al. Jul 2018 B2
10030267 Hindson et al. Jul 2018 B2
10041116 Hindson et al. Aug 2018 B2
10053723 Hindson et al. Aug 2018 B2
10059989 Giresi et al. Aug 2018 B2
10071377 Bharadwaj et al. Sep 2018 B2
10119167 Srinivasan et al. Nov 2018 B2
10137449 Bharadwaj et al. Nov 2018 B2
10144950 Nolan Dec 2018 B2
10150117 Bharadwaj et al. Dec 2018 B2
10150963 Hindson Dec 2018 B2
10150964 Hindson Dec 2018 B2
10150995 Giresi et al. Dec 2018 B1
10161007 Abate et al. Dec 2018 B2
10167509 Regan Jan 2019 B2
10174310 Nolan Jan 2019 B2
10208343 Hindson et al. Feb 2019 B2
10221436 Hardenbol et al. Mar 2019 B2
10221442 Hindson Mar 2019 B2
10227648 Hindson et al. Mar 2019 B2
10253364 Hindson et al. Apr 2019 B2
10273541 Hindson Apr 2019 B2
10287623 Jarosz May 2019 B2
10323278 Belgrader et al. Jun 2019 B2
10323279 Hindson et al. Jun 2019 B2
10337061 Hindson et al. Jul 2019 B2
10344329 Hindson et al. Jul 2019 B2
10347365 Wong et al. Jul 2019 B2
10357771 Bharadwaj et al. Jul 2019 B2
10395758 Schnall-Levin Aug 2019 B2
10400280 Hindson Sep 2019 B2
10428326 Belhocine et al. Oct 2019 B2
10450607 Hindson et al. Oct 2019 B2
10457986 Hindson et al. Oct 2019 B2
10480028 Hindson et al. Nov 2019 B2
10480029 Bent et al. Nov 2019 B2
10533221 Hindson Jan 2020 B2
10544413 Bharadwaj et al. Jan 2020 B2
10549279 Bharadwaj et al. Feb 2020 B2
10557158 Hardenbol et al. Feb 2020 B2
10584381 Hindson et al. Mar 2020 B2
10590244 Delaney et al. Mar 2020 B2
10597718 Hindson Mar 2020 B2
10612090 Hindson et al. Apr 2020 B2
10626458 Hindson et al. Apr 2020 B2
10669583 Hindson et al. Jun 2020 B2
10676789 Hindson et al. Jun 2020 B2
10745742 Bent et al. Aug 2020 B2
10752949 Hindson Aug 2020 B2
11021749 Hindson et al. Jun 2021 B2
11035002 Hindson et al. Jun 2021 B2
11078522 Hindson et al. Aug 2021 B2
20010020588 Adourian et al. Sep 2001 A1
20010036669 Jedrzejewski et al. Nov 2001 A1
20010041357 Fouillet et al. Nov 2001 A1
20010044109 Mandecki Nov 2001 A1
20010048900 Bardell et al. Dec 2001 A1
20010051348 Lee Dec 2001 A1
20010053519 Fodor et al. Dec 2001 A1
20020001856 Chow et al. Jan 2002 A1
20020005354 Spence et al. Jan 2002 A1
20020034737 Drmanac Mar 2002 A1
20020043463 Shenderov Apr 2002 A1
20020051971 Stuelpnagel et al. May 2002 A1
20020051992 Bridgham et al. May 2002 A1
20020058332 Quake et al. May 2002 A1
20020065609 Ashby et al. May 2002 A1
20020068278 Giese et al. Jun 2002 A1
20020089100 Kawasaki Jul 2002 A1
20020092767 Bjornson et al. Jul 2002 A1
20020113009 O'Connor et al. Aug 2002 A1
20020119455 Chan et al. Aug 2002 A1
20020119536 Stern Aug 2002 A1
20020119544 Yan et al. Aug 2002 A1
20020127736 Chou et al. Sep 2002 A1
20020131147 Paolini et al. Sep 2002 A1
20020160518 Hayenga et al. Oct 2002 A1
20020164820 Brown Nov 2002 A1
20020166582 O'Connor et al. Nov 2002 A1
20020172965 Kamb et al. Nov 2002 A1
20020175079 Christel et al. Nov 2002 A1
20020179849 Maher et al. Dec 2002 A1
20030005967 Karp Jan 2003 A1
20030007898 Bohm et al. Jan 2003 A1
20030008285 Fischer Jan 2003 A1
20030008323 Ravkin et al. Jan 2003 A1
20030022231 Wangh et al. Jan 2003 A1
20030027203 Fields Feb 2003 A1
20030027214 Kamb Feb 2003 A1
20030027221 Scott et al. Feb 2003 A1
20030028981 Chandler et al. Feb 2003 A1
20030032141 Nguyen et al. Feb 2003 A1
20030036206 Chien et al. Feb 2003 A1
20030039978 Hannah Feb 2003 A1
20030044777 Beattie Mar 2003 A1
20030044836 Levine et al. Mar 2003 A1
20030075446 Culbertson et al. Apr 2003 A1
20030082587 Seul et al. May 2003 A1
20030089605 Timperman May 2003 A1
20030104466 Knapp et al. Jun 2003 A1
20030108897 Drmanac Jun 2003 A1
20030124509 Kenis et al. Jul 2003 A1
20030148335 Shen et al. Aug 2003 A1
20030149307 Hai et al. Aug 2003 A1
20030170698 Gascoyne et al. Sep 2003 A1
20030182068 Battersby et al. Sep 2003 A1
20030207260 Trnovsky et al. Nov 2003 A1
20030215862 Parce et al. Nov 2003 A1
20040037813 Simpson et al. Feb 2004 A1
20040040851 Karger et al. Mar 2004 A1
20040063138 McGinnis et al. Apr 2004 A1
20040068019 Higuchi et al. Apr 2004 A1
20040081962 Chen et al. Apr 2004 A1
20040101680 Barber et al. May 2004 A1
20040101880 Rozwadowski et al. May 2004 A1
20040132122 Banerjee et al. Jul 2004 A1
20040185484 Costa et al. Sep 2004 A1
20040195728 Slomski et al. Oct 2004 A1
20040214175 McKernan et al. Oct 2004 A9
20040224331 Cantor et al. Nov 2004 A1
20040258701 Dominowski et al. Dec 2004 A1
20050019839 Jespersen et al. Jan 2005 A1
20050037397 Mirkin et al. Feb 2005 A1
20050042625 Schmidt et al. Feb 2005 A1
20050079510 Berka et al. Apr 2005 A1
20050130188 Walt et al. Jun 2005 A1
20050136417 Cole et al. Jun 2005 A1
20050172476 Stone et al. Aug 2005 A1
20050181379 Su et al. Aug 2005 A1
20050202429 Trau et al. Sep 2005 A1
20050202489 Cho et al. Sep 2005 A1
20050221339 Griffiths et al. Oct 2005 A1
20050244850 Huang et al. Nov 2005 A1
20050250147 Macevicz Nov 2005 A1
20050266582 Modlin et al. Dec 2005 A1
20050272159 Ismagilov et al. Dec 2005 A1
20050287572 Mathies et al. Dec 2005 A1
20060002890 Hersel et al. Jan 2006 A1
20060008799 Cai et al. Jan 2006 A1
20060020371 Ham et al. Jan 2006 A1
20060040382 Heffron et al. Feb 2006 A1
20060073487 Oliver et al. Apr 2006 A1
20060078888 Griffiths et al. Apr 2006 A1
20060153924 Griffiths et al. Jul 2006 A1
20060163385 Link et al. Jul 2006 A1
20060177832 Brenner Aug 2006 A1
20060177833 Brenner Aug 2006 A1
20060199193 Koo et al. Sep 2006 A1
20060240506 Kushmaro et al. Oct 2006 A1
20060257893 Takahashi et al. Nov 2006 A1
20060263888 Fritz et al. Nov 2006 A1
20060275782 Gunderson et al. Dec 2006 A1
20060286570 Rowlen et al. Dec 2006 A1
20060292583 Schneider et al. Dec 2006 A1
20070003442 Link et al. Jan 2007 A1
20070009954 Wang et al. Jan 2007 A1
20070020617 Trnovsky et al. Jan 2007 A1
20070020640 McCloskey et al. Jan 2007 A1
20070026401 Hofmann et al. Feb 2007 A1
20070031829 Yasuno et al. Feb 2007 A1
20070042400 Choi et al. Feb 2007 A1
20070042419 Barany et al. Feb 2007 A1
20070054119 Garstecki et al. Mar 2007 A1
20070072208 Drmanac Mar 2007 A1
20070077572 Tawfik et al. Apr 2007 A1
20070092914 Griffiths et al. Apr 2007 A1
20070099208 Drmanac et al. May 2007 A1
20070105972 Doyle et al. May 2007 A1
20070111241 Cereb et al. May 2007 A1
20070134277 Chen et al. Jun 2007 A1
20070141584 Roberts et al. Jun 2007 A1
20070154903 Marla et al. Jul 2007 A1
20070160503 Sethu et al. Jul 2007 A1
20070172873 Brenner et al. Jul 2007 A1
20070190543 Livak Aug 2007 A1
20070195127 Ahn et al. Aug 2007 A1
20070196397 Torii et al. Aug 2007 A1
20070207060 Zou et al. Sep 2007 A1
20070228588 Noritomi et al. Oct 2007 A1
20070231823 McKernan et al. Oct 2007 A1
20070238113 Kanda et al. Oct 2007 A1
20070259357 Brenner Nov 2007 A1
20070264320 Lee et al. Nov 2007 A1
20080003142 Link et al. Jan 2008 A1
20080004436 Tawfik et al. Jan 2008 A1
20080014589 Link et al. Jan 2008 A1
20080056948 Dale et al. Mar 2008 A1
20080124726 Monforte May 2008 A1
20080138878 Kubu et al. Jun 2008 A1
20080166720 Hsieh et al. Jul 2008 A1
20080213766 Brown et al. Sep 2008 A1
20080228268 Shannon et al. Sep 2008 A1
20080241820 Krutzik et al. Oct 2008 A1
20080242560 Gunderson et al. Oct 2008 A1
20080268431 Choy et al. Oct 2008 A1
20080268450 Nam et al. Oct 2008 A1
20080268507 Xu et al. Oct 2008 A1
20080295909 Locascio et al. Dec 2008 A1
20080299595 Wong et al. Dec 2008 A1
20090005252 Drmanac et al. Jan 2009 A1
20090011943 Drmanac et al. Jan 2009 A1
20090012187 Chu et al. Jan 2009 A1
20090025277 Takanashi Jan 2009 A1
20090035770 Mathies et al. Feb 2009 A1
20090047713 Handique Feb 2009 A1
20090048124 Leamon et al. Feb 2009 A1
20090053169 Castillo et al. Feb 2009 A1
20090062129 McKernan et al. Mar 2009 A1
20090068170 Weitz et al. Mar 2009 A1
20090098555 Roth et al. Apr 2009 A1
20090099041 Church et al. Apr 2009 A1
20090105959 Braverman et al. Apr 2009 A1
20090118488 Drmanac et al. May 2009 A1
20090131543 Weitz et al. May 2009 A1
20090134027 Jary May 2009 A1
20090137404 Drmanac et al. May 2009 A1
20090137414 Drmanac et al. May 2009 A1
20090143244 Bridgham et al. Jun 2009 A1
20090148961 Luchini et al. Jun 2009 A1
20090155563 Petsev et al. Jun 2009 A1
20090155780 Xiao et al. Jun 2009 A1
20090155781 Drmanac et al. Jun 2009 A1
20090197248 Griffiths et al. Aug 2009 A1
20090197772 Griffiths et al. Aug 2009 A1
20090202984 Cantor Aug 2009 A1
20090203531 Kurn Aug 2009 A1
20090235990 Beer Sep 2009 A1
20090264299 Drmanac et al. Oct 2009 A1
20090269248 Falb et al. Oct 2009 A1
20090286687 Dressman et al. Nov 2009 A1
20090325260 Otto et al. Dec 2009 A1
20100021973 Makarov et al. Jan 2010 A1
20100021984 Edd et al. Jan 2010 A1
20100022414 Link et al. Jan 2010 A1
20100035254 Williams Feb 2010 A1
20100055677 Colston, Jr. Mar 2010 A1
20100062494 Church et al. Mar 2010 A1
20100069263 Shendure et al. Mar 2010 A1
20100086914 Bentley et al. Apr 2010 A1
20100105112 Holtze et al. Apr 2010 A1
20100105866 Fraden et al. Apr 2010 A1
20100113296 Myerson May 2010 A1
20100120098 Grunenwald et al. May 2010 A1
20100130369 Shenderov et al. May 2010 A1
20100136544 Agresti et al. Jun 2010 A1
20100137163 Link et al. Jun 2010 A1
20100173394 Colston, Jr. et al. Jul 2010 A1
20100184928 Kumacheva Jul 2010 A1
20100187705 Lee et al. Jul 2010 A1
20100197507 Rothberg et al. Aug 2010 A1
20100203647 Hang et al. Aug 2010 A1
20100210479 Griffiths et al. Aug 2010 A1
20100216153 Lapidus et al. Aug 2010 A1
20100244818 Atwood Sep 2010 A1
20100248237 Froehlich et al. Sep 2010 A1
20100248991 Roesler et al. Sep 2010 A1
20100285975 Mathies et al. Nov 2010 A1
20100304982 Hinz et al. Dec 2010 A1
20110000560 Miller et al. Jan 2011 A1
20110008775 Gao et al. Jan 2011 A1
20110028412 Cappello et al. Feb 2011 A1
20110033548 Lai et al. Feb 2011 A1
20110033854 Drmanac et al. Feb 2011 A1
20110053798 Hindson et al. Mar 2011 A1
20110059556 Strey et al. Mar 2011 A1
20110071053 Drmanac et al. Mar 2011 A1
20110086780 Colston, Jr. et al. Apr 2011 A1
20110092376 Colston, Jr. et al. Apr 2011 A1
20110092392 Colston, Jr. et al. Apr 2011 A1
20110159499 Hindson et al. Jun 2011 A1
20110160078 Fodor et al. Jun 2011 A1
20110166034 Kwong et al. Jul 2011 A1
20110195496 Muraguchi et al. Aug 2011 A1
20110201526 Berka et al. Aug 2011 A1
20110212090 Pedersen et al. Sep 2011 A1
20110217736 Hindson Sep 2011 A1
20110218123 Weitz et al. Sep 2011 A1
20110250597 Larson et al. Oct 2011 A1
20110257889 Klammer et al. Oct 2011 A1
20110263457 Krutzik et al. Oct 2011 A1
20110267457 Weitz et al. Nov 2011 A1
20110281736 Drmanac et al. Nov 2011 A1
20110281738 Drmanac et al. Nov 2011 A1
20110287435 Grunenwald et al. Nov 2011 A1
20110287947 Chen et al. Nov 2011 A1
20110293701 Bratzler et al. Dec 2011 A1
20110305761 Shum et al. Dec 2011 A1
20110306141 Bronchetti et al. Dec 2011 A1
20110319281 Drmanac Dec 2011 A1
20120000777 Garrell et al. Jan 2012 A1
20120003657 Myllykangas et al. Jan 2012 A1
20120010091 Linnarson et al. Jan 2012 A1
20120010098 Griffiths et al. Jan 2012 A1
20120010107 Griffiths et al. Jan 2012 A1
20120014977 Furihata et al. Jan 2012 A1
20120015382 Weitz et al. Jan 2012 A1
20120015822 Weitz et al. Jan 2012 A1
20120034603 Oliphant et al. Feb 2012 A1
20120041727 Mishra et al. Feb 2012 A1
20120071331 Casbon et al. Mar 2012 A1
20120121481 Romanowsky et al. May 2012 A1
20120132288 Weitz et al. May 2012 A1
20120135893 Drmanac et al. May 2012 A1
20120165219 Van et al. Jun 2012 A1
20120172259 Rigatti et al. Jul 2012 A1
20120184449 Hixson et al. Jul 2012 A1
20120190032 Ness et al. Jul 2012 A1
20120190037 Durin et al. Jul 2012 A1
20120196288 Beer et al. Aug 2012 A1
20120208705 Steemers et al. Aug 2012 A1
20120208724 Steemers et al. Aug 2012 A1
20120211084 Weitz et al. Aug 2012 A1
20120219947 Yurkovetsky et al. Aug 2012 A1
20120220494 Samuels et al. Aug 2012 A1
20120220497 Jacobson et al. Aug 2012 A1
20120222748 Weitz et al. Sep 2012 A1
20120230338 Ganeshalingam et al. Sep 2012 A1
20120231972 Golyshin et al. Sep 2012 A1
20120252012 Armougom et al. Oct 2012 A1
20120253689 Rogan et al. Oct 2012 A1
20120289428 Duffy et al. Nov 2012 A1
20120295819 Leamon et al. Nov 2012 A1
20120297493 Cooper et al. Nov 2012 A1
20120309002 Link Dec 2012 A1
20120316074 Saxonov et al. Dec 2012 A1
20130017978 Kavanagh et al. Jan 2013 A1
20130018970 Woundy et al. Jan 2013 A1
20130022682 Lee et al. Jan 2013 A1
20130028812 Prieto et al. Jan 2013 A1
20130041004 Drager et al. Feb 2013 A1
20130046030 Rotem et al. Feb 2013 A1
20130059310 Brenner et al. Mar 2013 A1
20130078638 Berka et al. Mar 2013 A1
20130079231 Pushkarev et al. Mar 2013 A1
20130079251 Boles Mar 2013 A1
20130084243 Goetsch et al. Apr 2013 A1
20130096073 Sidelman Apr 2013 A1
20130109575 Kleinschmidt et al. May 2013 A1
20130109576 Shuber et al. May 2013 A1
20130109596 Peterson et al. May 2013 A1
20130121893 Delamarche et al. May 2013 A1
20130130919 Chen et al. May 2013 A1
20130157870 Pushkarev et al. Jun 2013 A1
20130157899 Adler, Jr. et al. Jun 2013 A1
20130171679 Lee et al. Jul 2013 A1
20130178368 Griffiths et al. Jul 2013 A1
20130189700 So et al. Jul 2013 A1
20130203605 Shendure et al. Aug 2013 A1
20130203675 Desimone et al. Aug 2013 A1
20130210639 Link et al. Aug 2013 A1
20130210991 Fonnum et al. Aug 2013 A1
20130211055 Raines et al. Aug 2013 A1
20130225418 Watson Aug 2013 A1
20130225623 Buxbaum et al. Aug 2013 A1
20130243689 Amiji et al. Sep 2013 A1
20130268206 Porreca et al. Oct 2013 A1
20130273640 Krishnan et al. Oct 2013 A1
20130274117 Church et al. Oct 2013 A1
20130296173 Callow et al. Nov 2013 A1
20130311106 White et al. Nov 2013 A1
20130343317 Etemad et al. Dec 2013 A1
20130344508 Schwartz et al. Dec 2013 A1
20140030350 Ashrafi et al. Jan 2014 A1
20140037514 Stone et al. Feb 2014 A1
20140038178 Otto et al. Feb 2014 A1
20140057799 Johnson et al. Feb 2014 A1
20140065234 Shum et al. Mar 2014 A1
20140080717 Li et al. Mar 2014 A1
20140093916 Belyaev et al. Apr 2014 A1
20140120529 Andersen et al. May 2014 A1
20140155274 Xie et al. Jun 2014 A1
20140155295 Hindson et al. Jun 2014 A1
20140194323 Gillevet et al. Jul 2014 A1
20140199331 Robillard et al. Jul 2014 A1
20140199730 Agresti et al. Jul 2014 A1
20140199731 Agresti et al. Jul 2014 A1
20140200166 Rooyen et al. Jul 2014 A1
20140206073 Park et al. Jul 2014 A1
20140206554 Hindson et al. Jul 2014 A1
20140214334 Plattner et al. Jul 2014 A1
20140221239 Carman et al. Aug 2014 A1
20140227684 Hindson et al. Aug 2014 A1
20140227706 Kato et al. Aug 2014 A1
20140228255 Hindson et al. Aug 2014 A1
20140235506 Hindson et al. Aug 2014 A1
20140242664 Zhang et al. Aug 2014 A1
20140243242 Nicol et al. Aug 2014 A1
20140272996 Bemis Sep 2014 A1
20140274740 Srinivasan et al. Sep 2014 A1
20140287963 Hindson et al. Sep 2014 A1
20140302503 Lowe et al. Oct 2014 A1
20140315725 Faham et al. Oct 2014 A1
20140315755 Chen et al. Oct 2014 A1
20140323316 Drmanac et al. Oct 2014 A1
20140338753 Sperling et al. Nov 2014 A1
20140357500 Vigneault et al. Dec 2014 A1
20140357530 Zhang et al. Dec 2014 A1
20140378322 Hindson et al. Dec 2014 A1
20140378345 Hindson et al. Dec 2014 A1
20140378349 Hindson et al. Dec 2014 A1
20140378350 Hindson et al. Dec 2014 A1
20150005188 Levner et al. Jan 2015 A1
20150005199 Hindson et al. Jan 2015 A1
20150005200 Hindson et al. Jan 2015 A1
20150011430 Saxonov Jan 2015 A1
20150011432 Saxonov et al. Jan 2015 A1
20150024950 Bielas et al. Jan 2015 A1
20150031037 Li et al. Jan 2015 A1
20150057163 Rotem et al. Feb 2015 A1
20150066385 Schnall-Levin et al. Mar 2015 A1
20150072396 Gee et al. Mar 2015 A1
20150072899 Ward et al. Mar 2015 A1
20150111256 Church et al. Apr 2015 A1
20150111788 Fernandez et al. Apr 2015 A1
20150119280 Srinivas et al. Apr 2015 A1
20150125904 Ting et al. May 2015 A1
20150133317 Robinson et al. May 2015 A1
20150133344 Shendure et al. May 2015 A1
20150211056 Um et al. Jul 2015 A1
20150218633 Hindson et al. Aug 2015 A1
20150220532 Wong Aug 2015 A1
20150224466 Hindson et al. Aug 2015 A1
20150225777 Hindson et al. Aug 2015 A1
20150225778 Hindson et al. Aug 2015 A1
20150225786 Litterst et al. Aug 2015 A1
20150232942 Abate et al. Aug 2015 A1
20150247182 Faham et al. Sep 2015 A1
20150258543 Baroud et al. Sep 2015 A1
20150259736 Steemers et al. Sep 2015 A1
20150267191 Steelman et al. Sep 2015 A1
20150267246 Baroud et al. Sep 2015 A1
20150291942 Gloeckner et al. Oct 2015 A1
20150292988 Bharadwaj et al. Oct 2015 A1
20150298091 Weitz et al. Oct 2015 A1
20150299772 Zhang Oct 2015 A1
20150299784 Fan et al. Oct 2015 A1
20150329617 Winther et al. Nov 2015 A1
20150329852 Nolan et al. Nov 2015 A1
20150329891 Tan et al. Nov 2015 A1
20150337298 Xi et al. Nov 2015 A1
20150353999 Agresti et al. Dec 2015 A1
20150361418 Reed et al. Dec 2015 A1
20150368638 Steemers et al. Dec 2015 A1
20150368694 Pan et al. Dec 2015 A1
20150376605 Jarosz et al. Dec 2015 A1
20150376608 Kaper et al. Dec 2015 A1
20150376609 Hindson et al. Dec 2015 A1
20150376700 Schnall-Levin et al. Dec 2015 A1
20150379196 Michael et al. Dec 2015 A1
20160008778 Weitz et al. Jan 2016 A1
20160024558 Hardenbol Jan 2016 A1
20160024572 Shishkin et al. Jan 2016 A1
20160025726 Altin et al. Jan 2016 A1
20160032282 Vigneault et al. Feb 2016 A1
20160034093 Xie et al. Feb 2016 A1
20160053253 Salathia et al. Feb 2016 A1
20160059204 Hindson et al. Mar 2016 A1
20160060621 Agresti et al. Mar 2016 A1
20160060691 Giresi et al. Mar 2016 A1
20160115474 Jelinek et al. Apr 2016 A1
20160122753 Mikkelsen et al. May 2016 A1
20160122817 Jarosz et al. May 2016 A1
20160145683 Fan et al. May 2016 A1
20160153005 Zhang et al. Jun 2016 A1
20160160235 Solodushko et al. Jun 2016 A1
20160177359 Ukanis et al. Jun 2016 A1
20160177375 Abate et al. Jun 2016 A1
20160194699 Borodina et al. Jul 2016 A1
20160201125 Samuels et al. Jul 2016 A1
20160203196 Schnall-Levin et al. Jul 2016 A1
20160208323 Bernstein et al. Jul 2016 A1
20160231324 Zhao et al. Aug 2016 A1
20160232291 Kyriazopoulou-Panagiotopoulou et al. Aug 2016 A1
20160244742 Linnarsson et al. Aug 2016 A1
20160244809 Belgrader et al. Aug 2016 A1
20160244811 Edwards Aug 2016 A1
20160244825 Vigneault et al. Aug 2016 A1
20160251697 Nolan et al. Sep 2016 A1
20160257984 Hardenbol et al. Sep 2016 A1
20160281160 Jarosz et al. Sep 2016 A1
20160289670 Samuels et al. Oct 2016 A1
20160289769 Schwartz et al. Oct 2016 A1
20160304860 Hindson et al. Oct 2016 A1
20160314242 Schnall-Levin et al. Oct 2016 A1
20160326583 Johnson et al. Nov 2016 A1
20160348093 Price et al. Dec 2016 A1
20160350478 Chin et al. Dec 2016 A1
20160376663 Brown Dec 2016 A1
20170009274 Abate et al. Jan 2017 A1
20170016041 Greenfield et al. Jan 2017 A1
20170114390 Hindson et al. Apr 2017 A1
20170128937 Hung et al. May 2017 A1
20170144161 Hindson et al. May 2017 A1
20170145476 Ryvkin et al. May 2017 A1
20170159109 Zheng et al. Jun 2017 A1
20170183701 Agresti et al. Jun 2017 A1
20170211127 Mikkelsen et al. Jul 2017 A1
20170235876 Jaffe et al. Aug 2017 A1
20170247757 Hindson et al. Aug 2017 A1
20170260584 Zheng et al. Sep 2017 A1
20170268056 Vigneault et al. Sep 2017 A1
20170321252 Hindson et al. Nov 2017 A1
20170335385 Hindson et al. Nov 2017 A1
20170342404 Hindson et al. Nov 2017 A1
20170343545 Hadrup et al. Nov 2017 A1
20170348691 Bharadwaj et al. Dec 2017 A1
20170356027 Hindson et al. Dec 2017 A1
20170362587 Hindson et al. Dec 2017 A1
20180008984 Bharadwaj et al. Jan 2018 A1
20180015472 Bharadwaj et al. Jan 2018 A1
20180015473 Bharadwaj et al. Jan 2018 A1
20180016634 Hindson et al. Jan 2018 A1
20180030512 Hindson et al. Feb 2018 A1
20180030515 Regev et al. Feb 2018 A1
20180051321 Hindson et al. Feb 2018 A1
20180057868 Walder et al. Mar 2018 A1
20180071695 Weitz et al. Mar 2018 A1
20180080021 Reuter et al. Mar 2018 A1
20180080075 Brenner et al. Mar 2018 A1
20180087050 Zheng et al. Mar 2018 A1
20180088112 Fan et al. Mar 2018 A1
20180094298 Hindson et al. Apr 2018 A1
20180094312 Hindson et al. Apr 2018 A1
20180094313 Hindson Apr 2018 A1
20180094314 Hindson et al. Apr 2018 A1
20180094315 Hindson et al. Apr 2018 A1
20180105808 Mikkelsen et al. Apr 2018 A1
20180112253 Hindson et al. Apr 2018 A1
20180112266 Hindson et al. Apr 2018 A1
20180179580 Hindson et al. Jun 2018 A1
20180179591 Belgrader et al. Jun 2018 A1
20180180601 Pedersen et al. Jun 2018 A1
20180195060 Wang et al. Jul 2018 A1
20180195112 Lebofsky et al. Jul 2018 A1
20180196781 Wong Jul 2018 A1
20180216162 Belhocine et al. Aug 2018 A1
20180237951 Bock et al. Aug 2018 A1
20180258466 Hindson et al. Sep 2018 A1
20180258482 Hindson et al. Sep 2018 A1
20180265928 Schnall-Levin et al. Sep 2018 A1
20180267036 Fan et al. Sep 2018 A1
20180273933 Gunderson et al. Sep 2018 A1
20180274027 Hindson et al. Sep 2018 A1
20180282804 Hindson et al. Oct 2018 A1
20180305685 Li et al. Oct 2018 A1
20180312822 Lee et al. Nov 2018 A1
20180312873 Zheng Nov 2018 A1
20180327839 Hindson et al. Nov 2018 A1
20180334670 Bharadwaj et al. Nov 2018 A1
20180335424 Chen et al. Nov 2018 A1
20180340169 Belhocine et al. Nov 2018 A1
20180340170 Belhocine et al. Nov 2018 A1
20180340171 Belhocine et al. Nov 2018 A1
20180340172 Belhocine et al. Nov 2018 A1
20180340939 Gaublomme et al. Nov 2018 A1
20180346970 Chang et al. Dec 2018 A1
20180346979 Hindson et al. Dec 2018 A1
20180363029 Hindson et al. Dec 2018 A1
20180371538 Blauwkamp et al. Dec 2018 A1
20180371540 Hindson et al. Dec 2018 A1
20180371545 Wong et al. Dec 2018 A1
20180376609 Ju et al. Dec 2018 A1
20190002967 Chen et al. Jan 2019 A1
20190024166 Hindson et al. Jan 2019 A1
20190032129 Hindson et al. Jan 2019 A1
20190032130 Giresi et al. Jan 2019 A1
20190040382 Steemers et al. Feb 2019 A1
20190040464 Giresi et al. Feb 2019 A1
20190060890 Bharadwaj et al. Feb 2019 A1
20190060904 Bharadwaj et al. Feb 2019 A1
20190060905 Bharadwaj et al. Feb 2019 A1
20190064173 Bharadwaj et al. Feb 2019 A1
20190071656 Chang et al. Mar 2019 A1
20190078150 Chen et al. Mar 2019 A1
20190085391 Hindson et al. Mar 2019 A1
20190100632 Delaney et al. Apr 2019 A1
20190127731 Mcdermott May 2019 A1
20190134633 Bharadwaj et al. May 2019 A1
20190136316 Hindson et al. May 2019 A1
20190136317 Hindson et al. May 2019 A1
20190136319 Hindson et al. May 2019 A1
20190153436 Belhocine et al. May 2019 A1
20190153532 Bharadwaj et al. May 2019 A1
20190169666 Hardenbol et al. Jun 2019 A1
20190169700 Abate et al. Jun 2019 A1
20190176152 Bharadwaj et al. Jun 2019 A1
20190203291 Hindson et al. Jul 2019 A1
20190241965 Abate et al. Aug 2019 A1
20190249226 Bent et al. Aug 2019 A1
20190270983 Belhocine et al. Sep 2019 A1
20190276817 Hindson et al. Sep 2019 A1
20190316197 Hindson et al. Oct 2019 A1
20190323088 Boutet et al. Oct 2019 A1
20190330701 Abate et al. Oct 2019 A1
20190344276 Bharadwaj et al. Nov 2019 A1
20190345636 Mcdermott et al. Nov 2019 A1
20190352717 Schnall-Levin Nov 2019 A1
20190367997 Bent et al. Dec 2019 A1
20190376058 Belhocine et al. Dec 2019 A1
20190376118 Belhocine et al. Dec 2019 A1
20200002763 Belgrader et al. Jan 2020 A1
20200005902 Mellen et al. Jan 2020 A1
20200020417 Schnall-Levin et al. Jan 2020 A1
20200024596 Belhocine et al. Jan 2020 A1
20200032335 Alvarado Martinez Jan 2020 A1
20200033237 Hindson et al. Jan 2020 A1
20200033366 Alvarado Martinez Jan 2020 A1
20200056223 Bell Feb 2020 A1
20200063191 Meer et al. Feb 2020 A1
20200199669 Hindson et al. Jun 2020 A1
Foreign Referenced Citations (282)
Number Date Country
102292455 Dec 2011 CN
102050953 Nov 2012 CN
103202812 Jul 2013 CN
0249007 Dec 1987 EP
0271281 Jun 1988 EP
0637996 Jul 1997 EP
1019496 Sep 2004 EP
1672064 Jun 2006 EP
1482036 Oct 2007 EP
1841879 Oct 2007 EP
1923471 May 2008 EP
1944368 Jul 2008 EP
1594980 Nov 2009 EP
1967592 Apr 2010 EP
2258846 Dec 2010 EP
2145955 Feb 2012 EP
1905828 Aug 2012 EP
2136786 Oct 2012 EP
1908832 Dec 2012 EP
2540389 Jan 2013 EP
2635679 Sep 2013 EP
2752664 Jul 2014 EP
2635679 Apr 2017 EP
3013957 Sep 2018 EP
2097692 May 1985 GB
2485850 May 2012 GB
S5949832 Mar 1984 JP
S60227826 Nov 1985 JP
2006507921 Mar 2006 JP
2006289250 Oct 2006 JP
2007015990 Jan 2007 JP
2007268350 Oct 2007 JP
2009513948 Apr 2009 JP
2009208074 Sep 2009 JP
2012131798 Jul 2012 JP
2012522517 Sep 2012 JP
20090081260 Jul 2009 KR
2321638 Apr 2008 RU
WO-8402000 May 1984 WO
WO-9301498 Jan 1993 WO
WO-9418218 Aug 1994 WO
WO-9419101 Sep 1994 WO
WO-9423699 Oct 1994 WO
WO-9530782 Nov 1995 WO
WO-9629629 Sep 1996 WO
WO-9641011 Dec 1996 WO
WO-9802237 Jan 1998 WO
WO-9852691 Nov 1998 WO
WO-9909217 Feb 1999 WO
WO-9942597 Aug 1999 WO
WO-9952708 Oct 1999 WO
WO-9967641 Dec 1999 WO
WO-0008212 Feb 2000 WO
WO-0023181 Apr 2000 WO
WO-0026412 May 2000 WO
WO-0034527 Jun 2000 WO
WO-0043766 Jul 2000 WO
WO-0070095 Nov 2000 WO
WO-0102850 Jan 2001 WO
WO-0114589 Mar 2001 WO
WO-0189787 Nov 2001 WO
WO-0190418 Nov 2001 WO
WO-0127610 Mar 2002 WO
WO-0231203 Apr 2002 WO
WO-02086148 Oct 2002 WO
WO-0218949 Jan 2003 WO
WO-03062462 Jul 2003 WO
WO-2004002627 Jan 2004 WO
WO-2004010106 Jan 2004 WO
WO-2004061083 Jul 2004 WO
WO-2004065617 Aug 2004 WO
WO-2004069849 Aug 2004 WO
WO-2004091763 Oct 2004 WO
WO-2004102204 Nov 2004 WO
WO-2004103565 Dec 2004 WO
WO-2004105734 Dec 2004 WO
WO-2005002730 Jan 2005 WO
WO-2005021151 Mar 2005 WO
WO-2005023331 Mar 2005 WO
WO-2005040406 May 2005 WO
WO-2005049787 Jun 2005 WO
WO-2005082098 Sep 2005 WO
WO-2006030993 Mar 2006 WO
WO-2006040551 Apr 2006 WO
WO-2006071770 Jul 2006 WO
WO-2006078841 Jul 2006 WO
WO-2006086210 Aug 2006 WO
WO-2006096571 Sep 2006 WO
WO-2007001448 Jan 2007 WO
WO-2007002490 Jan 2007 WO
WO-2007012638 Feb 2007 WO
WO-2007018601 Feb 2007 WO
WO-2007024840 Mar 2007 WO
WO-2007081385 Jul 2007 WO
WO-2007081387 Jul 2007 WO
WO-2007084192 Jul 2007 WO
WO-2007089541 Aug 2007 WO
WO-2007093819 Aug 2007 WO
WO-2007111937 Oct 2007 WO
WO-2007114794 Oct 2007 WO
WO-2007121489 Oct 2007 WO
WO-2007133710 Nov 2007 WO
WO-2007138178 Dec 2007 WO
WO-2007139766 Dec 2007 WO
WO-2007140015 Dec 2007 WO
WO-2007147079 Dec 2007 WO
WO-2007149432 Dec 2007 WO
WO-2008021123 Feb 2008 WO
WO-2008091792 Jul 2008 WO
WO-2008102057 Aug 2008 WO
WO-2008109176 Sep 2008 WO
WO-2008121342 Oct 2008 WO
WO-2008061193 Nov 2008 WO
WO-2008134153 Nov 2008 WO
WO-2008135512 Nov 2008 WO
WO-2008150432 Dec 2008 WO
WO-2008135512 Jan 2009 WO
WO-2009005680 Jan 2009 WO
WO-2009011808 Jan 2009 WO
WO-2009015296 Jan 2009 WO
WO-2009023821 Feb 2009 WO
WO-2009048532 Apr 2009 WO
WO-2009061372 May 2009 WO
WO-2009085215 Jul 2009 WO
WO-2009147386 Dec 2009 WO
WO-2009152928 Dec 2009 WO
WO-2010004018 Jan 2010 WO
WO-2010009735 Jan 2010 WO
WO-2010033200 Mar 2010 WO
WO-2010048605 Apr 2010 WO
WO-2010104604 Sep 2010 WO
WO-2010115154 Oct 2010 WO
WO-2010127304 Nov 2010 WO
WO-2010148039 Dec 2010 WO
WO-2010151776 Dec 2010 WO
WO-2010117620 Feb 2011 WO
WO-2011028539 Mar 2011 WO
WO-2011047870 Apr 2011 WO
WO-2011056546 May 2011 WO
WO-2011066476 Jun 2011 WO
WO-2011074960 Jun 2011 WO
WO-2011106314 Sep 2011 WO
WO-2011140627 Nov 2011 WO
WO-2011156529 Dec 2011 WO
WO-2012012037 Jan 2012 WO
WO-2012019765 Feb 2012 WO
WO-2011140510 Mar 2012 WO
WO-2012047889 Apr 2012 WO
WO-2012048340 Apr 2012 WO
WO-2012048341 Apr 2012 WO
WO-2012055929 May 2012 WO
WO-2012061832 May 2012 WO
WO-2012083225 Jun 2012 WO
WO-2012087736 Jun 2012 WO
WO-2012100216 Jul 2012 WO
WO-2012106546 Aug 2012 WO
WO-2012112804 Aug 2012 WO
WO-2012112970 Aug 2012 WO
WO-2012116250 Aug 2012 WO
WO-2012116331 Aug 2012 WO
WO-2012136734 Oct 2012 WO
WO-2012142531 Oct 2012 WO
WO-2012142611 Oct 2012 WO
WO-2012148497 Nov 2012 WO
WO-2012149042 Nov 2012 WO
WO-2012150317 Nov 2012 WO
WO-2012166425 Dec 2012 WO
WO-2012167142 Dec 2012 WO
WO-2013019751 Feb 2013 WO
WO-2013022961 Feb 2013 WO
WO-2013035114 Mar 2013 WO
WO-2013036929 Mar 2013 WO
WO-2013055955 Apr 2013 WO
WO-2013096643 Jun 2013 WO
WO-2013122996 Aug 2013 WO
WO-2013123125 Aug 2013 WO
WO-2013126741 Aug 2013 WO
WO-2013134261 Sep 2013 WO
WO-2013150083 Oct 2013 WO
WO-2013177220 Nov 2013 WO
WO-2013188872 Dec 2013 WO
WO-2014018460 Jan 2014 WO
WO-2014028378 Feb 2014 WO
WO-2014028537 Feb 2014 WO
WO-2014053854 Apr 2014 WO
WO-2014071361 May 2014 WO
WO-2014072703 May 2014 WO
WO-2014074611 May 2014 WO
WO-2014093676 Jun 2014 WO
WO-2014108810 Jul 2014 WO
WO-2014140309 Sep 2014 WO
WO-2014144495 Sep 2014 WO
WO-2014145047 Sep 2014 WO
WO-2014150931 Sep 2014 WO
WO-2014165559 Oct 2014 WO
WO-2014182835 Nov 2014 WO
WO-2014189957 Nov 2014 WO
WO-2014200767 Dec 2014 WO
WO-2014210353 Dec 2014 WO
WO-2015015199 Feb 2015 WO
WO-2015031691 Mar 2015 WO
WO-2015044428 Apr 2015 WO
WO-2014210353 Jul 2015 WO
WO-2015157567 Oct 2015 WO
WO-2015164212 Oct 2015 WO
WO-2015185067 Dec 2015 WO
WO-2015188839 Dec 2015 WO
WO-2015200891 Dec 2015 WO
WO-2015200893 Dec 2015 WO
WO-2016040476 Mar 2016 WO
WO-2016033251 Apr 2016 WO
WO-2016061517 Apr 2016 WO
WO-2016100976 Jun 2016 WO
WO-2016126871 Aug 2016 WO
WO-2016126882 Aug 2016 WO
WO-2016130578 Aug 2016 WO
WO-2016138496 Sep 2016 WO
WO-2016145409 Sep 2016 WO
WO-2016149661 Sep 2016 WO
WO-2016168584 Oct 2016 WO
WO-2016170126 Oct 2016 WO
WO-2016187256 Nov 2016 WO
WO-2016187717 Dec 2016 WO
WO-2016191618 Dec 2016 WO
WO-2016207647 Dec 2016 WO
WO-2016207653 Dec 2016 WO
WO-2016207661 Dec 2016 WO
WO-2017015075 Jan 2017 WO
WO-2017025594 Feb 2017 WO
WO-2017034970 Mar 2017 WO
WO-2017053905 Mar 2017 WO
WO-2017075265 May 2017 WO
WO-2017075294 May 2017 WO
WO-2017079593 May 2017 WO
WO-2017096158 Jun 2017 WO
WO-2017117358 Jul 2017 WO
WO-2017151828 Sep 2017 WO
WO-2017156336 Sep 2017 WO
WO-2017180420 Oct 2017 WO
WO-2017197343 Nov 2017 WO
WO-2017197343 Feb 2018 WO
WO-2018031631 Feb 2018 WO
WO-2018039338 Mar 2018 WO
WO-2018039969 Mar 2018 WO
WO-2018045186 Mar 2018 WO
WO-2018058073 Mar 2018 WO
WO-2018103025 Jun 2018 WO
WO-2018119301 Jun 2018 WO
WO-2018119447 Jun 2018 WO
WO-2018125982 Jul 2018 WO
WO-2018129368 Jul 2018 WO
WO-2018132635 Jul 2018 WO
WO-2018119447 Aug 2018 WO
WO-2018172726 Sep 2018 WO
WO-2018174827 Sep 2018 WO
WO-2018191701 Oct 2018 WO
WO-2018213643 Nov 2018 WO
WO-2018226546 Dec 2018 WO
WO-2018236615 Dec 2018 WO
WO-2018237209 Dec 2018 WO
WO-2019028166 Feb 2019 WO
WO-2019040637 Feb 2019 WO
WO-2019071039 Apr 2019 WO
WO-2019083852 May 2019 WO
WO-2019084043 May 2019 WO
WO-2019084165 May 2019 WO
WO-2019084328 May 2019 WO
WO-2019099751 May 2019 WO
WO-2019108851 Jun 2019 WO
WO-2019113235 Jun 2019 WO
WO-2019118355 Jun 2019 WO
WO-2019126789 Jun 2019 WO
WO-2019148042 Aug 2019 WO
WO-2019152108 Aug 2019 WO
WO-2019157529 Aug 2019 WO
WO-2019165318 Aug 2019 WO
WO-2019169028 Sep 2019 WO
WO-2019169347 Sep 2019 WO
WO-2019191321 Oct 2019 WO
WO-2019217758 Nov 2019 WO
WO-2020028882 Feb 2020 WO
WO-2020142779 Jul 2020 WO
Non-Patent Literature Citations (532)
Entry
Aikawa, et al. Spherical Phospholipid Polymer Hydrogels for Cell Encapsulation Prepared with a Flow-Focusing Microfluidic Channel Device. Langmuir. Jan. 31, 2012;28(4):2145-50. doi: 10.1021/la2037586. Epub Dec. 22, 2011.
Allazetta, et al. Microfluidic Synthesis of Cell-Type-Specific Artificial Extracellular Matrix Hydrogels. Biomacromolecules. Apr. 8, 2013;14(4):1122-31. doi: 10.1021/bm4000162. Epub Mar. 8, 2013.
Anonymous: “Dynal MPC(TM)-S”, Oct. 13, 2008 (Oct. 13, 2008), XP055603532, Retrieved from the Internet on Jul. 9, 2019; URL:< https://www.veritastk.co.jp/products/pdf/120%2020D.Dynal_MPC-S%28rev005%29.pdf>.
Bansal et al. “An MCMC algorithm for haplotype assembly from whole-genome sequence data,” (2008) Genome Res 18:1336-1346.
Bansal et al. “HapCUT: an efficient and accurate algorithm for the haplotype assembly problem,” Bioinformatics (2008) 24:i153-i159.
Baret, “Surfactants in droplet-based microfluidics” Lab Chip (12(3):422-433 (2012).
Bassett, et al. Competitive ligand exchange of crosslinking ions for ionotropic hydrogel formation. J. Mater. Chern. B, 2016,4, 6175-6182.
Bedtools: General Usage, http://bedtools.readthedocs.io/en/latest/content/generalusage.html; Retrieved from the Internet Jul. 8, 2016.
Beer et al. On-Chip, Real-Time, Single-Copy Polymerase Chain Reaction in Picoliter Droplets. Anal Chem 79:8471-8475 (2007).
Bentley et al. “Accurate whole human genome sequencing using reversible terminator chemistry,” (2008) Nature 456:53-59.
Bray, “The JavaScript Object Notation (JSON) Data Interchange Format,” Mar. 2014, retrieved from the Internet Feb. 15, 2015; https://tools.ietf.org/html/rfc7159.
Brenner, et al. “In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs.” Proc Natl Acad Sci USA. Feb. 15, 20005;97(4):1665-7.
Buenrostro, et al., “Tranposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position”, Nature Methods, 2013, 10(12): 1213-1218.
Chen et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nature Methods (2009) 6(9):677-681.
Chien et al. “Multiport flow-control system for lab-on-a-chip microfluidic devices”, Fresenius J. Anal Chem, 371:106-111 (Jul. 27, 2001).
Cleary et al. “Joint variant and de novo mutation identification on pedigrees from highthroughput sequencing data,”J Comput Biol (2014) 21:405-419.
Co-pending PCT/US2019/046940, filed Aug. 16, 2019.
Co-pending U.S. Appl. No. 16/575,280, filed Sep. 18, 2019.
Co-pending U.S. Appl. No. 16/434,076, filed Jun. 6, 2019.
Co-pending U.S. Appl. No. 16/434,084, filed Jun. 6, 2019.
Co-pending U.S. Appl. No. 16/434,095, filed Jun. 6, 2019.
Co-pending U.S. Appl. No. 16/434,102, filed Jun. 6, 2019.
Co-pending U.S. Appl. No. 16/519,863, filed Jul. 23, 2019.
Co-pending U.S. Appl. No. 16/530,930, filed Aug. 2, 2019.
Co-pending U.S. Appl. No. 16/698,740, filed Nov. 27, 2019.
Co-pending U.S. Appl. No. 16/717,375, filed Dec. 17, 2019.
Co-pending U.S. Appl. No. 16/725,673, filed Dec. 23, 2019.
Co-pending U.S. Appl. No. 16/736,323, filed Jan. 7, 2020.
Co-pending U.S. Appl. No. 16/750,757, filed Jan. 23, 2020.
Dangla, et al. Droplet microfluidics driven by gradients of confinement. Proc Natl Acad Sci U S A. Jan. 15, 2013; 110(3): 853-858. Published online Jan. 2, 2013. doi: 10.1073/pnas.1209186110.
Duffy et al., Rapid Protyping of Microfluidic Systems and Polydimethylsiloxane, Anal Chem 70:4974-4984 (1998).
Eid, et al. Real-time DNA sequencing from single polymerase molecules. Science. Jan. 2, 2009;323(5910):133-8. doi: 10.1126/science. 1162986. Epub Nov. 20, 2008.
Ekblom, R. et al. “A field guide to whole-genome sequencing, assembly and annotation” Evolutionary Apps (Jun. 24, 2014) 7(9):1026-1042.
Ellison, et al., EGFR Mutation Testing in Lung Ancer: A Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples, Journal of Clinical Pathology, 2013, 66:79-89.
Ellison et al. Mutations in Active-Site Residues of the Uracil-DNA Glycosytase Encoded by Vaccinia Virus are Incompatible with Virus Viability. J Virology (1996) 70(11):7965-7973.
Farrukh, et al. Bioconjugating Thiols to Poly(acrylamide) Gels for Cell Culture Using Methylsulfonyl Co-monomers. Angew Chem Int Ed Engl. Feb. 5, 2016;55(6):2092-6. doi: 10.1002/anie.201509986. Epub Jan. 6, 2016.
Fox, et al. Accuracy of Next Generation Sequencing Platforms. Next Gener Seq Appl. 2014;1. pii: 1000106.
Gordon et al. “Consed: A Graphical Tool for Sequence Finishing,” Genome Research (1998) 8:198-202.
Hamady, et al. Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nat Methods. Mar. 2008;5(3):235-7. doi: 10.1038/nmeth.1184. Epub Feb. 10, 2008.
Hamady, M. et al. “Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex” Nature Methods (2008) 5(3):235-237, Supplementary Data pp. 1-34.
Heng et al. “Fast and accurate long-read alignment with Burrows-Wheeler transform,” Bioinformatics (2010) 25(14): 1754-1760.
Henke, et al. Enzymatic Crosslinking of Polymer Conjugates is Superior over Ionic or UV Crosslinking for the On-Chip Production of Cell-Laden Microgels. Macromol Biosci. Oct. 2016;16(10): 1524-1532. doi: 10.1002/mabi.201600174. Epub Jul. 21, 2016.
Huang et al. EagleView: A genome assembly viewer for next-generation sequencing technologies, Genome Research (2008) 18:1538-1543.
Illumina, Inc. An Introduction to Next-Generation Sequencing Technology. Feb. 28, 2012.
Islam, et al. Highly multiplexed and strand-specific single-cell RNA 5′ end sequencing. Nat Protoc. Apr. 5, 2012;7(5):813-28. doi: 10.1038/nprot.2012.022.
Jaitin, et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science. Feb. 14, 2014;343(6172):776-9. doi: 10.1126/science.1247651.
Jarosz, M. et al. “Using 1ng of DNA to detect haplotype phasing and gene fusions from whole exome sequencing of cancer cell lines” Cancer Res (2015) 75(supp15):4742.
Jiang et al. Cell-laden microfluidic microgels fortissue regeneration. Lab Chip 16(23):4482-4506 (Nov. 2016).
Kanehisa et al. “KEGG: Kyoto Encyclopedia of Genes and Genomes,” Nucleic Acids Research (2000) 28:27-30.
Kim et al. “HapEdit: an accuracy assessment viewer for haplotype assembly using massively parallel DNA-sequencing technologies,” Nucleic Acids Research (2011) pp. 1-5.
Kobayashi, et al. Effect of slot aspect ratio on droplet formation from silicon straight-through microchannels. J Colloid Interface Sci. Nov. 1, 2004;279(1):277-80.
Kukwikila, et al. Assembly of a biocompatible triazole-linked gene by one-pot click-DNA ligation. Nature Chemistry (2017) doi:10.1038/nchem.2850.
Layer et al. “LUMPY: A probabilistic framework for structural variant discovery,” Genome Biology (2014) 15(6):R84.
Li, et al. Step-emulsification in a microfluidic device. Lab Chip. Feb. 21, 2015;15(4):1023-31. doi: 10.1039/c4lc01289e.
Lippert et al. “”Algorithmic strategies for the single nucleotide polymorphism haplotype assembly problem, Brief. Bionform (2002) 3:23-31.
Maan, et al. Spontaneous droplet formation techniques for monodisperse emulsions preparation—Perspectives for food applications. Journal of Food Engineering. vol. 107, Issues 3-4, Dec. 2011, pp. 334-346.
Madl, et al. “Bioorthogonal Strategies for Engineering Extracellular matrices”, Madal, Chritopher, Adv. Funct. Master. Jan. 19, 2018, vol. 28, 1706046, pp. 1-21.
Marquis, et al. Microfluidics-assisted diffusion self-assembly: toward the control of the shape and size of pectin hydrogel microparticles. Biomacromolecules. May 12, 2014;15(5):1568-78. doi: 10.1021/bm401596m. Epub Apr. 8, 2014.
McCoy, R. et al. “Illumina TruSeq Synthetic Long-Reads Empower De Novo Assembly and Resolve Complex, Highly-Repetitive Transposable Elements” PLOS (2014) 9(9):e1016689.
McKenna, Aaron et al. “The Genome Analysis Toolkit: A MapReduce Framework for Analyzing next-Generation DNA Sequencing Data.” Genome Research 20.9 (2010): 1297-1303. PMC. Web. Feb. 2, 2017.
Miller et al. “Assembly Algorithms for next-generation sequencing data,” Genomics, 95 (2010), pp. 315-327.
Myllykangas et al. “Efficient targeted resequencing of human germline and cancer genomes by oligonucleotide-selective sequencing,” Nat Biotechnol, (2011) 29:1024-1027.
Nisisako, T. et al., Microfluidics large-scale integration on a chip for mass production of monodisperse droplets and particles, The Royal Society of Chemistry: Lab Chip, (Nov. 23, 2007) 8:287-293.
Novak, R. et al., “Single cell multiplex gene detection and sequencing using microfluidicallygenerated agarose emulsions” Angew. Chem. Int. Ed. Engl. (2011) 50(2):390-395.
Pelton, et al. (2011) Microgels and Their Synthesis: An Introduction, in Microgel Suspensions: Fundamentals and Applications (eds A. Fernandez-Nieves, H. M. Wyss, J. Mattsson and D. A. Weitz), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, doi: 10.1002/9783527632992.ch1.
Priest, et al. Generation of Monodisperse Gel Emulsions in a Microfluidic Device, Applied Physics Letters, 88:024106 (2006).
Pushkarev et al. Single-molecule sequencing of an individual human genome, Nature Biotech (2009) 17:847-850.
Ritz, A. et al. “Characterization of structural variants with single molecule and hybrid sequencing approaches” Bioinformatics (2014) 30(24):3458-3466.
Sahin, et al. Microfluidic EDGE emulsification: the importance of interface interactions on droplet formation and pressure stability. Sci Rep. May 27, 2016;6:26407. doi: 10.1038/srep26407.
Sahiner. Single step poly(L-Lysine) microgel synthesis, characterization and biocompatibility tests. Polymer, vol. 121, Jul. 14, 2017, pp. 46-54.
Saikia, et al. Simultaneous multiplexed amplicon sequencing and transcriptome profiling in single cells. Nat Methods. Jan. 2019;16(1):59-62. doi: 10.1038/S41592-018-0259-9. Epub Dec. 17, 2018.
Seiffert, et al. Microfluidic fabrication of smart microgels from macromolecular precursors. 2010. Polymer.
Seiffert. Microgel capsules tailored by droplet-based microfluidics. Chemphyschem. Feb. 4, 2013;14(2):295-304. doi: 10.1002/cphc.201200749. Epub Dec. 6, 2012.
Shah, “Fabrication of mono disperse thermosensitive microgels and gel capsules in micro fluidic devices”, Soft Matter, 4:2303-2309 (2008).
Shelbourne et al., “Fast copper-free click DNA ligation by the ring-strain promoted alkyneazide cycloaddition reaction,” Chem. Commun., 2011, 47, 6257-6259.
Shendure, et al., Accurate Multiplex Polony Sequencing of an Evolved Bacterial Genome. Science 309.5741 (Sep. 2005): 1728-1732. XP002427180, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1117839.
Shih, et al. Photoclick Hydrogels Prepared from Functionalized Cyclodextrin and Poly(ethylene glycol) for Drug Delivery and in Situ Cell Encapsulation. Biomacromolecules. Jul. 13, 2015;16(7):1915-23. doi: 10.1021/acs.biomac.5b00471. Epub Jun. 3, 2015.
Spitale et al., “Structural imprints in vivo decode RNA regulatory mechanisms,” Nature. Mar. 26, 2015;519(7544):486-90; doi: 10.1038/nature14263. Epub Mar. 18, 2015.
SSH Tunnel—Local and Remote Port Forwarding Explained With Examples, Trackets Blog, http://blog.trackets.com/2014/05/17/ssh-tunnel-local-and-remote-port-forwarding-explained with-examples.html; Retrieved from the Internet Jul. 7, 2016.
Tam, et al. Engineering Cellular Microenvironments with Photo- and Enzymatically Responsive Hydrogels: Toward Biomimetic 3D Cell Culture Models. Acc Chem Res. Apr. 18, 2017;50(4):703-713. doi: 10.1021/acs.accounts.6b00543. Epub Mar. 27, 2017.
Tewhey et al. The importance of phase information for human genomics, Nat Rev Genet (2011) 12:215-223.
The SAM/BAM Format Specificatio Working Group, “Sequence Allignment/ Map Format Specification,” Dec. 28, 2014.
Turchinovich, et al. “Capture and Amplification by Tailing and Switching (CATS): An Ultrasensitive Ligation-Independent Method for Generation of DNA Libraries for Deep Sequencing from Picogram Amounts of DNA and RNA.” RNA Biology 11.7 (2014): 817-828. PMC. Web. Nov. 13, 2017.
Umbanhowar, P.B., et al., “Monodisperse Emulsion Generation via Drop Break off in a Coflowing Stream,” Langmuir, vol. 16, pp. 347-351 (2000).
Uttamapinant, et al. Fast, cell-compatible click chemistry with copper-chelating azides for biomolecular labeling.Angew. Chern. Int. End. Engl., Jun. 11, 2012: 51(24) pp. 5852-5856.
Van Duke, et al. Effect of viscosities of dispersed and continuous phases in microchannel oil-in-water emulsification. Microfluid Nanofluid (2010) 9: 77. https://doi.org/10.1007/s10404-009-0521-7.
Velasco, et al. Microfluidic encapsulation of cells in polymer microgels. Small. Jun. 11, 2012;8(11):1633-42. doi: 10.1002/smll.201102464. Epub Mar. 29, 2012.
Voskoboynik, A. et al. The genome sequence of the colonial chordate, Botryllus schlosseri. eLife, 2:e00569 (2013). doi: 10.7554/eLife.00569. Epub Jul. 2, 2013.
Wheeler et al., “Database resources of the National Center for Biotechnology Information,” Nucleic Acids Res. (2007) 35 (Database issue): D5-12.
Zerbino, Daniel, “Velvet Manual—version 1.1,” Aug. 15, 2008, pp. 1-22.
Zerbino, D.R. “Using the Velvet de novo assembler for short-read sequencing technologies” Curr Protoc Bioinformatics. Sep. 2010;Chapter 11:Unit 11.5. doi: 10.1002/0471250953.bi1105s31.
Zerbino et al. “Velvet: Algorithms for de novo short read assembly using de Bruijn graphs,” Genome Research (2008) 18:821-829.
Zhang, H. et al. Massively Parallel Single-Molecule and Single-Cell Emulsion Reverse Transcription Polymerase Chain Reaction using Agarose Droplet Microfluidics. Anal Chem (2012) 84:3599-3606.
Zhang, H. et al. “Massively Parallel Single-Molecule and Single-Cell Emulsion Reverse Transcription Polymerase Chain Reaction using Agarose Droplet Microfluidics” Anal Chem (2012) 84:3599-3606, Supporting Information.
Co-pending U.S. Appl. No. 16/844,141, filed Apr. 9, 2020.
Co-pending U.S. Appl. No. 16/852,906, filed Apr. 20, 2020.
AH006633.3 (Homo sapiens clone P1 and PAC max interactor 1 (MXI1) gene, complete cds, NCBI Reference Sequence, priority to Jun. 10, 2016, 5 pages) (Year:2016).
Ahern, H. The Scientist, vol. 20, pp. 20 and 22. Jul. 1995.
Ailenberg, et al. (2000) Controlled Hot Start and Improved Specificity in Carrying Out PCR Utilizing Touch-Up and Loop Incorporated Primers (TULIPS). BioTechniques, 29:1018-1024. (Year: 2000).
Anonymous: “Three Ways to Get Intimate with Epigenetic Marks”. Oct. 24, 2012. Retrieved from Internet: https://epigenie.com/three-ways-to-get-intimate-with-epigenetic-marks/.
Banchelli, et al. Phospholipid membranes decorated by cholesterol-based oligonucleotides as soft hybrid nanostructures. J Phys Chem B. Sep. 4, 2008;112(35):10942-52. doi: 10.1021/jp802415t. Epub Aug. 9, 2008.
Bentley, et al. 2008. Supplementary Information, pp. 1-55 Nature. Nov. 6, 2008; 456(7218):53-9.
Cejas, P. et al. “Chromatin immunoprecipitation from fixed clinical tissues reveals tumorspecific enhancer profiles” Nature Med (2016) 22(6):685-691.
Co-pending U.S. Appl. No. 16/228,261, filed Dec. 20, 2018.
Co-pending U.S. Appl. No. 16/228,362, filed Dec. 20, 2018.
Co-pending U.S. Appl. No. 16/230,936, filed Dec. 21, 2018.
Co-pending U.S. Appl. No. 16/231,142, filed Dec. 21, 2018.
Co-pending U.S. Appl. No. 16/231,185, filed Dec. 21, 2018.
Co-pending U.S. Appl. No. 16/242,962, filed Jan. 8, 2019.
Co-pending U.S. Appl. No. 16/246,322, filed Jan. 11, 2019.
Co-pending U.S. Appl. No. 16/249,688, filed Jan. 16, 2019.
Co-pending U.S. Appl. No. 16/294,769, filed Mar. 6, 2019.
Epicenter, EZ-Tn5 Transposase, Epicenter, 2012, 1-5. (Year: 2012).
Fanielli, M. et al. “Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples” PNAS (2010) 107(50):21535-21540.
Hebenstreit. Methods, Challenges and Potentials of Single Cell RNA-seq. Biology (Basel). Nov. 16, 2012;1(3):658-67. doi: 10.3390/biology1030658.
Mali, et al. Barcoding cells using cell-surface programmable DNA-binding domains. Nat Methods. May 2013;10(5):403-6. doi: 10.1038/nmeth.2407. Epub Mar. 17, 2013.
Meyer, et al. Targeted high-throughput sequencing of tagged nucleic acid samples. Nucleic Acids Res. 2007;35(15):e97.
Mignardi, M. et al. “Oligonucleotide gap-fill ligation for mutation detection and sequencing in situ” Nucl Acids Res (2015) 43(22):e151.
Pfeifer, et al. Bivalent cholesterol-based coupling of oligonucleotides to lipid membrane assemblies. J Am Chem Soc. Aug. 25, 2004;126(33):10224-5.
10X Genomics. 10x Genomics Chromium™ Single Cell 3′ Solution Utilized for Perturb-seq Approach. Press Release. Dec. 19, 2016. Retrieved from https://www.10xgenomics.eom/news/10x-genomics-chromium-single-cell-3-solution-utilized-perturb-seq-approach/.
Abate, et al. Beating Poisson encapsulation statistics using close-packed ordering. Lab Chip. Sep. 21, 2009;9(18):2628-31. doi: 10.1039/b909386a. Epub Jul. 28, 2009.
Abate, et al. High-throughput injection with microfluidics using picoinjectors. Proc Natl Acad Sci USA. Nov. 9, 2010;107(45):19163-6. doi: 10.1073/pNas.1006888107. Epub Oct. 20, 2010.
Abate et al., Valve-based flow focusing for drop formation. Appl Phys Lett. 2009;94. 3 pages.
Adamson, et al. A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. Cell. Dec. 15, 2016;167(7):1867-1882.e21. doi: 10.1016/j.cell.2016.11.048.
Adamson et al., “Production of arrays of chemically distinct nanolitre plugs via repeated splitting in microfluidic devices”, Lab Chip 6(9): 1178-1186 (Sep. 2006).
Adey, et al. Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density in vitro transposition. Genome Biology 11:R119 (2010).
Adey, et al., “Ultra-low-input, tagmentation-based whole-genome bisulfite sequencing”, Genome Research, 2012, 22 ;6): 1139-1143.
Agasti, et al. Photocleavable DNA barcode-antibody conjugates allow sensitive and multiplexed protein analysis in single cells. J Amer Chem SocePub, Nov. 2, 2012, vol. 134, No. 45, p. 18499-18502.
Agresti, et al. Selection of ribozymes that catalyse multiple-turnover Diels-Alder cycloadditions by using in vitro compartmentalization. Proc Natl Acad Sci USA. Nov. 8, 2005;102(45):16170-5. Epub Oct. 31, 2005.
Ahern, “Biochemical, Reagents Kits Offer Scientists Good Return on Investment” The Scientist (1995) 9(15):1-7.
Aitman, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature. Feb. 16, 2006;439(7078):851-5.
Akselband, “Enrichment of slow-growing marine microorganisms from mixed cultures using gel microdrop (GMD) growth assay and fluorescence-activated cell sorting”, J. Exp. Marine Bioi., 329: 196-205 (2006).
Akselband, “Rapid mycobacteria drug susceptibility testing using gel microdrop (GMD) growth assay and flow cytometry”, J. Microbiol. Methods, 62:181-197 (2005).
Altemos et al., “Genomic Characterization of Large Heterochromatic Gaps in the Human Genome Assembly,” PLOS Computational Biology, May 15, 2014, vol. 10, Issue 5, 14 pages.
Amini, S. et al. “Haplotype-resolved whole-genome sequencing by contiguity-preserving transposition and combinatorial indexing” Nature Genetics (2014) 46:1343-1349 doi:10.1038/ng.3119.
Anna, S.L., et al., “Formation of dispersions using “flow focusing” in microchannels,” Applied Physics Letters, vol. 82, No. 3, pp. 364-366 (2003).
Anonymous, “Oligo(dT)25 cellulose beads” NEB (2012) Retrieved from the Internet:https://www.neb.com/˜/media/Catalog/All-Products/286CA51268E24DE1B06F1CB288698B54/Datacards%20or%Manuals/S1408Datasheet-Lot0011205.pdf.
Anonymous, “Oligotex Handbook” Qiagen (2012) XP055314680, Retrieved from the Internet: URL:http://www.qiagen.com/de/resources/download.apsx?id=f9fald98-d54d-47e7-a20b-8b0cb8975009&lang=en.
Anonymous: “TCEP=HCI” Thermo Scientific, Dec. 31, 2013 (Dec. 31, 2013), XP055508461, Retrieved from the Internet: URL:https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0011306_TCEP_HCI_UG.pdf.
Anonymous: “Viscosity-Basic concepts” (2004) XP055314117, Retrieved from the Internet: URL:http://lhtc.epfl.ch/webdav/site/lhtc/shared/import/migration/2 VISCOSITY.pdf.
Ason et al. DNA sequence bias during Tn5 transposition. Journal of molecular biology 335.5 (2004): 1213-1225.
Attia, et al. Micro-injection moulding of polymer microfluidic devices. Microfluidics and nanofluidics. 2009; 7(1):1-28.
Balikova, et al. Autosomal-dominant microtia linked to five tandem copies of a copy-number variable region at chromosome 4p16. Am J Hum Genet. Jan. 2008;82(1):181-7. doi: 10.1016/j.ajhg.2007.08.001.
Baret, et al. Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity. Lab Chip. Jul. 7, 2009;9(13):1850-8. doi: 10.1039/b902504a. Epub Apr. 23, 2009.
BD. BD Rhapsody™ Single-Cell Analysis System: Analyze hundreds of genes across tens of thousands of single cells in parallel. BD, Becton, Dickinson and Company. BDGM1012 Rev. 1. 2017. 8 pages.
Bentzen, et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat Biotechnol. Oct. 2016;34(10):1037-1045. doi: 10.1038/nbt.3662. Epub Aug. 29, 2016.
Berkum, et al. Hi-C: a method to study the three-dimensional architecture of genomes. J Vis Exp. May 6, 2010;(39). pii: 1869. doi: 10.3791/1869.
Biles et al., Low-fidelity Pyrococcus furiosis DNA polymerase mutants useful in error-prone PCR. Nucl. Acids Res. 32(22):e176 2004.
Bjornsson et al., Intra-individual change overtime in DNA methylation with familial clustering, JAMA, Jun. 25, 2008, vol. 299 No. 24, pp. 2877-2883.
Bodi, K. et al. “Comparison of Commercially Available Target Enrichment Methods for Next-Generation Sequencing” J Biomolecular Techniques (2013) 24:73-86.
Boone, et al. Plastic advances microfluidic devices. The devices debuted in silicon and glass, but plastic fabrication may make them hugely successful in biotechnology application. Analytical Chemistry. Feb. 2002; 78A-86A.
Boulanger, et al., “Massively parallel haplotyping on microscopic beads for the high-throughput phase analysis of single molecules”, PLoS One, vol. 7:1-10, 2012.
Boyle, et al. “High-resolution genome-wide in vivo footprinting of diverse transcription factors in human cells”, Genome Res. Mar. 2011;21(3):456-64.
Braeckmans et al., Scanning the Code. Modern Drug Discovery. 2003:28-32.
Bransky, et al. A microfluidic droplet generator based on a piezoelectric actuator. Lab Chip. Feb. 21, 2009;9(4):516-20. doi: 10.1039/b814810d. Epub Nov. 20, 2008.
Brenner, et al. In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs. Proc Natl Acad Sci USA. Feb. 15, 2000;97(4):1665-70.
Briggs, et al. “Tumor-infiltrating immune repertoires captures by single-cell barcoding in emulsion” with Supplementary material. bioRxiv 134841; doi: https://doi.org/10.1101/134841. Posted May 5, 2017.
Brouzes, et al. Droplet microfluidic technology for single-cell high-throughput screening. Proc Natl Acad Sci USA. Aug. 25, 2009;106(34):14195-200. doi: 10.1073/pnas.0903542106. Epub Jul. 15, 2009.
Brown, K., Targeted Sequencing Using Droplet-Based Microfluidics, RainDance Technologies, 2009, 1-18.
Browning, et al. Haplotype phasing: existing methods and new developments. Nat Rev Genet. Sep. 16, 2011;12(10):703-14. doi: 10.1038/nrg3054. Review.
Buchman GW, et al. Selective RNA amplification: a novel method using dUMP-containing primersand uracil DNA glycosylase. PCR Methods Appl. Aug. 1993; 3(1):28-31.
Buenrostro, et al. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. CurrProtoc Mol Biol.; 109: 21.29.1-21.29.9. doi:10.1002/0471142727.mb2129s109.
Buenrostro, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. Jul. 23, 2015;523(7561):486-90. doi: 10.1038/nature14590. Epub Jun. 17, 2015.
Buenrostro, et al. “Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.” Nat Methods. Dec. 2013;10(12):1213-8. doi: 10.1038/nmeth.2688. Epub Oct. 6, 2013.
Burns, et al. An Integrated Nanoliter DNA Analysis Device. Science. Oct. 16, 1998;282(5388):484-7.
Burns, et al. Microfabricated structures for integrated DNA analysis. Proc Natl Acad Sci U S A. May 28, 1996; 93(11): 5556-5561.
Burns, et al. The intensification of rapid reactions in multiphase systems using slug flow in capillaries. Lab Chip. Sep. 2001;1(1):10-5. Epub Aug. 9, 2001.
Cappuzzo, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. Aug. 1, 2005;23(22):5007-18.
Carroll, “The selection of high-producing cell lines using flow cytometry and cell sorting”, Exp. Op. Bioi. Therp., 4:11 1821-1829 (2004).
Caruccio, et al. Nextera Technology for NGS DNA Library Preparation: Simultaneous Fragmentation and Tagging by In Vitro Transposition, Nextera Technology, 2009, 16-3, 1-3. (Year: 2009).
Caruccio N., Preparation of Next-Generation Sequencing Libraries Using Nextera Technology: Simultaneous DNA Fragmentation and Adaptor Tagging by In Vitro Transposition. Ch. 17 Methods in Microbiology 733:241 (2011).
Casbon, et al., “Reflex: intramolecular barcoding of long-range PCR products for sequencing multiple pooled DNAs”, Nucleic Acids Res., pp. 1-6, 2013.
Chang et al. Droplet-based microfluidic platform for heterogeneous enzymatic assays, 2013, Lab Chip, 13, 1817-1822 (Year: 2013).
Chaudhary “A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins” Proc. Natl. Acad. Sci USA 87: 1066-1070 (Feb. 1990).
Chechetkin et al., Sequencing by hybridization with the generic 6-mer oligonucleotide microarray: an advanced scheme for data processing. J Biomol Struct Dyn. Aug. 2000;l8(1):83-101.
Chen, et al. Chemical transfection of cells in picoliter aqueous droplets in fluorocarbon oil. Anal Chem. Nov. 15, 2011;83(22):8816-20. doi: 10.1021/ac2022794. Epub Oct. 17, 2011.
Choi, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. Jul. 1, 2008;68(13):4971-6. doi: 10.1158/0008-5472.CAN-07-6158.
Chokkalingam, et al. Probing cellular heterogeneity in cytokine-secreting immune cells using droplet-based microfluidics. Lab Chip. Dec. 21, 2013;13(24):4740-4. doi: 10.1039/c3lc50945a.
Chou, et al. Disposable Microdevices for DNA Analysis and Cell Sorting. Proc. Solid-State Sensor and ActuatorWorkshop, Hilton Head, SC. Jun. 8-11, 1998; 11-14.
Christian, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics.186 (2010): 757-761.
Christiansen et al. “The Covalent Eukaryotic Topoisomerase I-DNA Intermediate Catalyzes pH-dependent Hydrolysis and Alcoholysis” J Biol Chem (Apr. 14, 1994) 269(15):11367-11373.
Chu, et al. Controllable monodisperse multiple emulsions. Angew Chem Int Ed Engl. 2007;46(47):8970-4.
Chung, et al. Structural and molecular interrogation of intact biological systems. Nature. May 16, 2013;497(7449):332-7. doi: 10.1038/nature12107. Epub Apr. 10, 2013.
Clark, et al. Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity. Genome Biol. Apr. 18, 2016;17:72. doi: 10.1186/s13059-016-0944-x.
Clausell-Tormos et al., “Droplet-based microfluidic platforms for the encapsulation and screening of mammalian cells and multicellular organisms”, Chem. Biol. 15:427-437 (2008).
Cong, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 339.6121 (Feb. 15, 2013): 819-23. doi: 10.1126/science.1231143. Epub Jan. 3, 2013.
Cook, et al. Copy-number variations associated with neuropsychiatric conditions. Nature. Oct. 16, 2008;455(7215):919-23. doi: 10.1038/nature07458.
Co-pending U.S. Appl. No. 15/440,772, filed Feb. 23, 2017.
Co-pending U.S. Appl. No. 15/449,741, filed Mar. 3, 2017.
Co-pending U.S. Appl. No. 16/033,065, filed Jul. 11, 2018.
Co-pending U.S. Appl. No. 16/043,874, filed Jul. 24, 2018.
Co-pending U.S. Appl. No. 16/044,374, filed Jul. 24, 2018.
Co-pending U.S. Appl. No. 16/052,486, filed Aug. 1, 2018.
Co-pending U.S. Appl. No. 16/056,231, filed Aug. 6, 2018.
Co-pending U.S. Appl. No. 16/107,685, filed Aug. 21, 2018.
Co-pending U.S. Appl. No. 16/138,448, filed Sep. 21, 2018.
Co-pending U.S. Appl. No. 16/144,832, filed Sep. 27, 2018.
Co-pending U.S. Appl. No. 16/160,576, filed Oct. 15, 2018.
Co-pending U.S. Appl. No. 16/160,719, filed Oct. 15, 2018.
Co-pending U.S. Appl. No. 16/165,389, filed Oct. 19, 2018.
Co-pending U.S. Appl. No. 16/206,168, filed Nov. 30, 2018.
Co-pending U.S. Appl. No. 16/212,441, filed Dec. 6, 2018.
Coufal, et al. L1 retrotrans position in human neural progenitor cells. Nature. Aug. 27, 2009;460(7259):1127-31. doi: 10.1038/nature08248. Epub Aug. 5, 2009.
Curcio. Improved Techniques for High-Throughput Molecular Diagnostics. PhD Thesis. 2002.
Cusanovich; et al., “Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing. Sciencexpress, May 7, 2014, p. 1-9.”
Cusanovich, et al. Supplementary materials for Multiplex single-cell profiling of chromatin accessibility by combinatorial cellular indexing. Science. May 22, 2015;348(6237):910-4. doi: 10.1126/science.aab1601. Epub May 7, 2015.
Damean, et al. Simultaneous measurement of reactions in microdroplets filled by concentration gradients. Lab Chip. Jun. 21, 2009;9(12): 1707-13. doi: 10.1039/b821021g. Epub Mar. 19, 2009.
De Bruin et al., UBS Investment Research. Q-Series®: DNA Sequencing. UBS Securities LLC. Jul. 12, 2007. 15 pages.
Dekker, et al. Capturing chromosome conformation. Science. Feb. 15, 2002;295(5558):1306-11.
Delehanty, et al. Peptides for specific intracellular delivery and targeting of nanoparticles: implications for developing nanoparticle-mediated drug delivery. Ther Deliv. Sep. 2010;1(3):411-33.
Demirci, et al. Single cell epitaxy by acoustic picolitre droplets. Lab Chip. Sep. 2007;7(9):1139-45. Epub Jul. 10, 2007.
Depristo et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genet 43:491-498 (2011).
Dey, et al. Integrated genome and transcriptome sequencing of the same cell. Dey, Siddharth S. et al. “Integrated Genome and Transcriptome Sequencing from the Same Cell.” Nature biotechnology 33.3 (2015): 285-289. PMC. Web. Dec. 18, 2017.
Dixit, et al. Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens. Cell. Dec. 15, 2016;167(7):1853-1866.e17. doi: 10.1016/j.cell.2016.11.038.
Doerr, “The smallest bioreactor”, Nature Methods, 2:5 326 (2005).
Doshi, et al. Red blood cell-mimicking synthetic biomaterial particles. Proceedings of the National Academy of Sciences 106.51 (2009): 21495-21499.
Dowding, et al. Oil core/polymer shell microcapsules by internal phase separation from emulsion droplets. II: controlling the release profile of active molecules. Langmuir. Jun. 7, 2005;21(12):5278-84.
Draper, et al. Compartmentalization of electrophoretically separated analytes in a multiphase microfluidic platform. Anal Chem. Jul. 3, 2012;84(13):5801-8. doi: 10.1021/ac301141x. Epub Jun. 13, 2012.
Dressler, et al. Droplet-based microfluidics enabling impact on drug discovery. J Biomol Screen. Apr. 2014;19(4):483-96. doi: 10.1177/1087057113510401. Epub Nov. 15, 2013.
Dressman et al. Supplementary Information pp. 1-2 of article published 2003, PNAS 100(15:8817-22).
Dressman et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl. Acad. Sci. 2003. 100(15):8817-8822.
Drmanac et al., Sequencing by hybridization (SBH): advantages, achievements, and opportunities. AdvBiochem Eng Biotechnol. 2002;77 :75-101.
Droplet Based Sequencing (slides) dated (Mar. 12, 2008).
Eastburn, et al. Ultrahigh-throughput mammalian single-cell reverse-transcriptase polymerase chain reaction in microfluidic droplets. Anal Chem. Aug. 20, 2013;85(16):8016-21. doi: 10.1021/ac402057q. Epub Aug. 8, 2013.
Epicentre., “EZ-Tn5TM Custom Transposome Construction Kits”, http://www.epicentre.com, pp. 1-17, 2012.
Esser-Kahn, et al. Triggered release from polymer capsules. Macromolecules. 2011; 44:5539-5553.
Fabi, et al. Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer. J. Clin. Oncol. 2010; 28:15S. 2010 ASCO Meeting abstract Jun. 14, 2010:1059.
Fan, et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA. Oct. 21, 2008;105(42):16266-71. Epub Oct. 6, 2008.
Fan, et al. Whole-genome molecular haplotyping of single cells. Nature Biotechnology, vol. 29, No. 1. Jan. 1, 2011. pp. 51-57.
Fang, et al. Fluoride-cleavable biotinylation phosphoramidite for 5′-end-labeling and affinity purification of synthetic oligonucleotides. Nucleic Acids Res. Jan. 15, 2003;31(2):708-15.
Fisher, et al. A scalable, fully automated process for construction of sequence-ready human exo me targeted capture libraries. Genome Biol. 2011;12(1):R1. doi: 10.1186/GB-2011-12-1-r1. Epub Jan. 4, 2011.
Frampton, G.M. et al. “Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing” Nature Biotechnology (2013) 31(11):1023-1031. doi:10.1038/nbr.2696.
Fredrickson, et al. Macro-to-micro interfaces for microfluidic devices. Lab Chip. Dec. 2004;4(6):526-33. Epub Nov. 10, 2004.
Freiberg, et al. Polymer microspheres for controlled drug release. Int J Pharm. Sep. 10, 2004;282(1-2):1-18.
Fu, et al. A Microfabricated Fluorescence-Activated Cell Sorter. Nature Biotechnology.1999; 17:1109-1111.
Fulton, et al. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem. Sep. 1997;43(9):1749-56.
Gangadharan et al., DNA transposon Hermes insert into DNA in nucleosome-free regions in vivo, Proc nat Ad Sci, Dec. 21, 2010, vol. 107, No. 51, pp. 1966-1972.
Gao et al., Toehold of dsDNA Exchange Affects the Hydrogel Swelling Kinetic of a Polymer-dsDNA Hybrid Hydrogel, Royal Soc. Chem. 7:1741-1746 (Dec. 20, 2010).
Garstecki, et al. Formation of monodisperse bubbles in a microfluidic flow-focusing device. Applied Physics Letters. 2004; 85(13):2649-2651. DOI: 10.1063/1.1796526.
Gartner, et al. The Microfluidic Toolbox—examples for fluidic interfaces and standardization concepts. Proc. SPIE 4982, Microfluidics, BioMEMS, and Medical Microsystems, (Jan. 17, 2003); doi: 10.1117/12.479566.
Gericke, et al. Functional cellulose beads: preparation, characterization, and applications. Chemical reviews 113.7 (2013): 4812-4836.
Ghadessy, et al. Directed evolution of polymerase function by compartmentalized selfreplication. Proc Natl Acad Sci USA. 2001;98:4552-4557.
Gonzalez, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. Mar. 4, 2005;307(5714):1434-40. Epub Jan. 6, 2005.
Granieri, Lucia. Droplet-based microfluidics and engineering of tissue plasminogen activator for biomedical applications. Ph.D. Thesis, Nov. 13, 2009 (131 pages).
Grasland-Mongrain, et al. Droplet coalescence in microfluidic devices. Jan.-Jul. 2003. 31 pages. http://www.eleves.ens.fr/home/grasland/rapports/stage4.pdf.
Green et al. Insertion site preference of Mu, Tn5, and Tn7 transposons. Mobile DNA 3.1 (2012): 3.
Greenleaf, et al. Assaying the epigenome in limited numbers of cells. Methods. Jan. 15, 2015;72:51-6. doi: 10.1016/j.ymeth.2014.10.010. Epub Oct. 22, 2014.
Guo, et al. Droplet microfluidics for high-throughput biological assays. Lab Chip. Jun. 21, 2012;12(12):2146-55. doi: 10.1039/c2lc21147e. Epub Feb. 9, 2012.
Gyarmati, et al. Reversible disulphide formation in polymer networks: a versatile functional group from synthesis to applications. European Polymer Journal. 2013; 49:1268-1286.
Hamilton, A.J. “microRNA in erythrocytes” Biochem. Soc. Trans. (2010) 38, 229-231.
Han, SW et al. “Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing” PLOS One (2013) 8(5):e64271.
Han, X. et al. “CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation” Science Advances (2015) 1(7): E1500454 (8 pages).
Haring, et al. Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization. Plant Methods. 2007; 3: 11.
Hashimshony, et al. CEL-Seq: Single-Cell RNA-Seq by Multiplexed Linear Amplification. Cell Rep. Sep. 27, 2012;2(3):666-73. doi: 10.1016/j.celrep.2012.08.003. Epub Aug. 30, 2012.
He, “Selective Encapsulation of Single Cells and Subcellular Organelles into Picoliter- and Femtoliter-Volume Droplets” Anal. Chem 77: 1539-1544 (2005).
He, J. et al. “Genotyping-by-sequencing (GBS), an ultimate marker-assisted selections (MAS) tool to accelerate plant breeding” Frontiers in Plant Sci (Sep. 30, 2014) 5:1-8.
Hiatt, et al. Parallel, tag-directed assembly of locally derived short sequence reads. Nat Methods. Feb. 2010;7(2):119-22. doi: 10.1038/nmeth.1416. Epub Jan. 17, 2010.
Hirsch et al. (2002) “Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: uses for protein labeling, detection, and isolation.” Analytical of Biochemistry 308(2):343-357.
Hjerten, et al. General methods to render macroporous stationary phases nonporous and deformable, exemplified with agarose and silica beads and their use in high-performance ionexchange and hydrophobic-interaction chromatography of proteins. Chromatographia 31.1-2 (1991): 85-94.
Holtze, et al. Biocompatible surfactants for water-in-fluorocarbon emulsions. Lab Chip. Oct. 2008;8(10):1632-9. doi: 10.1039/b806706f. Epub Sep. 2, 2008.
Hosokawa, et al. Massively parallel whole genome amplification for single-cell sequencing using droplet microfluidics. Scientific Reports 7, Article No. 5199 (2017).
Hosono S, et al. Unbiased whole-genome amplification directly from clinical samples. Genome Res. May 2003; 13(5):954-64. Epub Apr. 14, 2003.
“How many species of bacteria are there” (wisegeek.com; accessed Jan. 21, 2014).
Hu et al., Shape Controllable Microgel Particles Prepared by Microfluidic Combining External Crosslinking, Biomicrofluidics 6:26502 (May 18, 2012).
Huebner, “Quantitative detection of protein expression in single cells using droplet microfluidics”, Chem. Commun. 1218-1220 (2007).
Hug, et al. Measurement of the number of molecules of a single mRNA species in a complex mRNA preparation. J Theor Biol. Apr. 21, 2003;221 (4):615-24.
Illumina Nextera Enrichment Sample Preparation Guide. Feb. 2013.
Illumina TruSeq Custom Enrichment Kit Data Sheet, (c) 2014.
Imburgio, et al., “Studies of promoter recognition and start site selection by T7 RNA polymerase using a comprehensive collection of promoter variants”, Biochemistry., 39:10419-30, 2000.
Ioannidis, N. Manufacturing of agarose-based chromatographic adsorbents with controlled pore and particle sizes. A thesis submitted to the University of Birmingham for the degree of Doctor of Philosophy. 2009.
Jena, et al. Cyclic olefin copolymer based microfluidic devices for biochip applications: Ultraviolet surface grafting using 2-methacryloyloxyethyl phosphorylcholine. Biomicrofluidics. Mar. 2012;6(1):12822-1282212. doi: 10.1063/1.3682098. Epub Mar. 15, 2012.
Joneja, et al. Linear nicking endonuclease-mediated strand-displacement DNA amplification. Anal Biochem. Jul. 1, 2011;414(1):58-69. doi: 10.1016/j.ab.2011.02.025. Epub Feb. 20, 2011.
JPK “Determining the elastic modulus of biological samples using atomic force microscopy” (https://www.jpk.com/ app-technotes-img/AFM/pdf/jpk-app-elastic-modulus.14-1.pdf) 2009, pp. 1-9 (Year: 2009).
Jung, et al. Micro machining of injection mold inserts for fluidic channel of polymeric biochips. Sensors. 2007; 7(8):1643-1654.
Kamperman, et al. Centering Single Cells in Microgels via Delayed Crosslinking Supports Long-Term 3D Culture by Preventing Cell Escape. Small. Jun. 2017;13(22). doi: 10.1002/smll.201603711. Epub Apr. 28, 2017.
Kaper, et al. Supporting Information for “Whole-genome haplotyping by dilution, amplification, and sequencing.” Proc Natl Acad Sci USA. Apr. 2, 2013;110(14):5552-7. doi: 10.1073/pnas.1218696110. Epub Mar. 18, 2013.
Kaper, et al. Whole-genome haplotyping by dilution, amplification, and sequencing. Proc Natl Acad Sci USA. Apr. 2, 2013;110(14):5552-7. doi: 10.1073/pnas.1218696110. Epub Mar. 18, 2013.
Karmakar, et al. Organocatalytic removal of formaldehyde adducts from RNA and DNA bases. Nat Chem. Sep. 2015;7(9):752-8. doi: 10.1038/nchem.2307. Epub Aug. 3, 2015.
Katsura, et al. Indirect micromanipulation of single molecules in water-in-oil emulsion. Electrophoresis. Jan. 2001;22(2):289-93.
Kebschull, et al. High-Throughput Mapping of Single-Neuron Projections by Sequencing of Barcoded RNA. Neuron. Sep. 7, 2016;91(5):975-87. doi: 10.1016/j.neuron.2016.07.036. Epub Aug. 18, 2016.
Kenis, et al. Microfabrication Inside Capillaries Using Multiphase Laminar Flow Patterning. Science. 1999; 285:83-85.
Khomiakova et al., Analysis of perfect and mismatched DNA duplexes by a generic hexanucleotide microchip. Mol Biol(Mosk). Jul.-Aug. 2003;37(4):726-41. Russian. Abstract only.
Kim et al., Albumin loaded microsphere of amphiphilic poly( ethylene glycol)/poly(a-ester) multiblock copolymer. Eu. J. Pharm. Sci. 2004;23:245-51. Available online Sep. 27, 2004.
Kim, et al. Fabrication of monodisperse gel shells and functional microgels in microfluidic devices. Angew Chem Int Ed Engl. 2007;46(11):1819-22.
Kim, et al. Rapid prototyping of microfluidic systems using a PDMS/polymer tape composite. Lab Chip. May 7, 2009;9(9):1290-3. doi: 10.1039/b818389a. Epub Feb. 10, 2009.
Kirkness et al. “Sequencing of isolated sperm cells for direct haplotyping of a human genome,” Genome Res (2013) 23:826-832.
Kitzman et al. “Haplotype-resolved genome sequencing of a Gujarati Indian individual.” Nat Biotechnol (2011) 29:59-63.
Kitzman, et al. Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med. Jun. 6, 2012;4(137): 137ra76. doi: 10.1126/scitranslmed.3004323.
Kivioja, et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. Nov. 20, 2011;9(1):72-4. doi: 10.1038/nmeth.1778.
Klein, et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell. May 21, 2015;161 (5):1187-201. doi: 10.1016/j.cell.2015.04.044.
Knapp, et al. Generating barcoded libraries for multiplex high-throughput sequencing. Methods Mol Biol. 2012;840:155-70. doi: 10.1007/978-1-61779-516-9_19.
Knight, et al. Subtle chromosomal rearrangements in children with unexplained mental retardation. Lancet. Nov. 13, 1999;354(9191):1676-81.
Kolodeziejczyk et al., “The technology and biology of single-cell RNA sequencing”, Molecular Cell, vol. 58 (May 21, 2015).
Korlach et al., Methods in Enzymology, Real-Time DNA Sequencing from Single Polymerase Molecules, (2010) 472:431-455.
Koster et al., “Drop-based microfluidic devices for encapsulation of single cells”, Lab on a Chip the Royal Soc. of Chem. 8:1110-1115 (2008).
Kozarewa, et al., “96-plex molecular barcoding for the Illumina Genome Analyzer”, Methods Mol Biol., 733:279-98, 2011.
Kozarewa, et al. “Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of GC-biased genomes”, Nat Methods., 6: 291-5, 2009.
Kutyavin, et al. Oligonucleotides containing 2-aminoadenine and 2-thiothymine act as selectively binding complementary agents. Biochemistry. Aug. 27, 1996;35(34):11170-6.
Kwok, et al., “Single-molecule analysis for molecular haplotyping”, Hum Mutat., 23:442-6, 2004.
Lagally, et al. Single-Molecular DNA Amplification and Analysis in an Integrated Microfluidic Device. Anal Chem. Feb. 1, 2001;73(3):565-70.
Lagus, et al. A review of the theory, methods and recent applications of high-throughput single-cell droplet microfluidics. J. Phys. D: Appl. Phys. (2013) 46:114005. (21 pages).
Lai; et al., “”Characterization and Use of Laser-Based Lysis for Cell Analysis On-Chip“, Journal of the Royal Society, Interface, vol. 5, Supplement 2, pages S113-S121, Oct. 2008, (Year:2008)”, Journal of the Royal Society, Interface, Oct. 2008, vol. 5, Supplement 2, S113-S121.
Laird et al., Hairpin-bisulfite PCR: Assessing epigenetic methylation patterns on complementary strands of individual DNA molecules, 2004, PNAS, 101, 204-209.
Lake, et al. “Integrative Single-Cell Analysis by Transcriptional and Epigenetic States in Human Adult Brain”. Apr. 19, 2017. doi: https://doi.org/10.1101/128520.
Lan, et al. “Single-cell genome sequencing at ultra-high-throughput with microfluidic droplet barcoding” with Supplementary Material. Nat Biotechnol. May 29, 2017. doi: 10.1038/nbt.3880. [Epub ahead of print].
Lander, et al. Initial sequencing and analysis of the human genome. Nature, 409 (Feb. 15, 2001): 860-921.
Lasken, et al. (1996) Archaebacterial DNA Polymerases Tightly Bind Uracil-containing DNA. The Journal of Biological Chemistry, 271 (30):17692-17696 (Year: 1996).
Lebedev, A. et al. “Hot Start PCR with heat-activatable primers: a novel approach for improved PCR performance” NAR (2008) 36(20):E131-1.
Lee, et al. ACT-PRESTO: Rapid and consistent tissue clearing and labeling method for3-dimensional (3D) imaging. Sci Rep. Jan. 11, 2016;6:18631. doi: 10.1038/srep18631.
Lee et al. Alginate: Properties and biomedical applications. Prog Polym Sci 37(1):106-126 (2012).
Lee, et al., “Highly multiplexed subcellular RNA sequencing in situ. Science. Mar. 21, 2014;343(6177):1360-3. doi: 10.1126/science.1250212. Epub Feb. 27, 2014.”
Lee, J-H. et al. “Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues” Nature Protocols (Feb. 12, 2015) 10(3):442-458.
Lennon; et al., “Lennon et al. A scalable, fully automated process for construction of sequence-ready barcoded libraries for 454. Genome Biology 11:R15 (2010).”
Li, et al. A single-cell-based platform for copy number variation profiling through digital counting of amplified genomic DNA fragments. ACS Appl Mater Interfaces. Mar. 24, 2017. doi: 10.1021/acsami.7b03146. [Epub ahead of print].
Li, Y., et al., “PEGylated PLGA Nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats,” Journal of Controlled Release, vol. 71, pp. 203-211 (2001).
Lienemann, et al. Single cell-laden protease-sensitive microniches for long-term culture in 3D. Lab Chip. Feb. 14, 2017;17(4):727-737. doi: 10.1039/c6lc01444e.
Linch, et al. Bone marrow processing and cryopreservation. Journal of Clinical Pathology; Feb. 1982, vol. 35, No. 2; pp. 186-190.
“List of sequenced bacterial genomes” (Wikipedia.com; accessed Jan. 24, 2014).
Liu, et al. Preparation of uniform-sized PLA microcapsules by combining Shirasu porous glass membrane emulsification technique and multiple emulsion-solvent evaporation method. J Control Release. Mar. 2, 2005;103(1):31-43. Epub Dec. 21, 2004.
Liu, et al. Smart thermo-triggered squirting capsules for Nanoparticle delivery. Soft Matter. 2010; 6(16):3759-3763.
Lo, et al. On the design of clone-based haplotyping. Genome Biol. 2013;14(9):R100.
Loscertales, I.G., et al., “Micro/Nano Encapsulation via Electrified Coaxial Liquid Jets,” Science, vol. 295, pp. 1695-1698 (2002).
Love, “A microengraving method for rapid selection of single cells producing antigen-specific antibodies”, Nature Biotech, 24:6 703 (Jun. 2006).
Lowe, Adam J. Norbornenes and [n]polynorbornanes as molecular scaffolds for anion recognition. Ph.D. Thesis (May 2010). (361 pages).
Lundin, et al., “Hierarchical molecular tagging to resolve long continuous sequences by massively parallel sequencing”, Sci Rep., 3:1186, 2003.
Lupski. Genomic rearrangements and sporadic disease. Nat Genet. Jul. 2007;39(7 Suppl):S43-7.
Macaulay; et al., “G&T-seq: parallel sequencing of single-cell genomes and transcriptomes. Nature Methods, 2015, p. 1-7.”
Macaulay, et al. Single-Cell Multiomics: Multiple Measurements from Single Cells. Trends in Genetics 33.2 (2017): 155-168. PMC. Web. Dec. 18, 2017.
Macosko, et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell. May 21, 2015;161(5):1202-14. doi: 10.1016/j.cell.2015.05.002.
Mair, et al. Injection molded microfluidic chips featuring integrated interconnects. Lab Chip. Oct. 2006;6(10): 1346-54. Epub Jul. 31, 2006.
Makino, et al. Preparation of hydrogel microcapsules: Effects of preparation conditions upon membrane properties. Colloids and Surfaces B: Biointerfaces. Nov. 1998; 12(2), 97-104.
Man. Monolithic Structures for Integrated Microfluidic Analysis. PhD Thesis. 2001.
Marcus. Gene method offers diagnostic hope. The Wall Street Journal. Jul. 11, 2012.
Margulies 2005 Supplementary methods (Year: 2005).
Margulies et al. “Genome sequencing in microfabricated high-density picoliter reactors”, Nature (2005) 437:376-380.
Maricic T, et al. Optimization of 454 sequencing library preparation from small amounts of DNA permits sequence determination of both DNA strands. Biotechniques. Jan. 2009; 46(1):51-2, 54-7.
Matochko, et al. Uniform amplification of phage display libraries in monodisperse emulsions. Methods. Sep. 2012;58(1):18-27. doi: 10.1016/j.ymeth.2012.07.012. Epub Jul. 20, 2012.
Mazutis, et al. Selective droplet coalescence using microfluidic systems. Lab Chip. Apr. 24, 2012;12(10):1800-6. doi: 10.1039/c2lc40121e. Epub Mar. 27, 2012.
McGinnis, et al. MULTI-seq: Scalable sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. bioRxiv 387241; doi: https://doi.org/10.1101/387241.
Merriman, et al. Progress in ion torrent semiconductor chip based sequencing. Electrophoresis. Dec. 2012;33(23):3397-417. doi: 10.1002/elps.201200424.
“Meyer, et al., From micrograms to picograms: quantitative PCR reduces the material demands of high-throughput sequencing, Nucleic Acids Research, 2008, vol. 36, No. 1, 6 pages”.
Microfluidic ChipShop. Microfluidic product catalogue. Mar. 2005.
Microfluidic ChipShop. Microfluidic product catalogue. Oct. 2009.
Miller JC, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 2007;25:778-785.
Miller-Stephenson Chemicals 157 FS Series catalog, www.miller-stephenon.com.
MiRNA (http://www.exiqon.com/what-are-microRNAs) accessed Oct. 19, 2017.
Mirzabekov, “DNA Sequencing by Hybridization—a Megasequencing Method and a Diagnostic Tool?” Trends in Biotechnology 12(1): 27-32 (1994).
Moore, et al. Behavior of capillary valves in centrifugal microfluidic devices prepared by three-dimensional printing. Microfluidics and Nanofluidics. 2011; 10(4):877-888.
Morgan, et al. Chapter 12: Human microbiome analysis. PLoS Comput Biol. 2012;8(12):e1002808. doi: 10.1371/journal.pcbi.1002808. Epub Dec. 27, 2012.
Morimoto, et al. Monodisperse semi-permeable microcapsules for continuous observation of cells. 2009. Lab Chip 9(15):2217-2223.
Mouritzen et al., Single nucleotide polymorphism genotyping using locked nucleic acid (LNa). Expert Rev Mol Diagn. Jan. 2003;3(1):27-38.
Mozhanova, A.A. et al. “Local elastic properties of biological materials studied by SFM” (2003) XP055314108, Retrieved from the Internet: URL:http://www.ntmdt.com/data/media/files/publications/2003/08.08_a.a.mozhanova_n.i.n_english.pdf.
Muotri, et al. L1 retrotransposition in neurons is modulated by MeCP2. Nature. Nov. 18, 2010;468(7322):443-6. doi: 10.1038/nature09544.
Myllykangas et al., Targeted Sequencing Library Preparation by Genomic DNA Circularization, BMC Biotechnology, 2011, 11(122), 1-12.
Nagano, et al. Single-cell Hi-C reveals cell-to-cell variability in chromosome structure. Nature. Oct. 3, 2013;502(7469):59-64. doi: 10.1038/nature12593. Epub Sep. 25, 2013.
Nagashima, et al. Preparation of monodisperse poly (acrylamide-co-acrylic acid) hydrogel microspheres by a membrane emulsification technique and their size-dependent surface properties. Colloids and Surfaces B: Biointerfaces. Jun. 15, 1998; 11(1-2), 47-56.
Narayanan, J. et al. “Determination of agarose gel pore size: Absorbance measurements vis a vis other techniques” Journal of Physics: Conference Series 28 (2006) 83-86 (Year: 2006).
Navin. The first five years of single-cell cancer genomics and beyond. Genome Res. Oct. 2015;25(10):1499-507. doi: 10.1101/gr.191098.115.
Nguyen, et al. In situ hybridization to chromosomes stabilized in gel microdrops. Cytometry. 1995;21:111-119.
Nisisako, et al. Droplet formation in a microchannel network. Lab Chip. Feb. 2002;2(1):24-6. Epub Jan. 18, 2002.
Nisisako, T. et al. “Droplet Formation in a Microchannel on PMMA Plate” Abstract. 2001 Kluwer Academic Publishers. p. 137-138.
Novak, et al. Single cell multiplex gene detection and sequencing using microfluidicallygenerated agarose emulsions. Angew Chem Int Ed Engl. Jan. 10, 2011;50(2):390-5. doi: 10.1002/anie.201006089.
Oberholzer, et al. Polymerase chain reaction in liposomes. Chem Biol. Oct. 1995;2(10):677-82.
Ogawa, et al. Production and characterization of O/W emulsions containing cationic droplets stabilized by lecithin-chitosan membranes. J Agric Food Chem. Apr. 23, 2003;51(9):2806-12.
Okushima, S., et al,. “Controlled Production ofMonodisperse Double Emulsions by Two-Step Droplet Breakup in Microfluidic Devices,” Langmuir, vol. 20, pp. 9905-9908 (2004).
Oligotex Handbook. For purification of poly A+ RNA from total RNA and directly from cultured cells or tissues as well as purification of polyadenylated in vitro transcripts. Jun. 2012.
Orakdogen, N. “Novel responsive poly(N,N-dimethylaminoethyl methacrylate) gel beads: preparation, mechanical properties and pH-dependent swelling behavior” J Polym Res (2012) 19:9914.
Oyola, et al., “Optimizing Illumina next-generation sequencing library preparation for extremely AT-biased genomes”, BMC Genomics.,13:1, 2012.
Pantel, et al. Detection methods of circulating tumor cells. J Thorac Dis. Oct. 2012;4(5):446-7. doi: 10.3978/j.issn.2072-1439.2012.08.15.
Park. ChIP-seq: advantages and challenges of a maturing technology. Nature Reviews Genetics vol. 10, pp. 669-680 (2009).
Patel, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. Jun. 20, 2014;344(6190): 1396-401. doi: 10.1126/science.1254257. Epub Jun. 12, 2014.
Perez, C., et al., “Poly(lactic acid)-poly(ethylene glycol) Nanoparticles as new carriers for the delivery of plasmid DNA,” Journal of Controlled Release, vol. 75, pp. 211-224 (2001).
Perrott, Jimmy. Optimization and Improvement of Emulsion PCR for the Ion Torrent Next-Generation Sequencing Platform. (2011) Thesis.
Peters, B.A. et al. Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. Nature, 487(7406):190-195 (Jul. 11, 2012).
Picot, J. et al. “A biomimetic microfluidic chip to study the circulation and mechanical retention of red blood cells in the spleen” Am J Hematology (Jan. 12, 2015) 90(4):339-345.
Pinto, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. Jul. 15, 2010;466(7304):368-72. doi: 10.1038/nature09146. Epub Jun. 9, 2010.
Plunkett, et al. Chymotrypsin responsive hydrogel: application of a disulfide exchange protocol for the preparation of methacrylamide containing peptides. Biomacromolecules. Mar.-Apr 2005;6(2):632-7.
“Portable Water Filters” (http://www.portablewaterfilters.org/water-filter-guide/particle-contaminant-size-chart-microns/) 2015, accessed Oct. 19, 2017.
Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science. 2003;300:763.
Pott, et al. Single-cell ATAC-seq: strength in numbers. Genome Biol. Aug. 21, 2015; 16:172. doi: 10.1186/s13059-015-0737-7.
Preissl, et al. Single nucleus analysis of the chromatin landscape in mouse forebrain development. Posted Jul. 4, 2017. bioRxiv 159137; doi: https://doi.org/10.1101/159137.
“U.S. Appl. No. 61/982,001, filed Apr. 21, 2014 (Year:2014)”.
Rakszewska, A. et al. “One drop at a time: toward droplet microfluidics as a versatile tool for single-cell analysis” NPG Asia Materials (2014) 6(10):e133 (12 pages).
Ram, et al. Strategy for microbiome analysis using 16S rRNA gene sequence analysis on the Illumina sequencing platform. Syst Biol Reprod Med. Jun. 2011;57(3):162-70. doi: 10.3109/19396368.2011.555598. Epub Mar. 1, 2011.
Ramsey, J.M. “The burgeoning power of the shrinking laboratory” Nature Biotech (1999) 17:1061-1062.
Ramskold et al. (2012) “Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells” Nature Biotechnology 30(8):777-782.
Ran et al. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8:2281-2308 (2013).
Reis, A. et al. “CRISPR/Cas9 and Targeted Genome Editing: A New Era in Molecular Biology” (2014) XP002766825: URL:https://ww.neb.com/tools-and-resources/feabture-articles/crispr-cas9-and-targeted-genome-editing-a-new-era-in-molecular-biology.
Reisner, et al., “Single-molecule denaturation mapping of DNA in nanofluidic channels”, Proc Natl Acad Sci U.S.A., 107: 13294-9, 2010.
Repp et al. “Genotyping by Multiplex Polymerase Chain Reaction for Detection of Endemic Hepatitis B Virus Transmission” J Clinical Microbiology (1993) 31:1095-1102.
Richardson, et al. Novel inhibition of archaeal family-D DNA polymerase by uracil. Nucleic acids research 41.7 (2013): 4207-4218.
Roche. Using Multiplex Identifier (MID) Adaptors for the GS FLX Titanium Chemistry Basic MID Set Genome Sequencer FLX System, Technical Bulletin 004-2009, (Apr. 1, 2009) pp. 1-7. URL:http://454.com/downloads/my454/documentation/technical-bulletins/TCB-09004 Using MultiplexIdentifierAdaptorsForTheGSFLXTitaniumSeriesChemistry-BasicMIDSet.pdf.
Roche. Using Multiplex Identifier (MID) Adaptors for the GS FLX Titanium Chemistry Extended MID Set Genome Sequencer FLX System, Technical Bulletin 005-2009, (Apr. 1, 2009) pp. 1-7. URL:http://454.com/downloads/my454/documentation/technical-bulletins/TCB-09005UsingMultiplexldentifierAdaptorsForTheGSFLXTitaniumChemistry-ExtendedMIDSet.pdf.
Rodrigue, S et al. “Whole genome amplification and de novo assembly of single bacterial cells” PLoS One. Sep. 2, 2009;4(9):e6864. doi: 10.1371/journal.pone.0006864.
Rogozin, et al. A highly conserved family of inactivated archaeal B family DNA polymerases. Biol Direct. Aug. 6, 2008;3:32. doi: 10.1186/1745-6150-3-32.
Ropers. New perspectives for the elucidation of genetic disorders. Am J Hum Genet. Aug. 2007;81 (2):199-207. Epub Jun. 29, 2007.
Rotem, et al. High-Throughput Single-Cell Labeling (Hi-SCL) for RNA-Seq Using Drop-Based Microfluidics. PLoS One. May 22, 2015;10(5):e0116328. doi: 10.1371/journal.pone.0116328. eCollection 2015.
Rotem, et al. Single Cell Chip-Seq Using Drop-Based Microfluidics. Abstract #50. Frontiers of Single Cell Analysis, Stanford University Sep. 5-7, 2013.
Rotem, et al. Single-cell ChlP-seq reveals cell subpopulations defined by chromatin state. Nat Biotechnol. Nov. 2015;33(11):1165-72. doi: 10.1038/nbt.3383. Epub Oct. 12, 2015.
Ryan, “Rapid assay for mycobacterial growth and antibiotic susceptibility using gel microdrop and encapsulation”, J. Clinical Microbial., 33:7 1720-1726 (1995).
Sakaguchi, et al. (1996) Cautionary Note on the Use of dUMP-Containing PCR Primers with Pfu and VentR. Biotechniques, 21(3): 369-370 (Year: 1996).
Sander JD, et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat. Methods. 2011;8:67-69.
Savva, et al. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. Feb. 9, 1995;373(6514):487-93.
Schirinzi et al., Combinatorial sequencing-by-hybridization: Analysis of the NF1 gene. Genet Test. 2006 Spring;10(1):8-17.
Schmeider, et al. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS One. Mar. 9, 2011;6(3):e17288. doi: 10.1371/journal.pone.0017288.
Schmitt, “Bead-based multiplex genotyping of human papillomaviruses”, J. Clinical Microbial., 44:2 504-512 (2006).
Schubert, et al. Microemulsifying fluorinated oils with mixtures of fluorinated and hydrogenated surfactants. Colloids and Surfaces A; Physicochemical and Engineering Aspects, 84(1994) 97-106.
Schwartz, et al., “Capturing native long-range contiguity by in situ library construction and optical sequencing”, PNAS (Nov. 2012), 109(46)18749-18754.
Sebat, et al. Strong association of de novo copy number mutations with autism. Science. Apr. 20, 2007;316(5823):445-9. Epub Mar. 15, 2007.
Seiffert, et al. Smart microgel capsules from macromolecular precursors. J Am Chem Soc. May 12, 2010;132(18):6606-9. doi: 10.1021/ja102156h.
Shahi, et al. Abseq: Ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding. Sci Rep. 2017; 7: 44447. Published online Mar. 14, 2017. doi: 10.1038/srep44447.
Shaikh, et al. A modular microfluidic architecture for integrated biochemical analysis. Proc Natl Acad Sci USA. Jul. 12, 2005;102(28):9745-50. Epub Jun. 28, 2005.
Shimkus, et al. A chemically cleavable biotinylated nucleotide: usefulness in the recovery of protein-DNA complexes from avidin affinity columns. Proc Natl Acad Sci USA. May 1985;82(9):2593-7.
Shlien, et al. Copy number variations and cancer. Genome Med. Jun. 16, 2009;1(6):62. doi: 10.1186/gm62.
Shlien, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci USA. Aug. 12, 2008;105(32):11264-9. doi: 10.1073/pnas.0802970105. Epub Aug. 6, 2008.
Shuttleworth, et al. Recognition of the pro-mutagenic base uracil by family B DNA polymerases from archaea. J Mol Biol. Mar. 26, 2004;337(3):621-34.
Sigma. Streptavidin-agarose (S1638) product information sheet, www.sigma-aldrich.com.
Simeonov et al., Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection. Nucleic Acids Res. Sep. 1, 2002;30(17):e91.
Simon, et al., “Using formaldehyde-assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA”, Nature Protocols, 2012, 7(2): 256-267.
Skerra. Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerases with proofreading activity. Nucleic Acids Res. Jul. 25, 1992; 20(14):3551-4.
Smith, et al. Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples. Nucleic Acids Research, 38(13): e142 (2010).
Song, et al., “DNase-seq: A High-Resolution Technique for Mapping Active Gene Regulatory Elements across the Senome from Mammalian Cells”, Cold Spring Harbor Laboratory Press, 2010, 2010(2), doi:10.1101/pdb.prot5384.
Song, et al. Reactions in droplets in microfluidic channels. Angew Chem Int Ed Engl. Nov. 13, 2006;45(44):7336-56.
Sorokin et al., Discrimination between perfect and mismatched duplexes with oligonucleotide gel microchips: role of thermodynamic and kinetic effects during hybridization. J Biomol Struct Dyn. Jun. 2005;22(6):725-34.
Holmberg, et al. The biotin-streptavidin interaction can be reversibly broken using water at elevated temperatures. Feb. 2, 2005. Electrophoresis, 26:501-510.
Invitrogen Dynal. Dynabeads M-280 Streptavidin 2006 product sheet.
Morton. Parameters of the human genome. Apr. 23, 1991. Proceedings of the National Academy of Sciences of the United States of America, 88: 7474-7476.
National Human Genome Research Institute (NHGRI). The Human Genome Project Completion: Frequently Asked Questions. Last Updated: Oct. 30, 2010.
Qiagen. Omniscript Reverse Transcription Handbook. Oct. 2010.
Spormann Laboratory, Polymerase Chain Reaction (PCR), Alfred Spormann Laboratory, 2009, 1-3. (Year: 2009).
Stoeckius, et al. Large-scale simultaneous measurement of epitopes and transcriptomes in single cells. bioRxiv 113068; doi: https://doi.org/10.1101/113068.
Stoeckius, et al. Simultaneous epitope and transcriptome measurement in single cells. Nature methods. Jul. 31, 2017. Supplemental Materials.
Su, et al., Microfluidics-Based Biochips: Technology Issues, Implementation Platforms, and Design-Automation Challenges. IEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems. 2006;25(2):211-23. (Feb. 2006).
Sun et al., Progress in research and application of liquid-phase chip technology. Chinese Journal Experimental Surgery. May 2005;22(5):639-40.
Susaki, et al. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell. Apr. 24, 2014;157(3):726-39. doi: 10.1016/j.cell.2014.03.042. Epub Apr. 17, 2014.
Syed, et al. Next-generation sequencing library preparation: simultaneous fragmentation and tagging using in vitro transposition. Nature Methods 2 pgs (Nov. 2009).
Tawfik, D.S., et al., “Man-made cell-like compartments for molecular evolution,” Nature Biotechnology, vol. 16, pp. 652-656 (1998).
Tayyab, S. et al. “Size exclusion chromatography and size exclusion HPLC of proteins” Biochem Ed, Pergamon, (1991) 19(3):149-152.
Tewhey, et al. Microdroplet-based PCR amplification for large-scale targeted sequencing. Nat Biotechnol. Nov. 2009;27(11):1025-31. doi: 10.1038/nbt.1583. Epub Nov. 1, 2009.
Tewhey et al., Supplementary Materials, Nature Biotechnology, 2009, 27(11), 1-22.
Thaxton, C.S. et al. “A Bio-Bar-Code Assay Based Upon Dithiothreitol Oligonucleotide Release” Anal Chem (2005) 77:8174-8178.
Theberge, et al. Microdroplets in microfluidics: an evolving platform for discoveries in chemistry and biology. Angew Chem Int Ed Engl. Aug. 9, 2010;49(34):5846-68. doi: 10.1002/anie.200906653.
Thermofisher, Protocols, M-270 Streptavidin, ThermoFisherScientific, 2007, 1-5. (Year: 2007).
Thorsen, et al. Dynamic pattern formation in a vesicle-generating microfluidic device. Physical Review Letters. American Physical Society. 2001; 86(18):4163-4166.
Tomer, et al. Advanced CLARITY for rapid and high-resolution imaging of intact tissues. Nat Protoc. Jul. 2014;9(7):1682-97. doi: 10.1038/nprot.2014.123. Epub Jun. 19, 2014.
Tonelli, et al. Perfluoropolyether functional oligomers: unusual reactivity in organic chemistry. Journal of fluorine chemistry. 2002; 118(1)″107-121.
Tubeleviciute, et al. Compartmentalized self-replication (CSR) selection of Thermococcus litoralis Sh1B DNa polymerase for diminished uracil binding. Protein Eng Des Sel. Aug. 2010;23(8):589-97. doi: 10.1093/protein/gzq032. Epub May 31, 2010.
Turner, et al. Assaying chromosomal inversions by single-molecule haplotyping. Nat Methods. Jun. 2006;3(6):439-45.
Turner, et al., “High-throughput haplotype determination over long distances by haplotype fusion PCR and ligation haplotyping”, Nat Protoc., 4:1771-83, 2009.
Turner, et al. Methods for genomic partitioning. Annu Rev Genomics Hum Genet. 2009;10:263-84. doi: 10.1146/annurev-genom-082908-150112. Review.
Ullal et al. Cancer Cell Profiling by Barcoding Allows Multiplexed Protein Analysis in Fine-Needle Aspirates. Sci Transl Med. Jan. 15, 2014; 6(219): 219ra9.
Ushijima et al., Detection and interpretation of altered methylation patterns in cancer cells, 2005, Nature reviews, 5, 223-231.
Van Nieuwerburgh, et al., “Illumina mate-paired DNA sequencing-library preparation using Cre-Lox recombination”, Nucleic Acids Res., 40:1-8, 2012.
Wagner, et al. Biocompatible fluorinated polyglycerols for droplet microfluidics as an alternative to PEG-based copolymer surfactants. Lab Chip. Jan. 7, 2016;16(1):65-9. doi: 10.1039/c5lc00823a. Epub Dec. 2, 2015.
Wang, et al. A novel thermo-induced self-bursting microcapsule with magnetic-targeting property. Chemphyschem. Oct. 5, 2009;10(14):2405-9.
Wang, et al. Digital karyotyping. Proc Natl Acad Sci USA. Dec. 10, 2002;99(25):16156-61. Epub Dec. 2, 2002.
Wang et al., “Self-Formed Adaptor PCR: a Simple and Efficient Method for Chromosome Walking”, Applied and Environmental Microbiology (Aug. 2007), 73(15):5048-5051.
Wang et al., Single nucleotide polymorphism discrimination assisted by improved base stacking hybridization using oligonucleotide microarrays. Biotechniques. 2003;35:300-08.
Ward, et al. Microfluidic flow focusing: Drop size and scaling in pressure versus flow-rate-driven pumping. Electrophoresis. Oct. 2005;26(19):3716-24.
Weaver, “Rapid clonal growth measurements at the single-cell level: gel microdroplets and flow cytometry”, Biotechnology, 9:873-877 (1991).
Weigl, et al. Microfluidic Diffusion-Based Separation and Detection. Science. 1999; pp. 346-347.
Wesolowska, et al. Cost-effective multiplexing before capture allows screening of 25 000 clinically relevant SNPs in childhood acute lymphoblastic leukemia. Leukemia. Jun. 2011;25(6):1001-6. doi: 10.1038/leu.2011.32. Epub Mar. 18, 2011.
Whitesides, “Soft lithography in biology and biochemistry”, Annual Review of Biomedical Engineering, 3:335-373 (2001).
Williams, et al. Amplification of complex gene libraries by emulsion PCR. Nature Methods. 2006;3(7):545-50.
Wiseman, R.W. et al. “Major histocompatibility complex genotyping with massively parallel pyrosequencing” Nature Medicine (Oct. 11, 2009) 15(11):1322-1326.
Wong, et al. Multiplexed Barcoded CRISPR-Cas9 Screening Enabled By CombiGEM. PNAS. Mar. 1, 2016, vol. 113, pp. 2544-2549.
Woo, et al. G/C-modified oligodeoxynucleotides with selective complementarity: synthesis and hybridization properties. Nucleic Acids Res. Jul. 1, 1996;24(13):2470-5.
Wood AJ, et al. Targeted genome editing across species using ZFNs and TALENs. Science. 2011;333:307.
Xi, et al. New library construction method for single-cell genomes. PLoS One. Jul. 19, 2017;12(7):e0181163. doi: 10.1371/journal.pone.0181163. eCollection 2017.
Xia and Whitesides, Soft Lithography, Angew. Chem. Int. Ed. 37:550-575 (1998).
Xia and Whitesides, Soft Lithography, Ann. Rev. Mat. Sci. 28:153-184 (1998).
Xiao, et al., “Determination of haplotypes from single DNA molecules: a method for singlemolecule barcoding”, Hum Mutat., 28:913-21,2007.
Yamamoto, et al. Chemical modification of Ce(IV)/EDTA-base artificial restriction DNA cutter for versatile manipulation of double-stranded DNA. Nucleic Acids Research. 2007; 35(7):e53.
Yan, Pu et al. “Rapid one-step construction of hairpin RNA” Biochem and Biophys Res Comm (Jun. 12, 2009) 383(4):464-468.
Zeng, et al. High-performance single cell genetic analysis using microfluidic emulsion generator arrays. Anal Chem. Apr. 15, 2010;82(8):3183-90. doi: 10.1021/ac902683t.
Zentner, et al. Surveying the epigenomic landscape, one base at a time. Genome Biol. Oct. 22, 2012;13(10):250. doi: 10.1186/gb4051.
Zhang, “Combinatorial marking of cells and organelles with reconstituted fluorescent proteins”, Cell, 119:137-144 (Oct. 1, 2004).
Zhang, et al. Degradable disulfide core-cross-linked micelles as a drug delivery system prepared from vinyl functionalized nucleosides via the RAFT process. Biomacromolecules. Nov. 2008;9(11):3321-31.doi: 10.1021/bm800867n. Epub Oct. 9, 2008.
Zhang, et al. One-step fabrication of supramolecular microcapsules from microfluidic droplets. Science. Feb. 10, 2012;335(6069):690-4. doi: 10.1126/science.1215416.
Zhang, et al. Reconstruction of DNA sequencing by hybridization. Bioinformatics. Jan. 2003;19(1):14-21.
Zhang F, et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat. Biotechnol. 2011;29:149-153.
Zhang. Genomics of inherited bone marrow failure and myelodysplasia. Dissertation [online], University of Washington. 2015 [Retrieved on May 3, 2017].
Zhao, J., et al., “Preparation of hemoglobin-loaded Nano-sized particles with porous structure as oxygen carriers,” Biomaterials, vol. 28, pp. 1414-1422 (2007).
Zheng, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. Jan. 16, 2017;8:14049. doi: 10.1038/ncomms14049.
Zheng, X.Y. et al. “Haplotyping germline and cancer genomes with high-throughput linked-read sequencing” Nature Biotech (Feb. 1, 2016) 34(3):303-311.
Zhou, Y. et al. “Development of an enzyme activity screening system for p-glucosidase-displaying yeasts using calcium alginate micro-beads and flow sorting” Appl Microbiol Biotechnol (2009) 84:375-382 (Year: 2009).
Zhu et al. Hydrogel Droplet Microfluidics for High-Throughput Single Molecule/Cell Analysis. Accounts of Chemical Research Article ASAP. DOI: 10.1021/acs.accounts.6b00370.
Zhu, et al. Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction. Biotechniques. Apr. 2001;30(4):892-7.
Zhu, et al. Synthesis and self-assembly of highly incompatible polybutadienepoly(hexafluoropropoylene oxide) diblock copolymers. Journal of Polymer Science Part B: Polymer Physics. 2005; 43(24):3685-3694.
Zimmermann et at., Microscale production of hybridomas by hypo-osmolar electrofusion. Hum| Antibodies Hybridomas. Jan. 1992;3(1 ): 14-8.
Zong et al. Genome-Wide Detection of Single Nucleotide and Copy Number Variations of a Single Human Cell. Science 338(6114):1622-1626 (2012).
Co-pending U.S. Appl. No. 16/196,684, filed Nov. 20, 2018.
Jin, et al. Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples. Nature. Dec. 3, 2015;528(7580):142-6. doi: 10.1038/nature15740.
10X Genomics, Inc. CG000153 Rev A. Chromium Single Cell DNA Reagent Kits User Guide. 2018.
10X Genomics, Inc. CG000184 Rev A. Chromium Single Cell 3′ Reagent Kits v3 User Guide with Feature Barcoding Technology for CRISPR Screening. 2018.
10X Genomics, Inc. CG000185 Rev B. Chromium Single Cell 3′ Reagent Kits User Guide with Feature Barcoding Technology for Cell Surface Protein. 2018.
10X Genomics, Inc. CG000208 Rev E. Chromium Next GEM Single Cell V(D)J reagent Kits v1.1 User Guide with Feature Barcode Technology for Cell Surface Protein. 2020.
10X Genomics, Inc. CG000209 Rev D. Chromium Next GEM Single Cell ATAC Reagent Kits v1.1 User Guide. 2020.
10X Genomics, Inc. CG000239 Rev B. Visium Spatial Gene Expression Reagent Kits User Guide. 2020.
10X Genomics, Inc. CG00026. Chromium Single Cell 3′ Reagent Kit User Guide. 2016.
10X Genomics, Inc. LIT00003 Rev B Chromium Genome Solution Application Note. 2017.
Co-pending U.S. Appl. No. 16/708,214, filed Dec. 9, 2019.
Co-pending U.S. Appl. No. 16/737,762, filed Jan. 8, 2020.
Co-pending U.S. Appl. No. 16/737,770, filed Jan. 8, 2020.
Co-pending U.S. Appl. No. 16/789,273, filed Feb. 12, 2020.
Co-pending U.S. Appl. No. 16/789,287, filed Feb. 12, 2020.
Co-pending U.S. Appl. No. 16/800,450, filed Feb. 25, 2020.
Co-pending U.S. Appl. No. 16/814,908, filed Mar. 10, 2020.
Devor, et at. Strategies for attaching oligonucleotides to solid supports. IDT DNA Rep (2005): 1-24.
Reuter, J.A et al. “Simul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling” Nature Methods (2016) 13(11):953-958.
Steinberg-Tatman, et al. Synthetic modification of silica beads that allows for sequential attachment of two different oligonucleotides.Bioconjugate chemistry 17.3 (2006): 841-848.
PCT/US2020/017785 Application filed on Feb. 11, 2020 by Ziraldo, Solongo B. et al.
PCT/US2020/017789 Application filed on Feb. 11, 2020 by Belhocine, Zahara Kamila et al.
Co-pending U.S. Appl. No. 16/998,414, filed Aug. 20, 2020.
Co-pending U.S. Appl. No. 16/998,425, filed Aug. 20, 2020.
Bentolila, et al. Single-step multicolor fluorescence in situ hybridization using semiconductor quantum dot-DNA conjugates. Cell Biochem Biophys. 2006;45(1):59-70.
Bystrykh, et al. Generalized DNA barcode design based on Hamming codes. PLoS One. 2012;7(5):e36852. doi: 10.1371/journal.pone.0036852. Epub May 17, 2012.
Co-pending U.S. Appl. No. 16/395,090, filed Apr. 25, 2019.
Co-pending U.S. Appl. No. 16/419,428, filed May 22, 2019.
Co-pending U.S. Appl. No. 16/419,461, filed May 22, 2019.
Co-pending U.S. Appl. No. 16/419,555, filed May 22, 2019.
Co-pending U.S. Appl. No. 16/419,630, filed May 22, 2019.
Co-pending U.S. Appl. No. 16/419,820, filed May 22, 2019.
Co-pending U.S. Appl. No. 16/435,362, filed Jun. 7, 2019.
Co-pending U.S. Appl. No. 16/435,417, filed Jun. 7, 2019.
Definition of “corresponding”, Merriam-Webster Online, downloaded from http://www.merriam-webster.com/dictionary/corresponding (Year: 2019).
Dhingra, et al. A complete solution for high throughput single cell targeted multiomic DNA and RNA sequencing for cancer research. Poster. AACR 2019.
Maeda, et al. Development of a DNA barcode tagging method for monitoring dynamic changes in gene expression by using an ultra high-throughput sequencer. Biotechniques. Jul. 2008;45(1):95-7. doi: 10.2144/000112814.
Mamedov, I.Z., et al. (2013), Preparing unbiased T-cell receptor and antibody cDNA libraries for the deep next generation sequencing profiling, Front Immunol 4: 456.
Co-pending U.S. Appl. No. 17/353,202, inventors Hindson; Benjamin et al., filed Jun. 21, 2021.
Co-pending U.S. Appl. No. 17/381,612, inventor Martinez; Luigi Jhon Alvarado, filed Jul. 21, 2021.
Xiong, et al., Responsive DNA-based hydrogels and their applications. Macromol Rapid Commun. Aug. 2013; 34(16): 1271-1283, doi:10.1002/marc.201300411.
Related Publications (1)
Number Date Country
20190276817 A1 Sep 2019 US
Provisional Applications (4)
Number Date Country
61762435 Feb 2013 US
61800223 Mar 2013 US
61840403 Jun 2013 US
61844804 Jul 2013 US
Continuations (3)
Number Date Country
Parent 15693374 Aug 2017 US
Child 16170980 US
Parent 15470814 Mar 2017 US
Child 15693374 US
Parent 14175935 Feb 2014 US
Child 15470814 US